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USING MACHINE LEARNING TO PREDICT ACUTE KIDNEY  
INJURIES AMONG PATIENTS TREATED WITH EMPIRIC ANTIBIOTICS 
 
Acute kidney injury (AKI) is a significant adverse effect of many medications that 
leads to increased morbidity, cost, and mortality among hospitalized patients. Recent 
literature supports a strong link between empiric combination antimicrobial therapy and 
increased AKI risk. As briefly summarized below, the following chapters describe my 
research conducted in this area.  
Chapter 1 presents and summarizes the published literature connecting 
combination antimicrobial therapy with increased AKI incidence. This chapter sets the 
specific aims I aim to achieve during my dissertation project. 
Chapter 2 describes a study in which patients receiving vancomycin (VAN) in 
combination with piperacillin-tazobactam (TZP) or cefepime (CFP). I matched over 
1,600 patients receiving both combinations and found a significantly lower incidence of 
AKI among patient receiving the CFP+VAN combination when controlling for 
confounders. The conclusion of this study is that VAN+TZP has significantly increased 
risk of AKI compared to CFP+VAN, confirming the results of previous literature. 
Chapter 3 presents a study of patients receiving VAN in combination with 
meropenem (MEM) or TZP. This study included over 10,000 patients and used inverse 
probability of treatment weighting to conserve data for this population. After controlling 
for confounders, VAN+TZP was associated with significantly more AKI than 
VAN+MEM. This study demonstrates that MEM is clinically viable alternative to TZP in 
empiric antimicrobial therapy.  
Chapter 4 describes a study in which patients receiving TZP or ampicillin-
sulbactam (SAM) with or without VAN were analyzed for AKI incidence. The purpose 
of this study was to identify whether the addition of a beta-lactamase inhibitor to a beta-
lactam increased the risk of AKI. This study included more than 2,400 patients receiving 
either agent and found that there were no differences in AKI among patients receiving 
SAM or TZP; however, AKI was significantly more common in the TZP group when 
stratified by VAN exposure. This study shows that comparisons of TZP to other beta-
lactams without beta-lactamase inhibitors are valid. 
 
Chapter 5 presents a study of almost 30,000 patients who received combination 
antimicrobial therapy over an 8-year period. This study demonstrates similar AKI 
incidence to previous literature and the studies presented in the previous chapters. 
Additionally, the results of the predictive models suggest that further work in this 
research area is needed. 
The studies conducted present a clear message that patients receiving VAN+TZP 
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Chapter 1: Systematic literature review 
Background 
Acute kidney injuries (AKI) are common in hospitalized patients, with approximately 
20% of adult inpatients and over 65% of critically ill patients experiencing AKI. In addition to 
high incidence among acutely ill patients, AKI is associated with increased mortality with 
unadjusted estimates of 23.9% mortality associated with one episode of AKI in adults.(1) Chief 
among modifiable risk factors are medications, which are commonly implicated in cases of AKI. 
(2)  
The glycopeptide antibiotic Vancomycin (VAN) is frequently implicated in AKI cases 
and has highly variable incidence of AKI associated with use. Estimates of VAN-associated AKI 
range from 1 to 42%, depending on the patient cohort studied.(3–5). Risk factors for VAN-
associated AKI include: concomitant administration of other nephrotoxic agents, prolonged 
duration of VAN therapy, daily VAN doses of 4 g or greater, and obesity.(6) The current 
methicillin-resistant Staphylococcus aureus treatment guidelines suggest targeting higher VAN 
levels to account for rising minimum-inhibitory concentrations.(7)  
Combination antimicrobial therapy with VAN and an antipseudomonal beta-lactam is 
frequently utilized as empiric therapy for acutely ill patients. Common antipseudomonal beta-
lactams include piperacillin-tazobactam (TZP), cefepime (CFP), and the carbapenems, 
meropenem (MEM), imipenem, and doripenem. While generally considered non-nephrotoxic, 
systemic use of early penicillins and first-generation cephalosporins are associated with cases of 
acute interstitial nephritis (AIN).(8) However, reports of AIN associated with CFP are 
published.(9) In registration trials, TZP was not associated with significant increases in AKI and 
therefore, AKI does not appear in the package inserts for TZP.(10) 
2 
 
Recent reports suggest that combination antimicrobial therapy with VAN and TZP is 
associated significantly increased AKI rates when compared to TZP monotherapy and other beta-
lactam/VAN combinations. This review focuses on the current literature regarding increases in 
AKI with beta-lactam and VAN combinations for empiric therapy. 
Methods 
A literature search was conducted using the PubMed database. Several queries were 
made with search terms including [“piperacillin”, “tazobactam”, “cefepime”, “meropenem”, 
“vancomycin”] and [“acute kidney injury”, “nephrotoxicity”]. English language studies of 
humans with available full-text articles were included in this review. Following screening of 
articles, additional articles were obtained from study bibliographies. Studies were separated based 
on comparator agents, target population, and evaluation of different IV administration modalities.  
Combination therapy with Vancomycin and Piperacillin-Tazobactam compared to 
Monotherapy 
VAN-associated nephrotoxicity is a well-characterized adverse effect of VAN therapy; 
however, prior to 2014, no studies had reported increased rates of AKI when combined with TZP. 
Table 1.1 summarizes the literature reviewed relating to VAN+TZP compared to monotherapy 
options.   
Vancomycin combined with piperacillin-tazobactam compared to vancomycin alone 
In a retrospective review of factors associated with VAN nephrotoxicity, Meaney and 
colleagues(11) evaluated 125 patients who received VAN for at least 3 days. Patients with 
underlying chronic kidney disease (CKD) and AKI on admission were excluded from the 
analysis. They defined AKI according to the vancomycin consensus guidelines (increase in serum 
creatinine [SCr] by 1.5 times baseline or by 0.5 mg/dL from baseline value).(6) Overall, they 
found 17.6% of patients experienced an AKI; however, when stratified by TZP administration, 
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patients with concomitant TZP administration were more likely to experience AKI (22.4% vs 6%; 
aOR 5.36, 95%CI 1.41-20.5). This study was primarily limited by small sample size and limited 
control for confounders of treatment selection. This was the first report of the interaction between 
VAN and TZP and increased AKI.  
Shortly after Meaney and colleagues, Burgess and Drew(12) conducted a retrospective 
cohort study in which 191 patients received VAN alone or VAN+TZP for at least 48 hours and 
found AKI rates were significantly elevated in combination therapy patients (16.3% vs 8.1%, p 
=0.041). After controlling for confounders, VAN+TZP therapy was associated with an adjusted 
odds ratio (aOR) of 2.48 (p=0.032). The use of one-sided statistical tests and small patient 
enrollment are significant limitations to this study.  
In a study of adult surgical patients, Davies and colleagues(13) were unable to find a 
significant difference in AKI incidence among patients receiving VAN+TZP, VAN monotherapy, 
and VAN combined with other beta-lactam agents. However, the numbers in this study included 
patients multiple times due to differing infection episodes and patients were able to receive 
different therapeutic options based on the episode.  
Anderson and colleagues(14) compared adult non-critically ill patients receiving 
VAN+TZP or VAN alone for at least 48 hours and found combination therapy significantly 
increased AKI incidence (24% vs 11%, p<0.001; aOR 2.14 [1.26-3.66]). This study was 
conducted in a military hospital and had a surprisingly high mean Charlson Comorbidity index 
for non-critically ill patients less than 65 years of age. 
Two studies examined the impact of antimicrobial stewardship interventions on AKI 
incidence among patients receiving VAN+TZP. Fodero and colleagues(15) found higher rates of 
AKI among combination therapy patients (12.8% vs 6.7%, p =0.04). Increased AKI odds 
persisted after controlling for confounders (aOR =3.21 [1.43-7.96]). Lorenz et al(16) examined 
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the impact of TZP restriction on AKI incidence and found significantly lower AKI incidence in 
the post-intervention cohort (9% vs 10%, p =0.039). In addition to the impact of the specific 
stewardship intervention, VAN+TZP had significantly higher AKI incidence throughout the study 
period (11.8% vs. 1.7%, p<0.0001). Additionally, increased duration of therapy for TZP and 
combination therapy were associated with increased AKI.  
Combination therapy compared to piperacillin-tazobactam monotherapy 
Kim et al,(17) conducted the first study of VAN+TZP with TZP as monotherapy. Patients 
receiving VAN+TZP had an AKI incidence of 18.8% compared to 4.0% for VAN monotherapy 
and 15.4% for TZP monotherapy. These results show that VAN monotherapy was associated with 
significantly less AKI compared to both VAN+TZP  (aORVAN vs VAN+TZP = 0.14 [0.04-0.52]) and 
TZP alone (aORVAN vs TZP = 0.15 [0.03-0.83]). However, TZP and VAN+TZP had similar rates and 
adjusted odds of AKI (aORTZP vs VAN = 0.91 [0.22-3.82]). Low patient enrollment in the TZP arm, 
36 patients compared to 101 for both VAN monotherapy and combination therapy, significantly 
limited the power of any analysis of TZP monotherapy. 
In the largest study to date of VAN+TZP associated AKI, Rutter et al(18) demonstrated 
significant differences in AKI incidence between VAN+TZP (21.0%), VAN monotherapy(8.3%), 
and TZP monotherapy (7.8%, p<0.0001). After controlling for confounders, AKI odds were 
significantly lower in TZP and VAN monotherapy compared to VAN+TZP therapy 
(aORTZPvsVAN+TZP = 0.42 [0.37-0.5] and aORVANvsVAN+TZP = 0.48 [0.41-0.57]). Patients who 
received combination therapy were significantly more ill at baseline compared to either 
monotherapy arm; however, the observed differences in AKI incidence were consistent across 




 Estimates of AKI incidence associated with VAN+TZP therapy range from 11.8% to 
24.0% compared to VAN monotherapy estimates of 4% to 22% and TZP monotherapy estimates 
of 1.7 to 15.4% of patients. While these values are similar, comparisons across studies is difficult 
due to differing patient populations and AKI definitions. It is clear from the presented literature 
that AKI incidence is significantly increased when the combination of VAN and TZP is utilized 
when compared to either agent as monotherapy with only one study failing to find a significant 
difference between these groups.  
 
Combination therapy with vancomycin and piperacillin-tazobactam compared to 
combination therapy with vancomycin and cefepime 
 The most common comparator for VAN+TZP in the literature to date is VAN+CFP due 
to the similarity in antimicrobial spectrum and clinical utility. Table 1.2 summarizes the 
published literature for studies comparing these two combination regimens.  
Vancomycin plus piperacillin-tazobactam compared to cefepime in general hospitalized patients 
 Moenster and colleagues(23) first studied the differences in AKI potential between 
VAN+TZP and VAN+CFP in single center retrospective review of 139 diabetic patients who 
suffered from osteomyelitis. This study estimated that AKI occurred in 29.3% of VAN+TZP 
patients compared to 13.3% in VAN+CFP patients. Due to small sample size in the VAN+CFP 
cohort, no statistical difference could be established with the adjusted odds ratio for AKI among 
VAN+TZP patients reaching 3.45 [95%CI 0.96-12.4]. This study is limited by its small sample 
size and narrow application due to patient population examined. Additionally, no inference 
regarding impact of additional concomitant nephrotoxins could be made due to the exclusion of 
patients who received specific agents.  
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 In a matched cohort study of 224 patients receiving VAN+TZP or VAN+CFP for at least 
48 hours, Gomes et al(24) found the AKI incidence among VAN+TZP was significantly higher 
than those receiving VAN+CFP (34.8% vs. 12.5%; p<0.0001). After matching and controlling for 
remaining confounders, treatment with VAN+TZP was associated with a 5.67 multiplicative 
increase in AKI odds when compared to VAN+CFP (95% CI 1.66-19.33). 
 Sutton and colleagues(25) reviewed 292 patients who received VAN from specific 
manufacturers for at least 48 hours. While no difference in AKI was observed between the two 
VAN products, investigators observed that patients receiving VAN+TZP had numerically higher 
rates of AKI (21.3%). In contrast, only 4.5% of patients who received CFP in addition to VAN 
experienced AKI. The odds of AKI were not statistically different (OR = 0.46 [0.15-1.35]) when 
compared. The study was not powered to investigate this finding and no attempts to control for 
differences between VAN+TZP and VAN+CFP patients were made. Although this study did not 
find a significant difference between the combination therapy options, it does assuage the 
concerns that different VAN products may be responsible for differing rates of AKI observed in 
other studies. 
 The largest study of VAN+TZP and VAN+CFP associated AKI was performed by Jeon 
et al.(26) Investigators evaluated 5,335 patients from multiple centers. In contrast to most other 
studies, VAN+CFP was the predominant combination therapy (3,355 patients compared to 1,980 
who received VAN+TZP). AKI incidence among VAN+TZP cohort was higher than rates among 
VAN+CFP patients (19.6% vs. 16.3%, p =0.002). Using a Cox proportional hazards model, the 
hazard of AKI for patients receiving VAN+TZP was significantly increased (aHR = 1.25 [1.11-
1.42]). Additionally, patients with renal impairment at baseline, defined by creatinine clearance 
less than 60 mL/min, were no more likely to experience AKI on VAN+TZP when compared to 
VAN+CFP (aHR=0.81 [0.65-1.01]). 
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 Navalkele and colleagues(27) conducted a matched retrospective study of 558 adults who 
received VAN+TZP or VAN+CFP. AKI incidence was significantly higher in the VAN+TZP 
cohort (29.0% vs. 11.1%) and adjusted hazard was significantly increased (aHR = 4.3 [2.7 – 
6.7]). Due to the matched covariates in this study, inferences about impact of concomitant 
nephrotoxins cannot be made. 
 In a prospective multicenter observational study, Mullins and colleagues compared AKI 
rates in patients who received VAN+TZP to those who received VAN+CFP or MEM for at least 
72 hours. Among the cohort receiving VAN+TZP the incidence of AKI was 29.8% compared to 
8.8% among the patients receiving VAN+CFP/MEM (p<0.001); however, incidence among the 
patients receiving VAN+CFP was only 5.9% (p<0.001 for comparison to VAN+TZP). 
Investigators only completed bivariable statistical analysis and report a crude odds ratio of 6.6 
[2.8-15.8] for AKI between VAN+TZP and VAN+CFP/MEM. Additionally, VAN troughs 
greater than 30 mg/L were significantly associated with AKI; however, the timing of VAN trough 
in relation to AKI was not clear and this may represent an effect of AKI not a cause. This study 
was limited by the choice to only complete bivariable analysis and small sample size. 
Vancomycin and piperacillin-tazobactam compared to vancomycin and cefepime in special 
populations 
 Hammond and colleagues(28) conducted the only published study of AKI incidence 
among combination therapy options in the critically ill population to date. Due to the severity of 
illness among the overall cohort, AKI incidence higher than previous studies; however, no 
difference in rates were noted between patients receiving VAN+TZP and those receiving 
VAN+CFP (32.7% vs. 28.8%, p=0.647). This study was significantly limited by small sample 
size of only 122 patients.  
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 Clemmons et al(29) conducted a retrospective cohort evaluation of adult patients 
undergoing hematopoietic cell transplantation (HCT) who received VAN+TZP or VAN+CFP. 
AKI incidence among VAN+TZP was significantly higher than the rate found in VAN+CFP 
(68% vs. 27%, p<0.001). After controlling for significant confounders of AKI among the cohort, 
VAN+TZP was associated with a 5.16 multiplicative increase in adjusted odds of AKI compared 
to VAN+CFP (95%CI 2.53-10.5). After stratification by allogeneic and autologous HCT, the 
association with AKI remained for VAN+TZP.  
Summary 
 Estimates of AKI for VAN+TZP in the previous studies ranged from 19.7% to 34.8% in 
the general population compared to 4.5% to 16.3% for VAN+CFP. AKI incidence is significantly 
higher among patients with increased severity of illness for both VAN+TZP and VAN+CFP.  
Vancomycin and piperacillin-tazobactam compared to other Gram-negative therapy 
options in combination with vancomycin 
 The study by Davies and colleagues was briefly presented in the VAN+TZP compared to 
monotherapy section of this review; however, this study presents the first attempt at identifying if 
AKI incidence was significantly different between other VAN+TZP and other beta-lactam agents. 
They estimate the AKI incidence of VAN+TZP to be 21% compared to 20% in VAN+CFP or 
MEM treated patients. They did not examine a group-wise comparison and report a p-value of 
0.89 for the Kruskal-Wallis test for the three groups in their study. This suggest there is no 
difference in AKI incidence; however, using infection episodes as the unit of observation may 
skew the results.  
 In a prospective observational study, Peyko and colleagues(31) evaluated 85 patients 
receiving either VAN+TZP or VAN+CFP or MEM. AKI incidence was significantly higher 
amongst the VAN+TZP cohort (37.3% vs. 7.7%, p=0.005). This study did not breakdown results 
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between CFP and MEM combination cohorts. The primary limitation of this study was the 
differences in severity of illness and potential for increased dosing intensity among the 
VAN+TZP cohort. While there was no measure for severity of illness included in the publication, 
more patients in the VAN+CFP/MEM had less severe infections compared to the VAN+TZP 
cohort. Increased infection severity may have increased the observed difference in AKI incidence 
in this study. 
 In a study by Al Yami(32), AKI incidence in VAN+TZP patients was estimated as 7.4% 
compared to 5.3% in VAN+MEM patients (p=0.4). This study is the only study to directly 
compare combination therapy with TZP to combination therapy with MEM only. However, AKI 
rates are far below reports from prior studies which limits the generalizability to a wider patient 
population. Other limitations include small sample size and no control of other nephrotoxic 
confounders. 
 Finally, Mullins et al(30) included patients who received VAN+MEM in their study. 
Investigators were unable to find a statistically meaningful difference between VAN+TZP 
(29.8%) and VAN+MEM (14.9%; p=0.54). This study has several limitations, as discussed 
previously, however, a specific limitation of this analysis is low patient enrollment in the 
VAN+MEM cohort (n=47 compared to 94 for VAN+TZP). 
Summary 
 Limited data comparing VAN+TZP to non-CFP beta-lactam agents exist; however, AKI 
incidence among VAN+TZP cohorts (21% to 37.3%) are similar to previous literature. AKI 
incidence among VAN combined with other beta-lactams ranges from 7.7% to 20%. Further 
study of alternative empiric combination therapy is warranted. 
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Impact of beta-lactam infusion method on AKI 
 Several studies have examined the rate of infusion of beta-lactam agents to determine if 
an association with increased AKI exists. McCormick and colleagues(33) published the first 
study on this topic. They included 200 patients who received TZP by either extended infusion 
(EI) or bolus infusion (BI) for at least 48 hours. They found AKI incidence of 9.5% overall and 
no statistical difference between EI and BI (9% vs 11%, p=0.637). The investigators did not 
specifically control for VAN exposure and excluded all patients who received a non-TZP beta-
lactam.  
 Karino et al(34) conducted a single-center retrospective review of 320 patients who 
received TZP as either EI or BI for at least 48 hours. In contrast to the study by McCormick and 
colleagues, investigators specifically included patients who received concomitant VAN. 
Estimates of AKI incidence between both EI and BI groups were not significantly different 
(32.5% vs. 33.1%, p=1). These rates of AKI are relatively high compared to previous studies; 
however, the majority of patients in both groups received concomitant nephrotoxins, which were 
associated with increased AKI odds in multivariable regression analysis.  
 In a matched cohort study, Cotner et al(35) examined 2,390 patients who received at least 
48 hours of TZP, CFP, or MEM as bolus or extended infusion. Importantly, not all patients 
received VAN in combination with beta-lactams. AKI incidence was similar between infusion 
methodologies (EI 21.6% vs. 18.6% for BI, p=0.104). In multivariable regression, infusion 
method did not have a statistical impact on AKI odds (aOR 1.07, 95%CI 0.83-1.39); however, 
when compared to CFP, TZP administration significantly increased AKI odds (aOR 1.95 [1.50-
2.52]). The addition of VAN was associated with a 1.6 time multiplicative increase in AKI odds 
(95% CI 1.16-2.21). Other nephrotoxins associated with significant increases in AKI odds in 
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multivariable regression included: aminoglycosides, amphotericin b, calcineurin inhibitors, loop 
diuretics, non-steroidal anti-inflammatory drugs, and vasopressors. 
 Mousavi and colleagues(36) conducted a retrospective review of 280 patients in a 1:1 
ratio of BI to EI who received VAN+TZP for at least 48 hours. Investigators mitigated the 
potential for severity of illness to confound results by matching patients based on level of care 
(IE. ICU patients who received EI were matched to ICU patients who received BI). This was 
primarily in response to a treatment algorithm that prevailed in the study institution during the 
study period. In total, 17.5% of patients experienced an AKI with no significant differences 
between EI and BI cohorts (17.9% vs 17.1%, p>0.99). 
Summary 
 AKI incidence among patients in studies of beta-lactam infusion methodology were 
similar to those reported in other studies. Limited data are published in this arena; however, it 
appears that infusion strategy does not influence AKI incidence in an appreciable way.  
Vancomycin and piperacillin-tazobactam associated AKI in the pediatric population 
 While the majority of data exist in the adult population, significant research has been 
conducted in pediatric patients. Pratt, et al published a case series of four pediatric cases of AKI 
associated with TZP administration in patients with underlying oncologic conditions.(37) 
Interestingly, VAN was utilized concomitantly in each case; however, interstitial nephritis was 
confirmed in 50% of cases, suggesting beta-lactam associated AKI.  
 In 2015, Knoderer and colleagues(38) published the first cohort study of AKI incidence 
in pediatric patients receiving VAN+TZP. The primary objective was to establish risk factors for 
late onset AKI in VAN therapy; therefore, inclusion was limited to patients who received VAN 
therapy for at least 8 days. In total, 167 patients were included for analysis, of which 69 received 
VAN+TZP compared to 98 who received VAN alone. AKI occurred in 18.8% of patients 
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receiving VAN+TZP compared to 8.2% in VAN alone (p=0.06). In addition to small sample size 
and limited power, the AKI incidence in VAN+TZP may be confounded due to significantly 
higher rates of concomitant amphotericin B administration.  
 McQueen and Clark(39) published the first directed analysis of VAN+TZP compared to 
VAN monotherapy in pediatric patients. Overall, 185 patients were included in this study and 
AKI occurred in 23.6% of the VAN+TZP cohort and 3.8% in the VAN alone cohort (p=0.0001). 
Investigators only completed bivariable analysis and therefore have no control for known 
confounders present in the patient population. Additionally, rather than selecting an equal 
population, the VAN monotherapy group was selected randomly from a larger cohort.  
 Abouelkheir, et al(40) published a large case report of pediatric patients less than 14 
years of age who received VAN for at least 48 hours. Of 132 patients, 8 experienced AKI related 
to study drug administration. This evaluation is unique in the use of validated methods to 
associated AKI with VAN administration. Using the World Health Organization Uppsala 
Monitoring Centre system for evaluation of case causality, 50% of AKI cases were rated as 
having certain causality. Of the 38 patients who received VAN+TZP, 21.0% experienced AKI 
compared to 2.1% of the 94 patients who received VAN alone (p=0.0007). These estimates are 
extrapolated from the data provided in the manuscript and represent unadjusted incidence. 
 Downes and colleagues(41) conducted the largest study to date in pediatric patients. They 
included 1,915 patients from multiple centers who received VAN in combination with an anti-
pseudomonal beta-lactam. Patients in the VAN+TZP cohort experienced AKI significantly more 
frequently compared to VAN in combination with other anti-pseudomonal beta-lactams (11.7% 
vs. 4.4%, p<0.001). While this study is robust, investigators only included patients who received 
study agents within 48 hours of admission and limited the analysis to AKI that occurred within 7 
days of admission, which may limit applicability of these findings to treatment of nosocomial 
infections or long courses of antibiotics. 
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 While all the previous studies included all patients, Holsen et al(42) compared patients 
admitted to the pediatric intensive care unit who received VAN+TZP or VAN in combination 
with ceftriaxone. In total, 93 patients met inclusion criteria with the majority (58) receiving 
VAN+TZP. AKI was significantly more common in VAN+TZP compared to VAN+ceftriaxone 
(25.9% vs. 8.6%, p=0.041). This finding was consistent in multivariable regression analysis (aOR 
4.55 [1.11-18.7]). Limitations of this study are primarily related to the lack of control for severity 
of illness differences between groups. TZP is typically utilized for empiric therapy or for severe 
infections, while ceftriaxone lacks similar indications and antimicrobial spectrum.  
Summary 
 Studies of pediatric patients estimate the AKI incidence associated with VAN+TZP 
therapy ranges from 11.7% to 23.9% of patients. VAN+TZP patients consistently experience 
higher rates of AKI than comparator groups. More research in critically ill pediatric patients is 
warranted. 
Further questions and aims to be addressed 
 While literature in this area continues to evolve, there are still several opportunities to 
improve upon what has been published. There is significant support for an interaction between 
VAN and TZP that increases AKI potential when compared to either agent as monotherapy.  
Aim 1: Compare AKI incidence rate among patients treated with VAN+TZP and VAN+CFP in a 
study large enough to robustly control for confounders 
  Due to similarity in antimicrobial spectrum and clinical utility, TZP is often compared to 
CFP and many studies have shown significant AKI increases with VAN+TZP. However, many of 
these studies were small single center studies with limited power to control for other confounders. 




Aim 2: Determine if beta-lactamase inhibitor influences AKI seen with TZP 
Many of the studies discussed previously took cues from comparative effectiveness 
research and compared agents with similar indications and spectrum of activity. However, one 
major difference between TZP and the comparators used is the presence of a beta-lacatamase 
inhibitor in combination with a beta-lactam agent. It is possible that the addition of this second 
beta-lactam-like agent contributes to the increased AKI potential noted with TZP. Unfortunately, 
ticarcillin-clavulanate, an agent with similar spectrum and indication to TZP, is no longer widely 
used. Another agent that is widely used, but lacks the indication for certain severe infections is 
ampicillin-sulbactam. We conducted a large retrospective review of TZP compared to ampicillin-
sulbactam, with and without concomitant VAN to identify differences in AKI. 
Aim 3: Compare AKI incidence between VAN+TZP and VAN+MEM 
 While there have been studies that include patients who received MEM in combination 
with VAN, many grouped MEM with other beta-lactam agents to increase sample size and 
statistical power. This may lead to bias in AKI incidence as MEM is typically reserved for 
patients with multidrug resistant infections, who typically have higher comorbidity than those 
without MDR organisms. These studies also suffered from small sample sizes. We conducted a 
large study and weighted patients according to their probability of receiving either treatment 
agent. 
Aim 4: Can machine learning methods accurately predict AKI occurrence in patients treated with 
empiric combination antimicrobial therapy? 
 Previous studies have relied on relatively small sample sizes to identify factors that are 
associated with increased AKI incidence. We leveraged our electronic data warehouse to develop 
sophisticated supervised learning algorithms to predict AKI occurrence at the patient level. 
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Furthermore, we framed the predictive models as a clinical decision support tool to demonstrate 




Table 1.1: Studies of AKI incidence with vancomycin combined with piperacillin-tazobactam 
compared to either agent as monotherapy 
Study Design Patient 
population 
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(20) AKI rates 
• VAN+TZP 24% 
• VAN 11% 
• p<0.001 














































(19) AKI rate 
• VAN+TZP: 
21.0% 
• VAN: 8.3% 
• TZP 7.8% 
• aORV:VAN+TZP = 
0.48 [0.41-0.57] 




Footnote: (6) – vancomycin consensus guidelines AKI definitions; (19) – RIFLE guidelines AKI 
definitions; (20) – Acute kidney injury network AKI definitions; (21) – KDIGO AKI guidelines; 
(22) – modified RIFLE for pediatrics; aHR – adjusted Hazard ratio; AKI – acute kidney injury; 
ANC – absolute neutrophil count; aOR – adjusted Odds ratio; BUN – blood urea nitrogen; CF – 
cystic fibrosis; CFP – cefepime; CKD – chronic kidney disease; CrCl – creatinine clearance; 
CRO – ceftriaxone; ECMO – extracorporeal membrane oxygenation; ESRD – end-stage renal 
disease; HCT – hematopoietic cell transplant; KDOQI - Kidney Disease Outcomes Quality 
Initiative; KW – Kruskal-Wallis test; MEM – meropenem; N – number; OR – odds ratio; PICU – 
pediatric intensive care unit; PMH – past medical history; RRT – renal replacement therapy; SCr 





Table 1.2: Studies comparing AKI incidence between vancomycin combined with piperacillin-
tazobactam and vancomycin combined with cefepime 
Study Design Patient 
Population 





































































































































































































Table 1.2 (continued) 
Hammond, 





































































VAN+TZP: 6   
(21) AKI rate 
• VAN+TZP 68% 
• VAN+CFP 27% 
• p<0.001 






Table 1.2 (continued) 








































• aHR 1.25 [1.11-
1.42] 
Navalkele, 








































































































   CFP: 101 





































• VTr > 30: 13.33 
[3.13-56.77] 
Footnote: (6) – vancomycin consensus guidelines AKI definitions; (19) – RIFLE guidelines AKI 
definitions; (20) – Acute kidney injury network AKI definitions; (21) – KDIGO AKI guidelines; 
(22) – modified RIFLE for pediatrics; aHR – adjusted Hazard ratio; AKI – acute kidney injury; 
ANC – absolute neutrophil count; aOR – adjusted Odds ratio; BUN – blood urea nitrogen; CF – 
cystic fibrosis; CFP – cefepime; CKD – chronic kidney disease; CrCl – creatinine clearance; 
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CRO – ceftriaxone; ECMO – extracorporeal membrane oxygenation; ESRD – end-stage renal 
disease; HCT – hematopoietic cell transplant; KDOQI - Kidney Disease Outcomes Quality 
Initiative; KW – Kruskal-Wallis test; MEM – meropenem; N – number; OR – odds ratio; PICU – 
pediatric intensive care unit; PMH – past medical history; RRT – renal replacement therapy; SCr 





Table 1.3: Studies comparing AKI incidence between vancomycin combined with piperacillin-
tazobactam and vancomycin with other gram-negative alternatives 
Study Design Patient 
Population 
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• VAN+TZP vs 
VAN+CFP/ME
M: OR = 6.65 
[2.79-15.84] 
Footnote: (6) – vancomycin consensus guidelines AKI definitions; (19) – RIFLE guidelines AKI 
definitions; (20) – Acute kidney injury network AKI definitions; (21) – KDIGO AKI guidelines; 
(22) – modified RIFLE for pediatrics; aHR – adjusted Hazard ratio; AKI – acute kidney injury; 
ANC – absolute neutrophil count; aOR – adjusted Odds ratio; BUN – blood urea nitrogen; CF – 
cystic fibrosis; CFP – cefepime; CKD – chronic kidney disease; CrCl – creatinine clearance; 
CRO – ceftriaxone; ECMO – extracorporeal membrane oxygenation; ESRD – end-stage renal 
disease; HCT – hematopoietic cell transplant; KDOQI - Kidney Disease Outcomes Quality 
Initiative; KW – Kruskal-Wallis test; MEM – meropenem; N – number; OR – odds ratio; PICU – 
pediatric intensive care unit; PMH – past medical history; RRT – renal replacement therapy; SCr 





Table 1.4: Studies of AKI incidence based on beta-lactam infusion method 
Study Design Patient 
Population 
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(19) AKI Rate 
• EI: 21.6% 
• BI: 18.6% 
• p=0.104 
  







Table 1.4 (continued) 
Mousav









• Adult patients 
who received 
VAN+TZP for 
at least 48 h in 
combo, had 1 
VTr, and had 
SCr, ICU 
matched 1:1 







EI to BI 
VAN+TZ
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(19) AKI rate 
• 17.5% 
overall 
• EI: 17.9% 
• BI: 17.1% 
• p>0.99 
Footnote: (6) – vancomycin consensus guidelines AKI definitions; (19) – RIFLE guidelines AKI 
definitions; (20) – Acute kidney injury network AKI definitions; (21) – KDIGO AKI guidelines; 
(22) – modified RIFLE for pediatrics; aHR – adjusted Hazard ratio; AKI – acute kidney injury; 
ANC – absolute neutrophil count; aOR – adjusted Odds ratio; BUN – blood urea nitrogen; CF – 
cystic fibrosis; CFP – cefepime; CKD – chronic kidney disease; CrCl – creatinine clearance; 
CRO – ceftriaxone; ECMO – extracorporeal membrane oxygenation; ESRD – end-stage renal 
disease; HCT – hematopoietic cell transplant; KDOQI - Kidney Disease Outcomes Quality 
Initiative; KW – Kruskal-Wallis test; MEM – meropenem; N – number; OR – odds ratio; PICU – 
pediatric intensive care unit; PMH – past medical history; RRT – renal replacement therapy; SCr 






Table 1.5: Studies of AKI associated with vancomycin and piperacillin-tazobactam therapy 
Study Design Patient 
Population 
Groups N AKI Findings 
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• p = 0.041 
• aOR 4.55 
[1.11-
18.7] 
Footnote: (6) – vancomycin consensus guidelines AKI definitions; (19) – RIFLE guidelines AKI 
definitions; (20) – Acute kidney injury network AKI definitions; (21) – KDIGO AKI guidelines; 
(22) – modified RIFLE for pediatrics; aHR – adjusted Hazard ratio; AKI – acute kidney injury; 
ANC – absolute neutrophil count; aOR – adjusted Odds ratio; BUN – blood urea nitrogen; CF – 
cystic fibrosis; CFP – cefepime; CKD – chronic kidney disease; CrCl – creatinine clearance; 
CRO – ceftriaxone; ECMO – extracorporeal membrane oxygenation; ESRD – end-stage renal 
disease; HCT – hematopoietic cell transplant; KDOQI - Kidney Disease Outcomes Quality 
Initiative; KW – Kruskal-Wallis test; MEM – meropenem; N – number; OR – odds ratio; PICU – 
pediatric intensive care unit; PMH – past medical history; RRT – renal replacement therapy; SCr 





Chapter 2: Nephrotoxicity during Vancomycin Therapy in Combination with 
Piperacillin-Tazobactam or Cefepime 
Rutter WC, Cox JN, Martin CA, Burgess DR, Burgess DS. Nephrotoxicity during Vancomycin 
Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrobial Agents and 
Chemotherapy. 2016 Nov 28;AAC.02089-16. 
Abstract  
Background: Recent reports have demonstrated that vancomycin (VAN) may lead to an increase 
in acute kidney injury (AKI) when combined with anti-pseudomonal beta-lactams. This study 
compared the incidence of AKI associated with VAN plus piperacillin-tazobactam (TZP) or 
cefepime (CFP). 
Methods: This was a retrospective, matched cohort study at an academic medical center between 
September 2010 and September 2014 including adult patients receiving VAN+TZP or VAN+CFP 
for at least 48 hours and without severe chronic or structural kidney disease, dialysis, pregnancy, 
cystic fibrosis, or hospital transfer. The primary outcome was difference in AKI incidence between 
VAN+TZP and VAN+CFP, evaluated using RIFLE criteria. Patients were matched based on: age, 
sex, severity of illness, baseline creatinine clearance, hypotension, number of nephrotoxicity risk 
factors, and IV contrast exposure. 
Key Results: In total, 4,193 patients met all inclusion criteria (3,605 received VAN+TZP and 
588 received VAN+CFP). The unadjusted AKI incidence was 21.4% in patients receiving 
VAN+TZP compared to 12.6% in VAN+CFP(p<0.001). After matching, 1,633 patients receiving 
VAN+TZP and 578 patients receiving VAN+CFP were evaluated. The AKI incidence remained 
higher in patients receiving VAN+TZP compared to VAN+CFP (21.4% vs. 12.5%, p<0.0001). 
This trend remained true for all classifications of the RIFLE criteria. After controlling for 
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remaining confounders, VAN+TZP therapy was associated with 2.18 times the odds of AKI 
compared to VAN+CFP (95% CI 1.64-2.94) in logistic regression. 
Conclusions: AKI was significantly more common in patients receiving vancomycin in 
combination with piperacillin-tazobactam than cefepime. This finding reinforces the need for 





 Nephrotoxicity is a well-established adverse effect of vancomycin therapy. Risk factors 
for increased acute kidney injury (AKI) with vancomycin include: administration with 
concomitant nephrotoxic agents, prolonged treatment durations greater than 7 days, daily 
vancomycin doses of 4 grams or greater, and obesity.(6) The incidence of AKI with vancomycin 
varies widely and is estimated to be 1.0 to 42%.(3–5) Additionally, current methicillin-resistant 
Staphylococcus aureus (MRSA) treatment guidelines advocate using more aggressive dosing to 
combat increasing minimum inhibitory concentrations (MICs) associated with treatment 
failure.(7) 
 The addition of an anti-pseudomonal beta-lactam agent, such as piperacillin/tazobactam 
(TZP) or cefepime (CFP), is common in hospitalized patients. Beta-lactam antibiotics, primarily 
penicillin agents and early first generation cephalosporins, have been associated with acute 
interstitial nephritis (AIN).(8) Cases of cefepime-associated AIN have only been reported 
recently.(9) Recent literature suggests that the combination of vancomycin (VAN) and TZP is 
more nephrotoxic than VAN monotherapy and VAN combined with CFP.(12,23,24) However, 
the impact of TZP and VAN therapy may not be consistent among all patient populations.(28) No 
clear mechanism for the increase in AKI incidence in combination therapy is known. The rate of 
AKI associated with VAN+TZP therapy in previous studies ranges from 9.5% to 34.8% in a 
variety of patient populations.(11–13,17,23,24,28,33,34) 
 The objective of this study was to evaluate the incidence of AKI between two commonly 
prescribed antibiotic regimens in hospitalized patients, piperacillin/tazobactam with vancomycin 
and cefepime with vancomycin. 
Methods 
Study Design and Setting 
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 This was a single-center, retrospective matched cohort study of patients admitted to 
University of Kentucky HealthCare Medical Center (UKMC) between September 1, 2010 and 
September 1, 2014. This study was reviewed and approved by the UK Institutional Review 
Board.  
 Patients received either the combination of VAN+TZP or VAN+CFP. VAN was dosed 
according to institutional policy.(43) Pharmacokinetic levels were monitored by pharmacists and 
dosage adjustments were made as clinically appropriate. 
Data source 
 Patient data were collected from the University of Kentucky Center for Clinical and 
Translational Science Enterprise Data Trust (EDT). The EDT contains clinical data from the 
inpatient population of UKMC from 2006 to present. Data stored in the EDT includes: 
demographics, financial classification (Medicare, Medicaid, private insurance), provider-level 
detail (service line), medical diagnosis (International Classification of Diseases 9 [ICD-9] codes), 
medical procedures (Current Procedural Terminology [CPT] codes), lab tests and results, 
medication administration details, visit details (age, length of stay, etc.), and vital signs.  
Patient selection  
 Patients were included if they were 18 years of age or older, hospitalized at UKMC 
between September 1, 2010 and September 1, 2014, and received either of the studied 
combinations for a minimum of 48 hours with at least 48 hours of overlapping antibiotic therapy. 
Patients were excluded if they had a past history of chronic kidney disease (Stage 3 or higher, via 
ICD-9 code), structural kidney disease, required dialysis, experienced AKI prior to antibiotic 
administration, experienced AKI within 48 hours of therapy initiation or greater than 7 days after 
the last dose of antibiotics, or had underlying renal dysfunction at the time of antibiotic initiation 
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(defined as an initial creatinine clearance ≤ 30 mL/min). Patients were also excluded from the 
study if they were pregnant, were diagnosed with cystic fibrosis, or were transferred from another 
hospital. Patients were followed throughout their stay until time of discharge. 
Data collection 
 Data collected for each patient included: demographic data, visit details (length of stay, 
admitting and primary diagnosis codes), severity of underlying illness as defined by the Charlson 
Comorbidity Index (CCI),(44) all serum creatinine levels drawn per visit, receipt of other 
nephrotoxic agents (listed in Table 1), and any receipt of intravenous contrast agents. The initial 
serum creatinine concentration was used as the patient’s baseline. Hypotension was defined as a 
diagnosis of hypotension by ICD-9 coding, mean arterial pressure less than 60mmHg, or use of 
vasopressor or inotrope therapy to maintain adequate perfusion. Contrast exposure was defined as 
exposure to an imaging procedure in which contrast is indicated, via Healthcare Common 
Procedure Coding System (HCPCS) codes. Doses and dosing schedules of studied antibiotics and 
all vancomycin serum concentrations were obtained. Antibiotic days of therapy were defined as 
receipt of at least one dose of antibiotic per day. 
Study Outcomes 
 The primary outcome was the difference in AKI incidence between VAN+TZP and 
VAN+CFP. Secondary outcomes were AKI incidence based on dosing schemes and duration of 
therapy, time to AKI from initiation of therapy, hospital length of stay, and mortality (defined as 
in-hospital mortality and transfer to a hospice facility). 
 Development of AKI was evaluated using Risk, Injury, Failure, Loss of kidney function, 
and End-stage kidney disease (RIFLE) criteria.(19) The RIFLE criteria consists of three severity 
classes (risk, injury, failure) and two outcomes classes (loss of kidney function, end stage kidney 
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disease). Risk was defined as a decrease in glomerular filtration rate (GFR) of at least 25%, injury 
was a decrease in GFR of at least 50%, and failure was defined as decrease in GFR of 75% or 
more. The outcomes classes require diagnosis based on duration of renal dysfunction and were 
not evaluated in this study. GFR was estimated with the adjusted Cockcroft-Gault equation.(45)  
Patient Matching 
 Antibiotic indications were unknown and antibiotic choice was prescriber specific, 
therefore, propensity scores for each patient were estimated to control for potential bias. Patients 
in the VAN+TZP group were matched three-to-one with the VAN+CFP group using a nearest 
neighbor propensity score algorithm(46) without replacement and caliper of 0.2 based on the 
following factors: age, gender, CCI, hypotension exposure, risk factor group (defined by number 
of nephrotoxic exposures: 0, 1, 2, 3, and ≥ 4), baseline creatinine clearance, and receipt of IV 
contrast. Additionally, patients were matched exactly on gender, hypotension exposure, risk 
factor group and IV contrast administration. 
Statistical Analysis 
 Characteristics between groups were described using basic descriptive statistics with 
continuous variables being compared by Student’s t-test or Wilcoxon Rank-Sum test and 
categorical variables compared with Chi-Square test or Fisher’s exact test, as appropriate. The 
average treatment effect was calculated by taking the average difference in incidence of AKI in 
1,000 counterfactual simulations after fitting logistic regression models based on each treatment 
group to the opposite population.(47,48) Following propensity score matching, simple logistic 
regression was performed on all variables. In addition to remaining covariate imbalances in the 
matched cohort, the variables with significant associations with AKI in univariate regressions 
were incorporated into the multivariate logistic regression. All statistical analysis was completed 
with RStudio v0.98 running R v3.1.2 (R Foundation for Statistical Computing, Vienna, 
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Austria).(49,50) Model fit was assessed with the standardized Hosmer-Lemeshow test(51) and C-
statistic. All tests were two-tailed and significance was defined at an alpha of 0.05. 
Results 
 Records for 10,141 patients were screened. After exclusion criteria were applied (Figure 
1), 4,193 patients were analyzed for all outcomes. Of 3,605 patients receiving VAN+TZP who 
were evaluated in the unmatched analysis, 1,633 patients were matched to 578 patients of 588 
(>98% matched) in the VAN+CFP group. Of the 152 patients excluded due to an AKI occurring 
within 48 hours after treatment initiation, 133 were from the VAN+TZP group (3.6% of 
VAN+TZP population) and 19 were from the VAN+CFP group (3.1% of VAN+CFP population). 
This difference was not statistically significant (p=0.68), suggesting that the assumption that 
AKIs occurring prior to 48 hours of treatment are independent of drug selection. 
 At baseline, VAN+TZP group was older (51.5±16.0 vs. 49.4±17.0 years, p=0.006) and 
more likely to be male (60.4% vs. 55.4%, p=0.03). Severity of illness was similar between 
groups, while patients in the VAN+CFP group had higher baseline CrCl (101 [IQR 74-125] vs 97 
[77-133] mL/min, p=0.01). Significant differences in nephrotoxic exposures existed between 
groups (Table 1). The median number of nephrotoxic risk factors in each group was 1 (IQR 0-2, 
p=0.2); however, VAN+CFP patients had more patients with ≥ 4 risk factors (7.8 vs. 3.8%, 
p=0.0003). Contrast exposure was more frequent in the VAN+CFP group (58.3 vs 45.3%, p 
<0.0001). Among patients who had VAN concentrations obtained, no significant difference in 
VAN exposure was found. However, the VAN+CFP group had statistically higher average daily 
VAN doses. Antibiotic days of therapy were similar between groups; however, due to the large 
sample size and statistical power, the p-values are reported as significant. 
 AKI incidence was significantly higher in patients receiving VAN+TZP compared to 
patients receiving VAN+CFP (21.4% vs. 12.6%, p<0.0001). Risk (11.7 vs 7.5%; p = 0.003) and 
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injury (6.8 vs. 4.6%; p = 0.004) classifications were more common in the VAN+TZP group. 
Failure classification was not significantly different between groups (Table 2).  
 Following matching, baseline covariates were well balanced with the remaining 
imbalances being present in acyclovir exposure, aminoglycoside exposure, and average daily 
VAN dose (Table 1). AKI remained more common in the VAN+TZP group (21.4% vs 12.5%, 
p<0.0001) with all levels of the RIFLE criteria being more common in the VAN+TZP group 
(Table 2). VAN+CFP treatment was associated with an average treatment effect of 10.1% (95% 
CI; 7.8 to 12.2%) reduction in AKI incidence compared to VAN+TZP.   
 After controlling for additional confounders present after matching in the multivariate 
regression analysis (Table 3), VAN+TZP was associated with 2.18 times the odds of AKI when 
compared to VAN+CFP (95% CI, 1.64-2.94). Other independent risk factors for AKI included 
dehydration and exposure to acyclovir, amphotericin B, or loop diuretics. VAN doses between 3 
and 4 g daily were associated with an increase in AKI (aOR 1.61; 95% CI 1.11-2.32) compared to 
those receiving between 1000 and 1500 mg per day. Duration of VAN treatment of at least 7 days 
was associated with 1.47 (95% CI 1.14-1.89) times the odds of AKI compared to those receiving 
VAN for less than 7 days. No evidence of overfitting was found (Hosmer-Lemeshow p-value = 
0.53) and the model was adequately predictive with a c-statistic of 0.7. 
 Analyses of secondary objectives are summarized in Table 4. There were no significant 
differences in length of stay or mortality. AKI occurred earlier in VAN+TZP patients in both 
cohorts The most common TZP dosing regimen in the VAN+TZP group was 3.375 g every 6 
hours (55.6%) with 4.5 g every 6 hours being the second most common (30.4%). AKI incidence 
was significantly higher in patients receiving TZP 4.5g every 6 hours compared to patients 
receiving TZP 3.375g every 6 hours (24.3% vs. 20.1%, p=0.008), but was only significant for risk 
when stratified based on RIFLE. The most common CFP regimen was 2 g every 8 hours (64.8%) 
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with 2 g every 12 hours being the second most common (23.8%). There was no difference in AKI 
among patients receiving the highest CFP dosing regimen compared to all other regimens (13.4% 
vs. 11.1%; p=0.5). 
Discussion 
 In this large retrospective review of patients receiving VAN-TZP or VAN-CFP, we found 
that the incidence of AKI was significantly higher in patients receiving VAN and TZP 
concomitantly. To our knowledge, this is the largest study to date that examines the difference in 
AKI incidence among patients treated with VAN and CFP or TZP. We found the AKI rate in 
patients treated with VAN-TZP to be 21.4% compared to the range of 9.5 to 34.8% found in the 
current literature.(11–13,17,23,24,28,33,34) The AKI incidence in the VAN-CFP group was 
similar to previous reports of 12.5%.(23,24) Of note, our findings in the VAN-CFP group were 
significantly lower than the Hammond, et al study (12.5 vs. 28.8%),(28) likely due to dissimilar 
patient populations. 
 In a 2014 review of 139 diabetic patients with osteomyelitis, VAN-TZP was associated 
with 29.3% incidence of acute renal failure (defined as an increase of 0.5 mg/dL in serum 
creatinine or 50% increase from baseline) compared to 13.3% in the VAN-CFP group 
(p=0.099).(23) Gomes and colleagues (2014) conducted a retrospective review of 224 patients 
receiving the combination of VAN and TZP or CFP.(24) In univariate analysis, VAN-TZP was 
associated with an AKI incidence of 34.8% compared to 12.5% for VAN-CFP (p<0.0001). 
Additionally, they found that TZP was an independent predictor of AKI in multiple logistic 
regression modelling. Finally, in a review of 122 critically ill patients, Hammond et al found no 
difference in AKI incidence among patients treated with VAN-TZP and VAN-CFP (32.7 vs 
28.8%, respectively; p=0.647).(28)  
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 Small sample sizes and lack of statistical power severely limit the application of the 
previous studies. In addition, aside from the Gomes study, confounding was not adequately 
addressed, further limiting their application.  Our study attempted to rectify these issues by 
including a larger number of patients (4,193 vs. 485 combined) and utilizing a propensity score 
matching algorithm to control for confounders. The difference in AKI incidence was maintained 
after controlling for confounders suggesting that the use of TZP is associated with increasing 
rates of AKI when compared to CFP when combined with VAN. 
 Vancomycin exposure was statistically different in both the unmatched and matched 
cohorts; however, the difference between median daily vancomycin doses is likely clinically 
irrelevant. To control for the statistical imbalance in doses greater than 4,000 mg per day, we 
included vancomycin dose in the multivariate regression analysis and found that vancomycin 
dose is largely uncorrelated with AKI incidence, with the exception of doses between 3,000 and 
3,999 mg per day. Additionally, we found that vancomycin duration of therapy greater than 7 
days was associated with higher rates of AKI, independent of treatment group. This may be 
related to the overall vancomycin exposure and warrants further study. However, when an 
interaction term between vancomycin dose and duration of therapy greater than 7 days was 
included in the multivariate logistic regression model, no significant interaction was found. 
Vancomycin troughs were analyzed, but no significant difference was found between groups and 
no association with AKI was found. This may be due to many patients not having trough values 
obtained; however, there were no significant differences in the number of troughs obtained 
between VAN+TZP or VAN+CFP in both unmatched and matched cohorts. 
 In our secondary outcomes, there was a numerically higher rate of in-hospital mortality 
among patients in the VAN+CFP group which did not reach statistical significance. This finding 
warrants further study; however, VAN+CFP patients had numerically higher rates of hypotension 
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which may indicate higher rates of acute illness not captured by surrogate variables and a 
predisposition to experience mortality. 
 We found several factors aside from treatment group that were independently associated 
with AKI incidence. This emphasizes that kidney injury is multifactorial. Additionally, use of 
other nephrotoxic agents may indicate underlying conditions not captured through our data 
analysis, such as use of loop diuretics in patients with uncontrolled heart failure, that may 
increase the risk of AKI independent of antibiotic selection. 
 This study has several limitations which must be addressed. Primarily, due to the 
retrospective nature of this analysis, demonstrating causality is difficult. However, several 
mechanisms to make the investigation more rigorous were applied, such as propensity score 
matching. In addition, rather than using parameter estimates from matched cohorts, counterfactual 
simulations were utilized to predict the average treatment effect on AKI incidence between 
groups.  We employed a rigorous study design that controlled for major confounders of AKI, 
such as concomitant nephrotoxic exposure, hypotension, and previous renal disease. Nephrotoxic 
potential of agents was assumed to be equal, which is not necessarily true. Additionally, the 
binary representation of nephrotoxic exposure does not describe the amount of the agent received; 
as such, our estimations of AKI odds may be artificially elevated. Finally, data was collected 
retrospectively from the electronic medical record and is subject to inaccuracies documented in 
the chart; however, any bias introduced should be nondifferential. 
 In conclusion, in this large retrospective study, we found that AKI incidence among 
patients treated with a combination of piperacillin-tazobactam and vancomycin was significantly 
higher than in patients who were treated with cefepime and vancomycin. This finding remained 
after propensity score matching and after controlling for remaining imbalances in covariates. A 
mechanism for the increase in AKI among patients treated with piperacillin-tazobactam compared 
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Figures and tables 
 
Table 2.1: Patient Demographic and Clinical Characteristics 
Variable 
Unmatched Cohort Characteristics Matched Cohort Characteristics 
VAN+TZP 
n = 3605 
VAN+CFP 
n = 588 
p value VAN+TZP 
n = 1633 
VAN+CFP 
n = 578 
p value 
Age (years)a 51.5 ±16 49.4±17 0.006 49.7±15.7 49.4±17 0.7 




3 (1-6) 3 (1-5) 0.2 3(1-5) 3 (1-5) 1 
Baseline ClCr 
(mL/min)b 








Hypotension 946 (26.2) 190 (32.3) 0.002 479 (29.3) 186 (32.2) 0.2 
Dehydration 220 (6.1) 36 (6.1) 1 98 (6.0) 34 (5.9) 1 
Nephrotoxic 
Drug Exposure 2190 (60.7) 349 (59.4) 0.5 939 (57.5) 340 (58.8) 0.6 
ACEI/ARB 841 (23.3) 139 (23.6) 0.9 370 (22.7) 135 (23.4) 0.8 
Acyclovir 70 (1.9) 33 (5.6) <0.0001 28 (1.7) 29 (5.0) <0.0001 
Aminoglycosid
e 473 (13.1) 101 (17.2) 0.01 209 (12.8) 98 (17.0) 0.02 
Amphotericin 
B 63 (1.7) 16 (2.7) 0.1 27 (1.7) 15 (2.6) 0.2 
Calcineurin 
Inhibitor 114 (3.2) 19 (3.2) 1 35 (2.1) 19 (3.3) 0.2 
Contrast Dye 1632 (45.3) 343 (58.3) <0.0001 921 (56.4) 336 (58.1) 0.5 
Foscarnet 9 (0.2) 1 (0.2) 1 3 (0.2) 1 (0.2) 1 
Loop diuretic 1121 (31.1) 166 (28.2) 0.2 496 (30.4) 160 (27.7) 0.2 
NSAID 547 (15.2) 88 (15.0) 0.9 242 (14.8) 83 (14.4) 0.8 
Sulfonamide 66 (1.8) 9 (1.5) 0.7 27 (1.7) 9 (1.6) 1 
Tenofovir 21 (0.6) 4 (0.7) 0.8 8 (0.5) 4 (0.7) 0.5 
Number of risk 
factors 
  0.0003   0.3 
0 1132 (31.4) 177 (30.1)  531 (32.5) 177 (30.6)  
1 1163 (32.3) 190 (32.3)   528 (32.3) 187 (32.4)   
2 795 (22.1) 113 (19.2)   335 (20.5) 113 (19.6)   
3 379 (10.5) 62 (10.5)   160 (10.4) 60 (10.4)   
≥4 136 (3.8) 46 (7.8)   79 (7.1) 41 (7.1)   
Daily VAN 


















Table 2.1 (continued) 
Max VTr   0.3   0.7 
<10mcg/mL 438 (20.8) 77 (21.1)  213 (21.8) 76 (21.1)  
10-15mcg/mL 507 (24.1) 100 (27.4)   231 (23.7) 98 (27.2)   
15-20mcg/mL 521 (24.8) 88 (24.1)   239 (24.9) 87 (24.2)   





5 (4-8) 5 (4-8) 0.05 5 (4-8) 5 (4-8) 0.4 
Combination 
Therapy 3 (3-5) 4 (3-6) 0.001 4 (3-5) 4 (3-6) 0.008 
CFP or TZP 
Therapy 5 (3-7) 5 (3-7) 0.8 5 (3-7) 5 (3-7) 0.2 
VAN Therapy 4 (3-6) 4 (3-7) <0.0001 4 (3-6) 4 (3-7) <0.0001 
 
Footnote for Table 2.1: 
Data are number (percentage) unless otherwise indicated; aMean ± standard deviation; bMedian 
(IQR). ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; 
ClCr = creatinine clearance; CFP = cefepime; NSAID = non-steroidal anti-inflammatory drug; TZP 




Table 2.2: Incidence of AKI in unmatched and matched cohorts 
Outcome 











Any AKI 771 (21.4%) 74 (12.6%) <0.0001 349 (21.4%) 72 (12.5%) <0.0001 
Risk 422 (11.7%) 44 (7.5%) 0.003 179 (11.0%) 42 (7.3%) 0.01 
Injury 244 (6.8%) 21 (3.6%) 0.004 113 (6.9%) 21 (3.6%) 0.006 
Failure 105 (2.9%) 9 (1.5%) 0.08 57 (3.5%) 9 (1.6%) 0.03 
Footnote for Table 2.2: 
Data are number (percentage); CFP = cefepime; TZP = piperacillin-tazobactam; VAN = 
vancomycin.   
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Table 2.3: Multivariate regression results in matched cohort 
Covariate Odds Ratio Confidence 
Interval 
p value 
Treatment Group    
VAN+TZP (reference) 
VAN+CFP 2.18 1.64-2.94 <0.001 
VAN Dose (mg/day)    
<1000mg 0.53 0.16-1.39 0.3 
1000-1499mg 1.01 0.72-1.42 0.9 
1500-1999mg (reference) 
2000-2499mg 1.08 0.79-1.48 0.6 
2500-2999mg 1.16 0.81-1.65 0.4 
3000-3999mg 1.61 1.11-2.32 0.01 
≥4000mg 1.3 0.5-3.05 0.6 
VAN Duration of Therapy ≥ 7 
days 1.47 1.14-1.89 0.003 
Acyclovir Exposure 2.22 1.17-4.07 0.01 
Amphotericin B Exposure 2.25 1.14-4.41 0.02 
Loop Diuretic Exposure 2.78 2.22-3.50 <0.001 
Calcineurin Inhibitor Exposure 1.62 0.85-2.98 0.1 
Dehydration Exposure 1.81 1.18-2.72 0.005 
Footnote for Table 2.3: 
CFP = cefepime; TZP = piperacillin-tazobactam; VAN = vancomycin.   
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Table 2.4: Secondary endpoints 
Footnote for Table 2.4: 
Data are number (percentage) unless otherwise indicated; aMedian (IQR). CFP = cefepime; TZP = 
piperacillin-tazobactam; VAN = vancomycin.  
  









Time to AKIa 5 (3-9) 8 (4-16.8) 0.0006 5 (3-9) 8 (4-17) 0.0004 
Hospital Length 
of Staya 
8 (4-15) 8 (4-17) 0.08 8 (4-15) 8 (5-17) 0.9 
In-hospital 
Mortality 
276 (7.7%) 53 (9.0%) 0.3 113 (6.9%) 53 (9.2%) 0.09 
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Figure 2.1: Patient selection diagram 
 
Footnote for Figure 2.1: 
CrCl=creatinine clearance; CFP = cefepime; OSH = outside hospital; TZP = piperacillin-
tazobactam; VAN = vancomycin.  
10,141 Patients received VAN+TZP or VAN+CFP 
4,193 Patients receiving VAN+TZP or VAN+CFP 
included in final population 
• VAN+TZP N = 3,605 
• VAN+CFP N = 588 
5,948 excluded for:  
• 3,146 Transferred from OSH 
• 1,739 Received < 48 hrs of combination 
therapy 
• 493 discharged in < 48 hrs 
• 152 AKI occurred within 48 hrs of 
treatment initiation 
• 109 Baseline CrCl < 30 mL/min 
• 108 AKI prior to treatment 
• 106 AKI occurred > 7 days after therapy 
completed 
• 77 No serum creatinine levels available 
• 14 Inappropriately low TZP doses 
• 4 Age < 18 years 
2,211 Patients receiving VAN+TZP or VAN+CFP 
included in matched population 
• VAN+TZP N = 1,633 
• VAN+CFP N = 578 
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Chapter 3: Incidence of Acute Kidney Injury Among Patients Treated with 
Piperacillin-Tazobactam or Meropenem in combination with Vancomycin 
Rutter WC, Burgess DS. Incidence of Acute Kidney Injury Among Patients Treated with 
Piperacillin-Tazobactam or Meropenem in combination with Vancomycin. Antimicrobial Agents 
and Chemotherapy (under review) 
Abstract  
Acute kidney injury increases during empiric antimicrobial therapy with the combination of 
piperacillin-tazobactam (TZP) and vancomycin (VAN) when compared to monotherapy or the 
combination of cefepime and VAN. Limited data regarding the impact of meropenem (MEM) 
combined with VAN exist. This study examined the AKI incidence among patients treated with 
MEM+VAN or TZP+VAN. Data were collected from the University of Kentucky Center for 
Clinical and Translational Science Enterprise Data Trust from September 2007 through October 
2015. Adults without previous renal disease, who received MEM+VAN or TZP+VAN for at least 
2 days were included. Inverse probability of treatment weighting was utilized to control for 
differences between groups. In total, 10,236 patients met inclusion criteria, with 9,898 receiving 
TZP+VAN and 338 receiving MEM+VAN. AKI occurred in 15.4% of MEM+VAN patients 
compared to 27.4% of TZP+VAN patients (p<0.001). TZP+VAN was associated with increased 
AKI compared to MEM+VAN (OR=2.53; 95%CI 1.82-3.52), after controlling for confounders. 
MEM+VAN should be considered an appropriate alternative therapy to TZP+VAN if 
nephrotoxicity is a major concern. The results of this study demonstrate that judicial use of 




 Empiric combination antimicrobial therapy is critical for the treatment of infections and 
sepsis.(54,55) Piperacillin-tazobactam (TZP) is a beta-lactam/beta-lactamase inhibitor 
combination that is frequently used concomitantly with vancomycin (VAN) for empiric coverage 
of infections. This combination provides coverage of clinically important gram-negative and 
gram-positive organisms. While generally considered safe, recent literature suggests a significant 
increase in the incidence of nephrotoxicity with the TZP+VAN combination when compared to 
either agent as monotherapy or to other empiric combination.(11,12,18,24,56,57) However, this 
phenomenon has not been noted in all studies.(23,28)  
 While studies have demonstrated that TZP+VAN has significantly increase AKI 
incidence compared to cefepime and VAN,(24,27,57) only one study to date has attempted to 
compare TZP+VAN to meropenem (MEM) and VAN.(58) In this study, Al Yami was unable to 
find a significant difference in AKI incidence among patients receiving TZP+VAN compared to 
MEM+VAN. However, this is limited by small sample size and lower than anticipated overall 
AKI incidence.  
 The current study was designed to determine if a difference in AKI incidence exists 
between TZP or MEM when combined with VAN, with the hypothesis that TZP+VAN would 
exhibit increased AKI incidence compared to MEM+VAN. 
Methods 
 This was an IRB-approved, retrospective cohort study of adult patients admitted to the 
University of Kentucky Medical Center (UKMC) between September 2007 and October 2015. 
Patients were included if they received MEM or TZP in combination with VAN for at least 2 
days. Patients with a past medical history of cystic fibrosis, chronic kidney disease, or 
hemodialysis were excluded. Additionally, pregnant or breastfeeding patients were excluded.  
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 Data were obtained from the University of Kentucky Center for Clinical and 
Translational Science Enterprise Data Trust (EDT). The EDT is an electronic repository of 
clinical data collected at UKMC and contains a copy of the digital health record. The EDT is 
updated nightly and contains: demographics, financial classification, provider-level detail, 
medical diagnosis, medical procedures, lab tests and results, medication administration details, 
visit details, and vital signs. Data collected included: patient demographics and visit information, 
antimicrobial drug administration data, concomitant nephrotoxin administration, laboratory 
results, and baseline comorbidity information. 
 The primary outcome of this study was the incidence of AKI as defined by the 
glomerular filtration rate (GFR) criteria of Risk, Injury, Failure, Loss, and End-stage (RIFLE) 
criteria.(19) GFR was estimated with the adjusted Cockcroft-Gault equation(45) at baseline and 
throughout each patient’s hospitalization. AKI that occurred before treatment, within 48 hours 
treatment initiation, or after 7 days after treatment discontinuation were excluded. Secondary 
outcomes included length of hospitalization and inpatient mortality, defined as mortality on date 
of discharge or transfer to hospice.  
 Severity of baseline comorbidity was assessed with the Charlson comorbidity index 
(CCI).(44) Hypotension was defined as mean arterial pressure < 65 mmHg or exposure to 
vasopressors. Concomitant nephrotoxin exposure was assessed as receiving at least one dose of 
the agent within 24 hours of initiation of TZP or MEM through the duration of therapy. 
Concomitant nephrotoxins analyzed included: aminoglycosides, amphotericin B, angiotensin 
converting enzyme inhibitors, angiotensin II receptor antagonists, IV radiocontrast dye, loop 
diuretics, non-steroidal anti-inflammatory drugs, calcineurin inhibitors, and vasopressors.  
 Basic descriptive statistics were performed. Continuous variables were assessed with the 
Student’s t test or Wilcoxon test as appropriate. Categorical variables were assessed with a chi-
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square or Fisher’s exact test. Following bivariable analysis, variables that significantly differed 
between groups were included in an inverse probability of treatment model to generate weights 
for the final logistic regression model of AKI odds.(59) Statistical significance was defined as 
alpha 0.05. All data analysis and statistical procedures were conducted with R v3.3.2 (Vienna, 
Austria) and RStudio v0.99.903 (Boston, MA). (49,50) 
Results 
 In total, 10,236 patients met all inclusion criteria, with 338 receiving MEM+VAN and 
9,898 receiving TZP+VAN. Mean age was 53.7 (±16.4) years of age and 58.8% of patients were 
males (Table 1). At baseline the MEM+VAN cohort tended to be more ill than those in the 
TZP+VAN cohort (CCI 4 [2-6] vs 3 [1-7], p=0.014) and more MEM+VAN patients had baseline 
CrCl ≥ 90 mL/min (58.5% vs 50.6%, p = 0.011). Significantly more patients had diabetes 
mellitus (34.0% vs. 28.0%, p=0.018) and hypotension (60.9% vs. 51.8%, p = 0.001) in the 
MEM+VAN group with a trend toward significance in heart failure. The MEM+VAN cohort 
were more likely to be exposed to concomitant aminoglycosides (3.5% vs. 1.5%, p = 0.007), 
calcineurin inhibitors (6.5% vs. 3.7%, p = 0.011), and vasopressors (16.3% vs. 11.3%, p = 0.006). 
 AKI occurred in 2,765 (27.0%) patients overall, with AKI being more common in the 
TZP+VAN group (27.4% vs. 15.4%, p<0.0001). Risk and injury stratifications were significantly 
more common among the TZP+VAN cohort (15.3% vs. 9.8%, p = 0.006, and 7.8% vs. 3.5%, p = 
0.005, respectively; Figure 1). There was no significant difference in failure stratification (4.2% 
vs. 2.1%, p = 0.068). 
In inverse probability weighted logistic regression, TZP+VAN treatment was associated with a 
significant increase AKI odds compared with MEM+VAN (odds ratio = 2.53; 95% confidence 
interval 1.82 – 3.52). 
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 Secondary endpoints did not differ between treatment group with 10.3% and 11.6% of 
patients in the MEM+VAN and TZP+VAN group experiencing mortality, respectively. Median 
length of stay was similar between cohorts (MEM+VAN 9 [6-15] vs. TZP+VAN 10 [5-18] days, 
p=0.482). 
Discussion 
 In this large retrospective study of AKI among patients receiving meropenem or 
piperacillin-tazobactam in combination with vancomycin, we found that combination therapy 
with piperacillin-tazobactam is associated with significant increases in AKI incidence when 
compared to meropenem combination therapy. To our knowledge, this is the largest study to 
examine this comparison.  
 Previous investigations of AKI related to TZP+VAN therapy have shown incidence 
ranges from 9.5% to 34.8%.(24,33) Our findings are consistent with this estimate with 27.4% of 
TZP+VAN patients experiencing an AKI during therapy. The rate of MEM+VAN-related AKI in 
the present study differ significantly from the study by Al Yami (15.4% vs. 5.33%).(58) This may 
be due to differences in patient populations or AKI definitions. It is important to note that our 
study included a heterogeneous population of critically ill and general medicine patients. 
Additionally, patients in the TZP+VAN cohort in the Al Yami study had lower AKI incidence 
compared to previous literature (7.41%). Our study differs by having a larger patient sample 
(10,236 vs. 183) than the previous study on this topic, ensuring statistical power to detect a 
difference in AKI incidence and control for confounding.  
 The current study has several limitations. This was a retrospective study, which limits the 
causal relationship between drug exposure and outcome; however, we established a temporal link 
and restriction that links the incidence of AKI with administration of the medications being 
studied. Additionally, to mimic randomization and limit the impact of confounders, we performed 
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inverse probability weighting to create a balanced pseudo-population on which the regression 
analysis was performed. Sensitivity analyses suggest that the inverse probability scores were 
adequate. Nephrotoxin exposures were assessed as binary variables, which does not account for 
any dosing frequency or intensity. This may change the estimate of the confounding variables; 
however, sensitivity analyses using nephrotoxin days of therapy, suggests that the binary 
treatment is acceptable. Further work to identify optimal handling of concomitant nephrotoxins is 
needed. Duration of beta-lactam infusion was not assessed in this study; however, previous 
studies demonstrate that AKI incidence is not associated with duration of infusion.(33,34,60) 
Despite the rigorous study design, there is a possibility of uncontrolled confounding, as unknown 
confounders may remain.  
 In conclusion, we found a significant increase in AKI with TZP+VAN treatment 
compared to MEM+VAN treatment. This finding further underscores the need for judicial use of 
TZP+VAN as empiric antimicrobial therapy. Meropenem may be an acceptable alternative to 
piperacillin-tazobactam when nephrotoxicity is a major concern. Further studies of alternative 
combination therapies are needed to determine what alternatives have the best safety profile. 
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Tables and Figures 
Table 3.1: Patient characteristics 
Variable 
Cohort  
n = 10,236 
VAN+MEM  
n = 338 
VAN+TZP 
n = 9,898 
p value 
Age (mean[SD]) 53.7 (16.4) 52.3 (16.7) 53.8 (16.4) 0.122 
Gender       0.003 
Male 6019 (58.8) 172 (50.9) 5847 (59.1)   
Female 4217 (41.2) 166 (49.1) 4051 (40.9)   
Caucasian 9201 (89.9) 317 (93.8) 8884 (89.8) 0.020 
Weight (mean[SD]) 83.3 (24.5) 84.1 (24.7) 83.3 (24.5) 0.591 
BMI (mean[SD]) 28.6 (16.8) 29 (8.3) 28.6 (17.0) 0.431 
Charlson comorbidity  
index (median [IQR]) 










Baseline CrCl group       0.011 
30-59 mL/min 2015 (19.7) 61 (18.0) 1954 (19.7)   
60-89 mL/min 3018 (29.5) 79 (23.4) 2939 (29.7)   
>=90 mL/min 5203 (50.8) 198 (58.5) 5005 (50.6)   
Comorbidities         
Diabetes mellitus 2886 ( 28.2) 115 (34.0) 2771 (28.0) 0.018 
Heart failure 1549 (15.1) 64 (18.9) 1485 (15.0) 0.057 
Hypertension 5530 (54.0) 192 (56.8) 5338 (53.9) 0.324 





Table 3.1 (continued) 
Concomitant  
nephrotoxins 
        
Aminoglycoside 1685 (16.5) 60 (17.7) 1625 (16.4) 0.565 
Amphotericin B 163 (1.6) 12 (3.5) 151 (1.5) 0.007 
ACE inhibitor 2029 (19.8) 63 (18.6) 1966 (19.9) 0.627 
ARB 303 (3.0) 9 (2.7) 294 (3.0) 0.869 
Contrast dye 522 (5.1) 38 (11.2) 484 (4.9) <0.001 
Loop diuretic 3708 (36.2) 105 (31.1) 3603 (36.4) 0.051 
NSAID 1558 (15.2) 43 (12.7) 1515 (15.3) 0.221 
Calcineurin inhibitor 386 (3.8) 22 (6.5) 364 (3.7) 0.011 





Figure 3.1: AKI rates among patients treated with piperacillin-tazobactam or meropenem in 





















Chapter 4: Acute kidney injury in patients treated with IV beta-lactam/beta-
lactamase inhibitor combinations 
Rutter WC, Burgess DS. Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-
Lactamase Inhibitor Combinations. Pharmacotherapy: The Journal of Human Pharmacology 
and Drug Therapy. 2017 May;37(5):593–8. 
Abstract  
Study Objective 
 Increased acute kidney injury incidence has been reported in patients receiving 
piperacillin-tazobactam (TZP) therapy compared to other beta-lactams. This study sought to 
determine if the addition of beta-lactamase inhibitors impact AKI incidence by comparing 
patients treated with TZP or ampicillin-sulbactam (SAM). 
Design  
 Retrospective cohort study 
Setting 
 Large academic tertiary care hospital 
Patients 
 Overall, 2,448 patients received TZP (N=1,836) or SAM (N=612) for at least 48 hours 
between 9/1/2007 and 9/30/2015. Patients were excluded for: pregnancy, cystic fibrosis, chronic 
kidney disease, and initial creatinine clearance (CrCl) < 30 mL/min. Patients were matched on: 
Charlson Comorbidity Index (CCI), initial CrCl, hypotension exposure, various nephrotoxic drug 
exposures, history of diabetes, heart failure, and hypertension. 
Measurements and Main results 
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  AKI occurred in 265 patients and was similar among both groups (TZP 11.4% vs SAM 
9.2%; p=0.14). After stratification by vancomycin exposure, and controlling for confounders, 
there was no difference in AKI odds between SAM and TZP (adjusted OR 0.87, 95% CI 0.59-
1.25). The addition of vancomycin to TZP increased odds of AKI compared to TZP alone 
(adjusted OR 1.77, 95% CI 1.26-2.46). Concomitant SAM and VAN therapy was not associated 
with a significant increase in AKI compared to SAM monotherapy (adjusted OR 1.01, 95% CI 
0.48-1.97). 
Conclusion 
 AKI rates were similar between TZP and SAM in a matched cohort. The addition of a 
beta-lactamase inhibitor is not likely the mechanism in the observed increased rates of AKI in 





 Piperacillin-tazobactam in combination with vancomycin has been associated with 
elevated rates of AKI in many small retrospective studies. The AKI incidence ranges from 9.5 to 
34.8%, depending on the target population.(12,13,17,23,24,28,33,34) The most common 
comparator agent has been cefepime(23,24,28), as piperacillin-tazobactam and cefepime share a 
similar niche in antipseudomonal therapy. In these comparisons, piperacillin-tazobactam is 
associated with higher rates of AKI. The mechanism for the increased AKI incidence observed is 
unknown; however, piperacillin-tazobactam is unique in that it contains a beta-lactam and a beta-
lactamase inhibitor, which is similar in structure to other beta-lactams.  
The primary objective of this study was to determine if there is a significant difference in 
AKI rate among patients who are treated with piperacillin-tazobactam or ampicillin-sulbactam. 
We hypothesize that these groups will have similar rates of AKI and therefore that the observed 
increase in AKI with piperacillin-tazobactam is not related to coadministration of a beta-lactam 
and beta-lactamase inhibitor. 
Methods 
 This was an IRB-approved retrospective cohort study at the University of Kentucky 
HealthCare between 9/1/2007 and 9/30/2015. Adult patients receiving piperacillin-tazobactam 
(TZP) or ampicillin-sulbactam (SAM) for a least 48 hours were included. Patients were excluded 
if they were pregnant, had a past medical history of cystic fibrosis or chronic kidney disease, and 
if their initial creatinine clearance (CrCl) was less than 30 mL/min. Additionally, patients 
receiving other beta-lactam agents were excluded. To account for the impact of vancomycin on 
AKI, a subanalysis stratified by vancomycin exposure was conducted. 
 The primary outcome of this study was incidence of AKI, as defined by the RIFLE 
criteria.(19) Creatinine clearance was utilized as a marker for GFR and was estimated by the 
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adjusted Cockcroft-Gault equation.(45) Exposure to other nephrotoxic agents was defined as 
receipt of at least one dose within 24 hours of treatment initiation through treatment 
discontinuation. Nephrotoxic agents included in this analysis were: aminoglycosides, 
amphotericin B, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, 
intravenous radiocontrast dye, loop diuretics, non-steroidal antiinflamatory drugs, calcineurin 
inhibitors, vancomycin, and vasopressors. Hypotension was a composite of mean arterial pressure 
less than 65 mmHg, systolic blood pressure less than 90 mmHg, or vasopressor exposure during 
treatment. Charlson comorbidity index (CCI) was used to approximate underlying severity of 
chronic illness.(44) 
 Data was collected from the University of Kentucky Center for Clinical and Translational 
Science Enterprise Data Trust (EDT) and included demographic data, drug dosing and 
administration data, laboratory data, and comorbidity data. The EDT contains electronic medical 
record data from University of Kentucky HealthCare from 2006 to present. Data stored in the 
EDT includes: patient demographics, financial classification (Medicare, Medicaid, private 
insurance), provider-level details, diagnoses, procedures, lab tests and results, medication 
administration, visit details (age, length of stay, etc.), and vital signs. Patients were followed from 
admission to discharge. 
Descriptive statistics were performed. Comparisons of continuous variables were 
completed with Student’s t test or the Wilcoxon’s rank-sum test. Categorical variables were 
compared with chi-squared or Fisher’s exact tests as appropriate. Patients in the TZP and SAM 
groups were propensity score matched(46) based on: CCI; initial CrCl (30-59, 60-89, and >90 
mL/min); hypotension exposure, exposure to aminoglycosides, amphotericin B, ACE inhibitors, 
loop diuretics, calcineurin inhibitors, or vancomycin; history of diabetes, heart failure, and 
hypertension, in a 3 to 1 fashion between TZP and SAM groups. These variables were selected 
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based on unadjusted associations with AKI in bivariate analysis and were equally weighted in the 
final propensity score model. Variables were analyzed in bivariate logistic regression with AKI as 
the response variable and all variables that were significant in simple regressions were included in 
the initial multivariate logistic regression of AKI. Variables were removed from the multivariate 
model in a step-wise fashion to minimize the Akaike Information Criterion for the final 
multivariate model presented. Additionally, goodness-of-fit was tested with the Hosmer-
Lemeshow test and the area under the receiver-operator-characteristic curve (ROC) or c-statistic. 
All tests were two-tailed with an alpha of 0.05 consider significant. All data analyses were 
performed with R v3.1.3 and RStudio v0.98.(49,50) 
Results 
 Following matching, 2,448 patients were analyzed for the primary outcome, with 1,836 
patients receiving TZP and 612 receiving SAM. Baseline covariates (Table 1) were evenly 
distributed between both groups, with the exceptions of CCI (5 [IQR 2-9] vs. 4 [IQR 1-9] in SAM 
and TZP groups, respectively; p=0.002) and IV radiocontrast dye exposure (3.3% vs. 5.8% in 
SAM and TZP groups, respectively; p=0.02). Overall AKI incidence was similar between SAM 
(9.2%) and TZP (11.4%, p=0.15); however, TZP patients experienced higher rates of GFR 
decreases of greater than 50% (1.5% vs. 1.1%, p=0.02) and greater than 75% (1.3% vs. 0.2%, 
p=0.0001) (Table 2).  
 Vancomycin exposure was significantly associated with AKI independent of treatment 
group on bivariate logistic regression (OR 1.07; 95% CI 1.04-1.1). Table 3 shows the results of 
the subanalysis between groups stratified by vancomycin exposure. AKI incidence was lowest in 
the SAM group (8.9%) and highest in the TZP plus vancomycin group (18.1%). TZP alone was 
associated with a 9.5% AKI rate and SAM plus vancomycin had a 10.2% AKI rate. These 
stratified groupings were used in the multivariate regression model (Table 4). There was no 
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observed difference in odds of AKI between SAM and TZP (aOR 0.87, 95% CI 0.59-1.25); 
however, the addition of vancomycin to TZP significantly increases the odds of AKI compared to 
TZP monotherapy (aOR 1.77, 95% CI 1.26-2.46). This was not seen with concomitant VAN and 
SAM therapy compared to SAM monotherapy (aOR 1.01; 95% CI 0.48-1.97).    
Additional factors that were independently predictive of AKI included duration of beta-
lactam therapy, history of heart failure diagnosis, loop diuretic exposure and calcineurin inhibitor 
exposure (Table 4). There is no evidence of overfitting in the model with a Hosmer-Lemeshow p 
value of 0.37 and the model had an AUC under the ROC of 0.71. 
Discussion 
 In this large retrospective cohort study, the AKI incidence between two common beta-
lactam/beta-lactamase inhibitor combinations was found to be similar after controlling for 
confounding factors associated with AKI. To our knowledge, this is the first study to examine this 
relationship.  
Previous literature in this area has shown high variability in the rates of AKI associated 
with TZP, mainly as combination therapy with vancomycin.  Kim and colleagues reported TZP 
monotherapy-associated AKI to be approximately 15.4%, which was not significantly different 
from the combination therapy arm.(17) AKI rates when TZP is combined with VAN range from 
9.5 to 34.8%.(12,13,17,23,24,28,33,34) Few studies have compared AKI incidence among 
different treatment regimens, but the most common comparator is cefepime due to the similar 
niche in therapy. Gomes and colleagues found TZP combined with VAN had significantly higher 
rates of AKI compared to the combination of cefepime and VAN (34.8% vs 12.5%).(24) In a 
study of diabetic osteomyelitis patients, although not statistically significant, TZP-VAN was 
associated with an AKI rate of 29.3% compared to 13.3% for cefepime-VAN.(23) Additionally, 
in critically ill patients, no difference in AKI incidence was noted between TZP or CFP when 
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combined with VAN.(28) These studies used varying definitions of AKI and examined relatively 
small sample sizes. Additionally, although cefepime and TZP are commonly interchanged 
clinically, TZP is distinct due to the addition of a beta-lactamase inhibitor to the beta-lactam.  The 
unadjusted AKI rate in our study among patients in the TZP arm was 22.2%; however, following 
matching the AKI rate was only 11.4% in the TZP group (p=0.15). After stratification by 
vancomycin use, TZP-VAN was shown to have higher rates of AKI compared to TZP alone 
(18.1% vs. 9.5%; aOR 1.77; 95%CI 1.26-2.46), which is consistent with prior literature.  
 Ampicillin-sulbactam is another beta-lactam/beta-lactamase inhibitor combination used 
intravenously for the treatment of a variety of infections. Nephrotoxicity data for SAM are 
limited; however, one small study of high dose SAM for multidrug resistant Acinetobacter 
baumanii pneumonia found AKI rates of approximately 15.3%.(52) Another study, examining 
SAM use in multidrug resistant Acinetobacter baumanii infections found AKI renal failure 
occurred in 26% of patients.(53) These findings are limited by sample size and selection of 
critically ill patients, who have higher rates of nephrotoxicity. In contrast, we found that AKI 
occurred in 9.2% of patients receiving SAM. Distinct data for patients receiving SAM in 
combination with vancomycin is not readily available from the previous SAM studies. When 
stratified by vancomycin exposure, we found a numerical, but statistically insignificant increase 
in AKI (10.2% SAM-VAN vs 8.9% SAM alone; aOR 1.01, 95% CI 0.48-1.97). 
 Despite the marked interest in the increase in nephrotoxicity noted with combination TZP 
and VAN therapy, there have been no hypothesized pathophysiological mechanisms for this 
finding. We considered the addition of tazobactam to piperacillin as a possible contributing factor 
to the increase in AKI due to the administration of two beta-lactam-like agents. This is 
specifically important when comparing TZP-VAN to other beta-lactam combinations that only 
contain a single beta-lactam agent, such as cefepime or meropenem. Nephrotoxicity data for beta-
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lactamase inhibitors administered alone are lacking. Ampicillin-sulbactam is the only beta-
lactam/beta-lactamase inhibitor agent commonly used as an alternative to TZP at our institution. 
This study shows that AKI rates are similar among beta-lactam/beta-lactamase inhibitor 
combinations at our institution and that the combination of vancomycin and piperacillin-
tazobactam is a major factor in AKI. 
 This study is not without limitations. While we employed a robust analysis via matching 
patients on several possible confounders, there is still the possibility of unmeasured confounders 
being present in our sample. However, we did control for many nephrotoxic exposures, such as 
hypotension and other nephrotoxic drug administration, which should explain the majority of 
confounding in this study. Additionally, we attempted to control for the temporal relation of 
nephrotoxic exposure to the treatment window of the study agents. For other nephrotoxic agents, 
dose-response relationships were not assessed and all exposures were defined as receipt of at least 
one dose within 24 hours prior to initiation of study agents. This may overestimate the impact of 
those exposures on AKI, which in turn would bias our results towards the null hypothesis. 
Differences in chronic illness, via CCI, between groups could bias results toward SAM being 
more nephrotoxic than TZP; however, our results state the opposite. Critical illness is not well 
captured by the CCI and there remains a chance that there is a higher proportion of critically ill 
patients in the TZP arm. To combat this, we matched on presence of hypotension during the 
treatment period and baseline severity of illness. Finally, it is unclear if the nephrotoxic potentials 
of the beta-lactam agents are similar. Due to the timeframe of this study, no patients received 
piperacillin monotherapy which precludes any inference regarding the additional nephrotoxic 
potential of tazobactam. Further prospective studies of combination antimicrobial chemotherapy 




 AKI rate between piperacillin-tazobactam and ampicillin-sulbactam were similar in our 
large matched cohort study. Additionally, concomitant vancomycin exposure was associated with 
significant increases in AKI incidence. The magnitude of increase was significantly different for 





Tables and Figures 
Table 4.1: Patient demographics among matched cohort 
Variable SAM (N=612) TZP (N=1,836) p 
Age (median [IQR]) 52 (42-62) 53 (40-63) 0.7 
Male Gender 338 (55.2%) 954 (52.0%) 0.2 
Caucasian Race 554 (90.5%) 1,648 (89.8%) 0.6 
Weight, kg (mean[SD]) 79.9 (22.4) 80.5 (23.8) 0.8 
BMI (mean[SD]) 27.7 (7.0) 27.8 (8.8) 0.9 
CCI (median [IQR]) 5 (2-9) 4 (1-9) 0.002 
Initial CrCl (median [IQR]) 100 (77.8-127.5) 103.9 (76.8-130.9) 0.4 
Initial CrCl (mL/min)   0.8 
30-59 64 (10.5%) 181 (9.9%)  
60-89 165 (27.0%) 482 (26.3%)  
≥90 383 (62.6%) 1,173 (63.9%)  
Hypotension 42 (6.9%) 144 (7.8%) 0.5 
Comorbidities 
Diabetes 119 (19.4%) 336 (18.3%) 0.6 
Heart Failure 28 (4.6%) 56 (3.1%) 0.1 
Hypertension 267 (43.6%) 779 (42.4%) 0.6 
Concomitant nephrotoxic agents 
Aminoglycoside 17 (2.8%) 36 (2.0%) 0.3 
Amphotericin B 1 (0.2%) 3 (0.2%) 1 
ACE inhibitor 88 (14.4%) 217 (11.8%) 0.1 
ARB 25 (4.1%) 59 (3.2%) 0.4 
IV Contrast 20 (3.3%) 107 (5.8%) 0.02 
Loop diuretic 92 (15.0%) 242 (13.2%) 0.3 
NSAID 106 (17.2%) 294 (16.0%) 0.5 
Calcineurin inhibitors 21 (3.4%) 57 (3.1%) 0.8 
Vancomycin 128 (20.9%) 397 (21.6%) 0.7 
Vasopressors 4 (0.7%) 12 (0.7%) 1 
Beta-lactam duration of therapy 
(days; median [IQR]) 
4 (2-5) 4 (3-6) <0.00001 
Vancomycin duration of therapy 






Table 3.1 footnote: 
Data are N(%) unless specified otherwise. ACE – angiotensin converting enzyme; ARB – 
Angiotensin II receptor blocker; IQR – interquartile range; NSAID – nonsteroidal anti-
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Table 4.2: Primary outcome 
 Outcome SAM TZP p-value 
AKI 56 (9.15%) 209 (11.38%) 0.14 
Risk 48 (7.84%) 159 (8.66%)  
Injury 7 (1.14%) 27 (1.47%)  
Failure 1 (0.16%) 23 (1.25%)  
Table 2.2 footnote: 
AKI – acute kidney injury; TZP – piperacillin-tazobactam; SAM – ampicillin-sulbactam; Risk: ≥ 




Table 4.3: Differences in AKI stratified by vancomycin exposure for patients treated with 
piperacillin-tazobactam or ampicillin-sulbactam 










AKI 43 (8.9%) 137 (9.5%) 0.74 13 (10.2%) 72 (18.1%) 0.038 
Risk 38 (7.8%) 112 (7.8%)  10 (7.8%) 47 (11.8%)  
Injury 4 (0.8%) 15 (1.0%)  3 (2.3%) 12 (3.0%)  
Failure 1 (0.2%) 10 (0.7%)  0 (0%) 13 (3.3%)  
 
Table 3.3 footnote: 
AKI – acute kidney injury; TZP – piperacillin-tazobactam; SAM – ampicillin-sulbactam; VAN – 
vancomycin; Risk: ≥ 25% decrease in CrCl; Injury: ≥ 50% decrease in CrCl; Failure: ≥ 75% 




Table 4.4: Bivariate and Multivariate AKI associations 
 
Bivariate Multivariate 
Variable OR 95% CI p aOR 95% CI p 
Treatment characteristics 
Treatment group 
TZP (reference) (reference) 
SAM 0.93 0.64 – 1.32 0.678 0.87 0.59 – 1.25 0.465 
SAM+VAN 1.07 0.56 – 1.89 0.815 0.88 0.44 – 1.61 0.691 
VAN+TZP 2.11 1.54 – 2.86 <0.001 1.77 1.26 – 2.46 0.001 
Duration of beta-
lactam therapy 
(per day increase) 
1.12 1.08 – 1.16 <0.001 1.08 1.04 – 1.12 <0.001 
Patient characteristics 
Age (per year 
increase) 
1 0.99 – 1.01 0.875 
   
CCI (per point 
increase) 
1.01 0.98 – 1.04 0.348 
   
Male gender 1.19 0.92 – 1.54 0.187 
   
Caucasian race 1.14 0.75 – 1.81 0.57 
   
Baseline creatinine clearance (mL/min) 
30-59 (reference) (reference) 
60-59 0.59 0.36 – 0.98 0.039 0.64 0.38 – 1.10 0.1 
≥90 1.15 0.76 – 1.80 0.521 1.55 1.00 – 2.50 0.062 
Heart failure 2.52 1.45 – 4.18 0.001 2.06 1.11 – 3.66 0.016 
Diabetes 1.39 1.02 – 1.88 0.034 1.32 0.94 – 1.83 0.104 
Hypertension 1.12 0.87 – 1.45 0.374 
   
Hypotension† 2.05 1.37 – 3.00 <0.001 
   
Concomitant nephrotoxins 
Aminoglycoside 2.76 1.40 – 5.10 0.002 1.89 0.88 – 3.78 0.086 
Amphotericin B 2.75 0.14 – 21.59 0.381 
   
ACE inhibitor 1.24 0.85 – 1.77 0.239 
   
ARB 0.51 0.18 – 1.15 0.151 
   
IV Radiocontrast 
Dye 
0.94 0.50 – 1.63 0.826 
   
Loop diuretic 3.59 2.68 – 4.79 <0.001 3.06 2.22 – 4.19 <0.001 
Calcineurin 
inhibitor 
3.44 2.02 – 5.65 <0.001 4.28 2.42 – 7.35 <0.001 
NSAID 0.79 0.54 – 1.12 0.2 
   
Vasopressor 2.77 0.77 – 8.02 0.079 
   
 
Table 3.4 footnote: 
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AKI – acute kidney injury; ACE – angiotensin converting enzyme; aOR – adjusted odds ratio; 
ARB – angiotensin II receptor antagonist; CCI – Charlson Comorbidity Index; CI – confidence 
interval; NSAID – nonsteroidal anti-inflammatory drug; OR – odds ratio; TZP – piperacillin-
tazobactam; SAM – ampicillin-sulbactam; VAN – vancomycin;  




Chapter 5: Predicting AKI in patients treated with empiric antimicrobial therapy 
with machine learning 
Background 
 Acute kidney injury (AKI) is associated with significant morbidity and mortality.(61) 
There are a variety of causes and mechanisms for AKI. One common cause of AKI is 
vancomycin (VAN), which is a glycopeptide antibiotic active against gram-positive bacteria, such 
as Staphylococcus aureus.(62) Vancomycin-related AKI is a well-defined, with incidence ranging 
from 5 to 43% in a variety of patients.(62) There is a wide variation in the incidence of VAN-
associated AKI due to study differences, such as patient population examined, historical dosing 
strategies, and impurities in early drug formulations. Contemporary literature suggests that 
approximately 21% of critically ill patients treated with VAN will develop AKI(63), compared to 
approximately 14% of adult internal medicine patients.(64)  
Recent literature implicates concomitant VAN and piperacillin-tazobactam (TZP) therapy 
in the increased incidence of AKI.(64) Piperacillin-tazobactam is a beta lactam/beta-lactamase 
inhibitor combination that has antimicrobial activity against many gram-negative pathogens, 
including Pseudomonas, and anaerobic pathogens. Piperacillin-tazobactam is generally 
considered safe with AKI incidence less than 1% in approval studies; however, the package insert 
does list acute renal failure as a possible serious adverse effect.(10) This finding has been 
reproduced many times with AKI incidence in patients treated with VAN+TZP ranging from 9.5 
to 34.8%.(17,23,24,33,34,65,66) Additionally, VAN+TZP has been shown to have higher AKI 
incidence compared to cefepime combined with VAN.(24,66) Despite these findings, no literature 
has examined the problem of predicting which patients receiving combination antimicrobial 
therapy are at risk for AKI. While statistical models have been developed in previous studies, 
these approaches have been limited to covariates that are known confounders.  
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Machine learning is gaining popularity in bioinformatics in several areas, such as omics, 
biomedical imaging, and biomedical signal processing.(67) Different techniques are better suited 
for each field of bioinformatics; however, there are many opportunities to utilize different 
techniques to represent the data. For example, convolutional neural networks have been utilized 
successfully in biomedical image processing but recurrent neural networks can be used as many 
images have a sequential component.(67) Recently, recurrent neural networks were utilized to 
predict onset of heart failure from electronic medical record data.(68) The model generated in this 
study outperformed the traditional machine learning approaches in accuracy. This study 
demonstrates the feasibility of applying complex deep learning techniques to sequential electronic 
medical record data. 
The objective of this study was to predict AKI in patients receiving combination empiric 
antimicrobial therapy via a variety of machine-learning models. This was done to include a large 
variety of variables and account for non-linear relationships, which would be difficult to do in a 
statistical model.  
Methods 
Patient population 
 This was a retrospective cohort study of patients at the University of Kentucky Medical 
Center who received vancomycin (VAN) in combination with piperacillin-tazobactam (TZP), 
cefepime (CFP), or meropenem (MEM) for at least 48 hours. All patients, 18 years of age and 
older admitted between July 1, 2008 and June 30, 2017 at the University of Kentucky HealthCare 
enterprise were eligible for inclusion. While data is available for some situations starting in 2006, 
the most reliable data is present from 2008 and on. In contrast to previous studies on this topic, 
patients with previous renal disease (defined by ICD-9 or ICD-10 codes) were eligible for 
inclusion. Patients were grouped based on the beta-lactam agent utilized for therapy. In cases of 




Patient-specific data was collected from the University of Kentucky Enterprise Data 
Trust (EDT). The EDT is a large relational database containing a copy of the electronic medical 
record from UK HealthCare. Data, updated nightly, is available since 2006 and includes:  
demographics (age, gender, marital status, race); financial classification; provider-level detail 
(service); medical diagnoses (ICD 9 and ICD 10); medical procedures (inpatient facility and 
technical procedures, CPT codes); lab tests and results (chemistry, coagulation, hematology, 
urinalysis, etc.); medications received; visit details (age at visit, length of stay, financial 
classification, service unit, weekend admission); and vital signs (height, weight, BMI, direct 
arterial blood pressure, noninvasive blood pressure, heart rate, pulse oximetry, respiratory rate, 
temperature, death status, tobacco status). 
Data collected included gender, age, race, transfer from outside facility, ICU status on 
admission, laboratory values obtained throughout admission, height and weight on admission, 
hospital and ICU length of stay, antibiotic dose, antibiotic blood levels, duration of therapy, 
medical diagnoses, and all lab tests and results. Vital signs throughout hospital stay, mechanical 
ventilation status, history of cardiac arrest, and mental status (via Glasgow Coma Scale) on 
admission were collected. Patient data were aggregated on an encounter-day level. Categorical 
data was converted to binary indicator variables via one-hot encoding. Features were selected 
from the EHR in the 72 hours prior to the index date. 
Data analysis 
 The primary outcome of this study was empirical antibiotic therapy associated AKI as 
determined by the risk, injury, failure, loss, and end-stage (RIFLE) criteria.(19) To determine 
changes in renal function, creatinine clearance was calculated by the adjusted Cockcroft-Gault 
equation.(45) The first creatinine clearance obtained during the hospital admission was used as 
the patient’s baseline renal function. Patient index dates were set to 48 hours after the initiation of 
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combination therapy. To mimic application of predictive models in a real-world setting, data 
occurring prior to the index date were included in the predictive models. As the majority of 
patients had less than 5 days of pre-index data, initial models used only data from the 3 days prior 
to index date.  
 Basic descriptive statistics for the entire cohort and each therapy group were performed. 
Continuous data were compared with ANOVA or Kruskal-Wallis tests while categorical data 
were compared with chi-square tests. Bivariable logistic regression was performed to analyze 
associations of treatment group with AKI incidence. 
 Data were separated into training and validation datasets in a 95:5 ratio, the training 
dataset was then partitioned into a 90:10 split for model training and testing. Models examined 
included: Naïve Bayes classifier, Random Forest classifier, L2-regularized logistic regression 
classifier, and Neural Network models. All models were repeated 100 times with different 
training/test splits. Random selection of outcome was used as a baseline to demonstrate model 
effectiveness.  
In total four neural network models were evaluated. All neural network models relied on 
the rectified linear unit activation (ReLU) function for hidden layers and a softmax activation 
function for the output layer. The ReLU function returns all positive inputs to a node or zero if 
the input is negative, this was selected to produce only positive outputs. Neural network model 1 
(NN1) contains two hidden layers of 100 nodes; NN2 contains three 100-node hidden layers. 
NN3 contains two hidden layers, the first with 500 nodes, followed by a 100-node layer. NN4 is 
similar to NN1; however, after each hidden layer, a dropout layer was included to reduce 
overfitting. These networks were built to test whether increased model capacity (NN1 vs NN2 
and NN3) or complexity (NN1 vs NN4) improved results. Neural networks were trained with a 




Model performance was assessed on the validation set and metrics included accuracy, 
precision, recall, area under the receiver operator curve, and F1 score. In addition to model 
metrics, the top ten features from random forest and L2-regularized logistic regression classifiers 
were extracted. 
 All statistical tests and procedures were performed in R and RStudio.(49,50) Machine 
learning tasks were completed using Python 3.5.2 (69) , scikit-learn v0.18.1 (70), Keras v 2.0.8 
(71) and TensorFlow v 1.3.0.(72) 
Results 
 In total, 29,647 patients were included in this study with 67.2% of patients receiving 
VAN+TZP, 28.1% receiving VAN+CFP, and 4.7% receiving VAN+MEM. Basic patient 
demographics and summary statistics are presented in Table 5.1. In summary, the mean age of 
patients was 53.9 (SD 16.48) years and 57.4% were male. Baseline creatinine clearance was 
approximately 87.4 (SD 51.3) mL/min. There were significant differences between treatment 
groups in age; however, each group had similar proportion of elderly patients.  
 Unadjusted outcomes are shown in Table 5.2. The antimicrobial-associated AKI 
incidence among all patients was 24.7% and was significantly increased in the VAN+TZP group 
compared to both VAN+CFP and VAN+MEM (Table 5.3). Rates of inpatient mortality were 
similar among groups and was 11.3% overall. Median length of hospitalization was 10 days (IQR 
5-20 days). 
 Model metrics are summarized in Table 5.4. All models performed better than random 
selection (RS) in all metrics, except random forest in recall (RF 0.170 [0.166-0.173] vs RS 0.255 
[0.251-0.261]; p<0.0001; Table 5.5) and F1 score (RF 0.266 [0.261-0.271] vs RS 0.256 [0.252-
0.260]; p =0.93). 
The most accurate model in the validation cohort was NN 4 (79.8% [95% CI 79.6 to 
80.1%; Figure 5.2), which is expected with the addition of dropout layers to the model 
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architecture. Naïve Bayes classifier was the least accurate of the models (64.1% [63.9 to 64.4%], 
p<0.0001 for pairwise comparisons). NN 1, 2, and 3 had similar accuracy rates. Results in the 
precision metric were similar to that of accuracy (Figure 5.3). 
 Naïve Bayes classifier demonstrated significantly highest recall when compared to other 
models (0.593 [0.588 to 0.598], p<0.0001 for all pairwise comparisons; Figure 5.4). Among the 
neural network models, NN 3 had the highest recall (0.479 [0.463-0.495]) and NN 4 had the 
lowest recall (0.398 [0.387-0.410], p<0.0001 for pairwise comparisons between other neural 
networks). Recall was statistically similar between NN 1 and 2. 
Neural Network 3 performed the best in terms of AUC under the receiver operating curve 
(0.683 [0.678-0.687]; Figure 5.5); however, this result was not statistically different from the 
results from NN1 (0.679 [0.675-0.683], p=0.4) and NN2 (0.678 [0.674-0.682], p=0.28). NN 4 
performed significantly worse in AUC compared to other neural network models and had similar 
performance to L2 logistic regression. Results for F1 followed similar trends to AUC (Figure 
5.6), with NN3 performing the best but not having significant differences from NN1 and NN2. 
The maximum F1 score of 0.521 (0.513-0.529) suggests that further work is need to optimize the 
models prior to production. 
The top ten features from L2 regression and random forest classifiers are shown in Table 
5.6. Common features between the models included GFR estimates on index date and serum 
creatinine measurements. Amphotericin B administration on index date was included in the L2 
model, while TZP was included in the random forest model. 
Discussion 
 In this large retrospective review of patients receiving empiric combination 
antimicrobials, AKI occurred in 24.7% of patients. This is the largest study of this topic to date. 
Without adjustment for confounders, AKI was significantly more likely in patients who received 
the combination of vancomycin and piperacillin-tazobactam compared to either cefepime or 
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meropenem and vancomycin. Interestingly, we found that patients who receive meropenem and 
vancomycin were more likely to experience AKI than those who received cefepime. This may 
due to increased severity of illness amongst the meropenem cohort as this difference was not 
noted in a smaller retrospective study.(73) 
 We successfully utilized a variety of machine learning methods to predict AKI in these 
patients using the data available at 48 hours of therapy. This was primarily done to simulate the 
use of these findings as a clinical decision support tool to help determine the likelihood of AKI. 
While the f1 measures of the models were not optimal, the models were still able to predict AKI 
with only 72 hours of clinical data and may represent a viable clinical tool to inform physician 
decision making. Model accuracy may improve with longer lookback periods, the inclusion of 
outpatient data, or the use of more sophisticated methods.  
 There are several limitations of this study. While the observed AKI incidence was similar 
to previous studies in this area, we did not attempt to control for confounders while presenting the 
AKI incidence between different treatment groups. This was done primarily due to the intent of 
our study being to develop a predictive model rather than examine the established link between 
increased AKI and VAN+TZP therapy. Another significant limitation is the conversion of 
numeric variables to categorical variables to account for data missingness. The conversion to a 
categorical data point allowed the model to evaluate if not ordering a lab or test had significant 
associations with AKI occurring at a later time point. While this allowed for the investigation of 
missing lab values, it does increase the sparsity of data, which may limit the interpretation of our 
results. Receipt of specific medications were treated as binary variables on the patient-day level. 
This limits inferences surrounding increasing dosing intensity and increased AKI incidence. 
However, in previous research sensitivity analyses demonstrated that this binary treatment of 
medication administration did not perform significantly worse at predicting AKI in statistical 
models than using number of doses or dose amounts. While we included patients with significant 
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baseline renal impairment, the definition for baseline creatinine clearance may mask AKI in 
patients with low baseline values.  
 In conclusion, AKI continues to be an important adverse effect associated with 
combination antimicrobial therapy. Specifically, vancomycin in combination with piperacillin-
tazobactam continues to have higher AKI rates than either cefepime or meropenem when 
combined with vancomycin. Machine learning models performed well in testing and training 




Tables and Figures 
Table 5.1: Patient demographics 
Variable Cohort VAN+CFP VAN+MEM VAN+TZP p-value 
N 29,647 8,333 1,390 19,924 
 
Mean Age (SD) 53.86 





Median Age (IQR) 55 (42-65) 55 (42-65) 54 (39-65) 55 (43-65) 0.0008 










































Footnote: N – number, VAN – vancomycin, CFP – cefepime, MEM – meropenem, TZP – 





Table 5.2: Unadjusted outcome results 
Outcome Cohort VAN+CFP VAN+MEM VAN+TZP p-value 
Length of hospital 
stay [mean (SD)] 16.1 (20.5) 17.1 (21.1) 19.7 (29.8) 15.5 (19.3) <0.0001 
Length of hospital 
stay [median 
(IQR)] 
10 (5-20) 11 (5-21) 12 (7-22) 10 (5-19) <0.0001 
Inpatient mortality 3358 




(19.2%) 318 (22.9%) 5403 (27.1%) <0.0001 
Footnote: VAN – vancomycin, CFP – cefepime, MEM – meropenem, TZP – piperacillin-




Table 5.3: Bivariable odds ratios of AKI among different treatment groups 
VAN+CFP VAN+MEM VAN+TZP 
(ref) 1.24 [1.09-1.43] 1.57 [1.47-1.67] 
0.80 [0.7-0.92] (ref) 1.25 [1.10-1.43] 
0.64 [0.6-0.68] 0.80 [0.7-0.91] (ref) 





Table 5.4: Machine learning model metrics on validation set 
Model Accuracy Precision (PPV) Recall AUC F1 Score 








































































Footnote: L2 – L2 penalized logistic regression, NB – Naïve Bayes Classifier, NN – Neural 




Table 5.5: Pairwise t-test p-values for model metrics 
Accuracy 
Model L2 NB NN1 NN2 NN3 NN4 RF  
NB <0.0001 
      
NN1 <0.0001 <0.0001 
     
NN2 <0.0001 <0.0001 0.47 
    
NN3 0.08 <0.0001 0.04 0.01 
   
NN4 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
  
RF <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
 
RS <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Precision 
Model L2 NB NN1 NN2 NN3 NN4 RF 
NB <0.0001 
      
NN1 0.00 <0.0001 
     
NN2 <0.0001 <0.0001 0.49 
    
NN3 0.24 <0.0001 0.23 0.01 
   
NN4 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
  
RF <0.0001 <0.0001 0.24 0.51 0.0010 <0.0001 
 
RS <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Recall 
Model L2 NB NN1 NN2 NN3 NN4 RF  
NB <0.0001 
      
NN1 0.003 <0.0001 
     
NN2 0.017 <0.0001 0.496 
    
NN3 <0.0001 <0.0001 0.017 0.004 
   
NN4 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
  
RF <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
 
RS <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
AUC 
Model L2 NB NN1 NN2 NN3 NN4 RF 
NB <0.0001 
      
NN1 <0.0001 <0.0001 
     
NN2 <0.0001 <0.0001 1 
    
NN3 <0.0001 <0.0001 0.40 0.28 
   
NN4 1 <0.0001 <0.0001 <0.0001 <0.0001 
  
RF <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
 




Table 5.5 (continued) 
F1 score 
Model L2 NB NN1 NN2 NN3 NN4 RF  
NB <0.0001 
      
NN1 <0.0001 <0.0001 
     
NN2 <0.0001 <0.0001 0.93 
    
NN3 <0.0001 <0.0001 0.93 0.93 
   
NN4 0.93 <0.0001 <0.0001 <0.0001 <0.0001 
  
RF <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
 
RS <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.93 
Footnote: L2 – L2 penalized logistic regression, NB – Naïve Bayes Classifier, NN – Neural 





Table 5.6: Top ten features in RF and L2 models 
L2 regularized logistic regression Random forest 
Urine Casts ordered on T-1 Baseline CrCl 
GFR if African American on T0 GFR if African American on T0 
Serum IgE on T-2 GFR on T0 
Serum Creatinine on T0 Serum Creatinine on T0 
Urine Creatinine on T0 Oxygen saturation on T0 
MRI Upper Extremity Joint with and without IV 
Contrast Left on T-1 Age 
Amikacin Trough ordered on T-1 TZP given on T-1 
GFR on T0 Serum Phosphorus on T0 
Amphotericin B given on T0 RBC Count on T0 
Liver Abscess/Cyst percutaneous drainage on T0 TZP given on T0 
Footnote: T0 – index date, T-1 – index date – 1, T-2 – index date -2, TZP – piperacillin-
tazobactam, GFR – glomerular filtration rate (estimated by MDRD equation), RBC – red blood 








Footnote: L2 – L2 penalized logistic regression, NB – Naïve Bayes Classifier, NN – Neural 




Figure 5.2: Comparison of accuracy between models 
  
Footnote: Note Y-axis scale. L2 – L2 penalized logistic regression, NB – Naïve Bayes Classifier, 





Figure 5.3: Comparison of precision between models 
  
Footnote: L2 – L2 penalized logistic regression, NB – Naïve Bayes Classifier, NN – Neural 





Figure 5.4: Comparison of recall between models 
 
Footnote: L2 – L2 penalized logistic regression, NB – Naïve Bayes Classifier, NN – Neural 





Figure 5.5: Comparison of AUC between models 
 
Footnote: L2 – L2 penalized logistic regression, NB – Naïve Bayes Classifier, NN – Neural 





Figure 5.6: Comparison of F1 score between models 
 
Footnote: L2 – L2 penalized logistic regression, NB – Naïve Bayes Classifier, NN – Neural 




Chapter 6: Conclusions and Future Directions 
Conclusions 
 The presented research clearly demonstrates an association between AKI and 
combination therapy with VAN and TZP. While this finding is certainly not novel, as shown by 
the volume of literature reviewed in Chapter 1, the studies presented are among the largest in 
terms of sample population. Additionally, a common definition of AKI was shared among the 
studies, allowing for comparisons of findings between studies.  
 Chapter 2 demonstrates a significant difference in AKI incidence between VAN+TZP 
and VAN+CFP. While this difference was demonstrated in previous literature, this study 
leveraged the large sample size to control for a variety of confounders and presents a robust 
association between VAN+TZP and AKI.  
 From available literature, it was unclear if VAN+TZP was more nephrotoxic when 
compared to non-CFP agents. Chapter 3 presents the most robust study of VAN+TZP compared 
to VAN+MEM. The results clearly show an increase in AKI incidence observed in the 
VAN+TZP cohort. This is a valuable finding as MEM and TZP have similar bacterial spectra and 
clinical indications. Further research into the comparisons of TZP alternatives are warranted. For 
example, CFP and MEM should be compared directly to determine if either agent possesses a 
significant advantage over the other in regards to renal disease. 
 Previous literature failed to investigate a potential mechanism for the observed increase 
in renal insult with TZP compared to other beta-lactam agents. Chapter 4 presents the novel 
investigation of the impact of the addition of beta-lactamase inhibitors on nephrotoxicity. Results 
suggest that the addition of a second beta-lactam-like agent is not the mechanism for increased 
AKI seen with TZP. Interestingly, the addition of VAN to either agent resulted in increased AKI 
incidence; however, the magnitude of AKI increase was significantly larger in the TZP cohort.  
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 In summary, Chapters 2 through 4 clearly demonstrate a need for antimicrobial 
stewardship interventions related to the use of empiric combination broad-spectrum antibiotics. A 
proposed stewardship tool is the 48-hour antibiotic timeout, in which the multidisciplinary care 
team reviews a patient’s history and determines an appropriate course of therapy based on the 
available data. Chapter 5 proposes the use of machine learning algorithms as a clinical decision 
support tool at 48 hours of therapy. Neural network models appear to have an advantage in 
predicting future AKI events from the data presented. While further optimization may increase 
the model utility, the presented models can still provide valuable information to providers. 
Future Directions 
 While the literature continues to evolve in this field, several knowledge gaps remain. A 
continued focus in identifying AKI-associated risk factors in special populations is needed. In the 
critically ill population, only one published study of AKI incidence among patients receiving 
VAN+TZP and VAN+CFP exists.(28) The results of this evaluation were inconclusive due to 
small sample size, but suggest that no difference in AKI incidence exists between these 
combinations. This finding is discordant with the body of literature that demonstrates significant 
differences in AKI incidence and propensity.  
 Cystic fibrosis patients exhibit altered pharmacokinetics and pharmacodynamics and as 
such may respond differently to nephrotoxins.(74,75) These metabolic alterations have been 
controlled for in other fields of research through stratification of patients by cystic fibrosis 
status.(76) One important potential confounder in our cystic fibrosis population is the utilization 
of extended infusion beta-lactam therapy. Specific dosing protocols for extended infusion 
antibiotics did not exist in our institution until fairly recently and it is difficult to ascertain clinical 
reasoning behind the decision to utilize extended infusion previously. However, all studies 
currently published examining AKI incidence among different beta-lactam infusion strategies 
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have shown no statistically meaningful differences.(33–36) Additional considerations include 
high utilization of aminoglycoside antibiotics, long-term hospitalizations, and frequent exposure 
to the healthcare system. 
 People who inject drugs (PWID) are at higher risk of severe, deep-seeded infections that 
require long-term antimicrobial therapy. In addition to the need for long-term therapy, PWID tend 
to be younger and have fewer comorbidities than the population typically represented in the AKI 
literature. As such, a directed evaluation of empiric combination therapy associated AKI in PWID 
should be conducted.  
 The vast majority of studies in this field have been single center retrospective 
evaluations. This is problematic due to an inability to demonstrate clear causality. Additionally, 
institution-specific confounders may exist and limit the generalizability of the findings to outside 
hospitals. Specifically, community hospitals may have difficulty assessing how these findings 
impact their patient population which tends to be less acutely ill than those of large academic 
tertiary medical centers.  
 Our approach to predicting AKI with machine learning models is promising. We were 
able to predict AKI with approximately 80% accuracy; however, there is still much room for 
improvement. More sophisticated modeling techniques may improve accuracy significantly. The 
incorporation of features from medical progress notes can provide additional details into the 
patients’ health status. Leveraging natural language processing and medical ontologies can 







Appendix A: Chapter 2 code 
Data wrangling 
runanalysis<-function(){   
demo<-
read.csv('demo.csv', colClasses='character')    ##Imports RAW files 
  
meds<-read.csv('New_meds.csv', colClasses='character')   
   
meds2<-
meds                                           ##Cleaning up the med
ication dataset for better analysis.   
meds2$drug<-
meds2$Name                                ##Using a separate dataset
 so nothing is changed in the origninal unintentionally   
meds2$drug<-sub('Inj\\.','',meds2$drug)   
meds2$drug<-sub('\\(Drip\\)','',meds2$drug)   
meds2$drug<-sub('\\(PEDIATRIC\\)','',meds2$drug)   
meds2$drug<-sub('\\(IntraMuscular\\)','',meds2$drug)   
meds2$drug<-sub('-','',meds2$drug)   
meds2$drug<-sub('Inj','',meds2$drug)   
   
library(stringr)                                      ##Load the str
ingr package for access to the str_trim which eliminates whitespace 
  
meds2$drug<-
str_trim(meds2$drug)                      ##generated in the steps a
bove   
meds2$drug<-sub('zzz','',meds2$drug)   
meds2$drug<-
sub('Piperacillin / Tazobactam','PTZ',meds2$drug)  ##So you don't ha
ve to type piperacillin/tazobactam over and over   
   
cef<-
meds2[meds2$drug =='Cefepime',]                  ##Generating lists 
of unique patients who received Cefepime   
cefid<-cef$Encounter.ID   
cefid<-cefid[!duplicated(cefid)]   
   
vanc<-
meds2[meds2$drug =='Vancomycin',]               ##Same as above with
 Vancomycin   
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vid<-vanc$Encounter.ID   
vid<-vid[!duplicated(vid)]   
   
ptz<-
meds2[meds2$drug =='PTZ',]                       ##And piperacillin/
tazobactam   
pid<-ptz$Encounter.ID   
pid<-pid[!duplicated(pid)]   
   
meds<-
meds2                                           ##Cleaning environme
nt and RAM   
rm(meds2)   
   
cvp<-
subset(demo, demo$ENCNTR_ID %in% cefid &         ##subsets all patie
nts who received all three drugs for later use    
              demo$ENCNTR_ID %in% vid &    
              demo$ENCNTR_ID %in% pid)   
cv<- subset(demo, demo$ENCNTR_ID %in% cefid           ##all patients
 who received ONLY cefepime and vanc   
            & demo$ENCNTR_ID %in% vid &    
              !(demo$ENCNTR_ID %in% cvp$ENCNTR_ID))   
pv<- subset(demo, demo$ENCNTR_ID %in% pid &           ##all patients
 who received ONLY PTZ and vanc   
              demo$ENCNTR_ID %in% vid &    
              !(demo$ENCNTR_ID %in% cvp$ENCNTR_ID))   
   
cv$LENGTH_OF_STAY_NUM<-
as.numeric(cv$LENGTH_OF_STAY_NUM)      ##Variable cleanup   
cv<-subset(cv, cv$LENGTH_OF_STAY_NUM >=2)   
pv$LENGTH_OF_STAY_NUM<-as.numeric(pv$LENGTH_OF_STAY_NUM)   
pv<-subset(pv, pv$LENGTH_OF_STAY_NUM >=2)   
   
cmeds<-
subset(meds, meds$Encounter.ID %in% cv$ENCNTR_ID)      ##subsetting 
the meds for only those received the drugs we care about   
pmeds<-subset(meds, meds$Encounter.ID %in% pv$ENCNTR_ID)   
   
source('f:/Jessica data/Test/overlap.R')              ##Load the 'ov
erlap' script which takes a frame of meds and gives a list of those 
  
                                                      ##who received
 vancomycin and the drug specified by the drg variable for 2 days   
   
cmeds$date<-
sapply(strsplit(cmeds$Performed.Date.Time,' '),'[',1)        ##clean
ing the meds dataset for the cefepime group   
cmeds$time<-sapply(strsplit(cmeds$Performed.Date.Time,' '),'[',2)   
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cmeds$ampm<-sapply(strsplit(cmeds$Performed.Date.Time,' '),'[',3)   
cmeds$time2<-paste(cmeds$time, cmeds$ampm)   
cmeds$time<-cmeds$time2   
cmeds$ampm<-NULL   
cmeds$time2<-NULL   
cmeds$date<-as.Date(cmeds$date,format ="%m/%d/%Y")   
   
   
pmeds$date<-
sapply(strsplit(pmeds$Performed.Date.Time,' '),'[',1)        ##and t
he PTZ group   
pmeds$time<-sapply(strsplit(pmeds$Performed.Date.Time,' '),'[',2)   
pmeds$ampm<-sapply(strsplit(pmeds$Performed.Date.Time,' '),'[',3)   
pmeds$time2<-paste(pmeds$time, pmeds$ampm)   
pmeds$time<-pmeds$time2   
pmeds$ampm<-NULL   
pmeds$time2<-NULL   
pmeds$date<-as.Date(pmeds$date,format ="%m/%d/%Y")   
   
overlap(cmeds, drg='Cefepime')                        ##Find the ove
rlap between the cefepime and vancomycin treatment. Takes a while.   
overlap(pmeds, drg='PTZ')                             ##Same as abov
e for the PTZ. Takes EVEN LONGER... pick up a book.   
   
library(plyr)                                         ## load the 'p
lyr' package for access to ldply function which takes a list and    
                                                      ##and outputs 
a data fram with variables V1, V2, V3...VN.    
cvinc<-
ldply(Cefepime_Vanc_included)                  ##Change the list of 
EIDs and number of overlap to a dataframe   
pvinc<-ldply(PTZ_Vanc_included)   
   
names(cvinc)[names(cvinc)=='V1']<-
'EID'               ##rename V1 to a descriptive variable   
names(pvinc)[names(pvinc)=='V1']<-'EID'   
   
cv2<-
subset(cv, cv$ENCNTR_ID %in% cvinc$EID)          ##subset the cefepi
me patients to those only receiving both drugs for >=2days   
pv2<-
subset(pv, pv$ENCNTR_ID %in% pvinc$EID)          ##same as above wit
h PTZ. Using new variables to avoid any unwanted changes   
   
cv2$group<-
'CV'                                       ##Adding group variable f




'PV'                                       ##this variable will main
tain data   
   
cv<-
cv2                                               ##Cleaning environ
ment and RAM   
pv<-pv2   
rm(cv2,pv2,Cefepime_Vanc_included, PTZ_Vanc_included)   
cv$AGE<-
as.numeric(cv$AGE)                            ##Changing character t
o numeric variable for analysis   
pv$AGE<-as.numeric(pv$AGE)   
   
cv<-
subset(cv, cv$AGE >=18)                           ##ONLY adults >= 1
8 kept for both groups   
pv<-subset(pv, pv$AGE >=18)   
   
cv2<-
subset(cv, !(cv$ADMT_SRC_CD_DES=='HOSPITAL TRANSFER')&!(cv$ADMT_SRC_
CD_DES=='OTHER HEALTH FACIL')      ##Eliminating transfers   
            &!(cv$ADMT_SRC_CD_DES=="TRANS FM UK GOOD SAM")&!(cv$ADMT
_SRC_CD_DES=="TRANSFER FROM SNF"))   
   
pv2<-
subset(pv, !(pv$ADMT_SRC_CD_DES=='HOSPITAL TRANSFER')&!(pv$ADMT_SRC_
CD_DES=='OTHER HEALTH FACIL')   
            &!(pv$ADMT_SRC_CD_DES=="TRANS FM UK GOOD SAM")&!(pv$ADMT
_SRC_CD_DES=="TRANSFER FROM SNF"))   
   
cv<-
cv2                                               ##Cleaning environ
ment and RAM   
pv<-pv2   
rm(cv2,pv2, pvinc, cvinc)   
   
labs<-
read.csv('New Labs.csv', colClasses='character')           ##imports
 the labs dataset, VERY large   
labs$date<-
sapply(strsplit(labs$ENTRD_DT_TM,' '),'[',1)          ##Cleaning dat
a up   
labs$time<-sapply(strsplit(labs$ENTRD_DT_TM,' '),'[',2)   
labs$ampm<-sapply(strsplit(labs$ENTRD_DT_TM,' '),'[',3)   
labs$time2<-paste(labs$time, labs$ampm)   
labs$time<-labs$time2   
labs$ampm<-NULL   
labs$time2<-NULL   
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labs$date<-as.Date(labs$date,format ="%m/%d/%Y")   
   
source('f:/Jessica data/Test/first_scr.R')            ##loads 'first
_scr' function which takes the labs data and pulls the first value   
                                                      ##and outputs 
a list with EID and value number   
scr<-
subset(labs, labs$ITEM_NAME=='Creatinine Level') ##subset labs for j
ust the SCr values   
firstscr(scr)                                         ##Obtains firs
t SCr for the values in the entire labs set.    
                                                      ##Consider sub
setting to the labs for the CV and PV groups.    
                                                      ##VERY CPU int
ensive. Grab a coffee break. Outputs list 'eid_test2'   
scr_list<-ldply(eid_test2)   
names(scr_list)[names(scr_list)=='V1']<-
"EID"         ##adding descriptive variable names   
names(scr_list)[names(scr_list)=='V2']<-"baseline_scr"   
   
cvscr<-
subset(scr_list, scr_list$EID %in% cv$ENCNTR_ID)  ##finding the SCrs
 for patients in our datasets   
pvscr<-subset(scr_list, scr_list$EID %in% pv$ENCNTR_ID)   
   
names(cv)[names(cv)=="ENCNTR_ID"]<-
'EID'              ##changing ENCNTR_ID to EID for merging purposes.
 Also, EID is easier to type   
names(pv)[names(pv)=="ENCNTR_ID"]<-'EID'   
   
cv2<-
merge(cv,cvscr, by="EID")                        ##merge function wi
ll overwrite any data if a mistake is made, so using new variables   
pv2<-merge(pv,pvscr, by='EID')   
   
cv<-cv2   
pv<-pv2   
rm(pv2,cv2, cvscr,pvscr,eid_test2)                              ##cl
eaning environment and RAM. This computer needs more RAM   
   
cvscr<-
subset(scr, scr$ENCNTR_ID %in% cv$EID)           ##subsetting the da
ta for SCr for quicker computing. Reusing variable names from    
pvscr<-
subset(scr, scr$ENCNTR_ID %in% pv$EID)           ##before is probabl
y not the best idea   
   
source('f:/Jessica data/Test/maxscr.R')               ##load the 'ma
xscr' function which outputs the list of maximum scr and EID   
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maxscr(cvscr)                                         ##outputs max_
scr_list, if it is run on the next data set, you lose the data just 
generated   
c_max_scr_list<-
max_scr_list                          ##this overcomes that   
maxscr(pvscr)                                         ##rerun the sc
ript on the PTZ data set, takes a little longer   
p_max_scr_list<-
max_scr_list                          ##probably not needed but for 
consistency purposes   
   
max_cvscr<-
ldply(c_max_scr_list)                      ##converting lists to dat
aframes   
max_pvscr<-ldply(p_max_scr_list)   
   
names(max_cvscr)[names(max_cvscr)=='V1']<-
'EID'       ##changing variable names to something that makes sense 
  
names(max_cvscr)[names(max_cvscr)=='V2']<-'max_scr'   
names(max_pvscr)[names(max_pvscr)=='V1']<-'EID'   
names(max_pvscr)[names(max_pvscr)=='V2']<-'max_scr'   
   
cv2<-
merge(cv,max_cvscr, by='EID', all=T)             ##merging datasets,
 all=T is added to preserve any patients with a baseline but no max 
  
pv2<-
merge(pv,max_pvscr, by='EID', all=T)             ##which shouldn't h
appen, but this is just a precaution to maintain the data.   
   
cv<-
cv2                                               ##Cleaning the env
ironment again.    
pv<-pv2   
rm(cv2,pv2,cvscr,pvscr,max_cvscr,max_pvscr,scr,   
   scr_list, c_max_scr_list,p_max_scr_list, max_scr_list)   
   
cmeds<-
subset(cmeds, cmeds$Encounter.ID %in% cv$EID)  ##eliminating data ab
out patients not continuing in the data.   
pmeds<-subset(pmeds, pmeds$Encounter.ID %in% pv$EID)   
   
cvp<-
rbind(cv,pv)                                    ##The moment we've b
een waiting for! The datasets are merged into one   
                                                     ##It may have b
een able to be merged earlier but now we are really done   
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                                                     ##generating ce
fepime or PTZ specific data from the original sets.   
                                                     ##This also all
ows me to subset the vancomycin use data to only those patients   
vanc<-
subset(vanc, vanc$Encounter.ID %in% cvp$EID)   ##we still have in th
e data. Alternatively, I could have created cv and pv specific   
                                                     ##vancomycin da
tasets and rbind'd them together. But this works just as well.   
                                                     ##The vanc data
set will be used in a bit. First, time to generate some more data.   
   
rm(cv,pv)                                            ##these exist i
n cvp and are no longer needed.    
   
cvp$baseline_scr<-
as.numeric(cvp$baseline_scr)       ##Changing these character 'numbe
rs' to numeric ones for use!   
cvp$max_scr<-as.numeric(cvp$max_scr)   
cvp<-subset(cvp, is.na(cvp$baseline_scr)==F)   
                                                                    
      ## calculate baseline creatinine clearance for all pts   
for(i in 1:length(cvp$EID)){   
  if(cvp$GENDER[i]=='FEMALE'){   
    cvp$baseline_crcl[i]<- (0.85*((140-
cvp$AGE[i])/cvp$baseline_scr[i]))   
  }   
  else{   
    cvp$baseline_crcl[i]<- ((140-cvp$AGE[i])/cvp$baseline_scr[i])   
  }   
}   
                                                                    
##calculate minimum creatinine clearance for all pts   
for(i in 1:length(cvp$EID)){   
  if(cvp$GENDER[i]=='FEMALE'){   
    cvp$min_crcl[i]<- (0.85*((140-cvp$AGE[i])/cvp$max_scr[i]))   
  }   
  else{   
    cvp$min_crcl[i]<- ((140-cvp$AGE[i])/cvp$max_scr[i])   
  }   
}   
   
cvp$percent_change<-(cvp$min_crcl/cvp$baseline_crcl-
1)*100        ##calculate percent change from baseline so that decre
ases are negative   
   
for(i in 1:length(cvp$EID)){                                      ##
assign RIFLE labels to appropriate degrees of renal impairment   
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  if (cvp$percent_change[i]>=0){                                  ##
if percent_change is >=0, the max SCr is equal to baseline, suggesti
ng GFR improvement   
    cvp$RIFLE[i]<-"No injury"   
  }   
  else {   
    if (abs(cvp$percent_change[i])<25){   
      cvp$RIFLE[i]<-'No injury'   
    }   
    if (abs(cvp$percent_change[i])>=25 & abs(cvp$percent_change[i])<
50){   
      cvp$RIFLE[i] <-'RISK'   
    }   
    if (abs(cvp$percent_change[i])>=50 & abs(cvp$percent_change[i])<
75){   
      cvp$RIFLE[i] <-'INJURY'   
    }   
    if (abs(cvp$percent_change[i])>=75){   
      cvp$RIFLE[i] <- 'Failure'   
    }   
  }   
}   
   
for(i in 1:length(cvp$EID)){                                    ##As
signs binary outcome for AKI (Risk, Injury, Failure) vs No AKI   
  if(cvp$RIFLE[i] =='No injury'){                               ##Ca
n convert to a 0/1 answer for modeling.    
    cvp$AKI[i]<-"No AKI"   
  }   
  else{   
    cvp$AKI[i]<-'AKI'   
  }   
}   
   
#               Starting here we do a lot of loading scripts    
   
source('f:/Jessica data/Test/first_vanc.R')          ##Firstvanc fin
ds the first vancomycin trough   
vanc<-
rbind(pmeds,cmeds)                             ##recreates the vanco
mycin dataset with some of the manipulated time variables   
vanc<-
subset(vanc, vanc$drug=='Vancomycin')          ##Selects only vancom
ycin   
vanc$Dose<-as.numeric(vanc$Dose)   
   
source('f:/Jessica data/Test/test_avgvanc.R')        ##test_avgvanc 
calculates the average daily dose of vancomycin for the entire time 
on therapy   
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for (i in 1:length(vanc$Encounter.ID)){              ##First need to
 standardize the doses in MG instead of G, multiplying 1g by 1000 to
 get 1000 mg   
  if(vanc$drug[i] =='Vancomycin'){   
    if (vanc$UOM[i] =='gram'){   
      vanc$UOM[i] <- 'MG'   
      vanc$Dose[i] <- vanc$Dose[i]*1000    
    }   
  }   
}   
for (i in 1:length(vanc$Encounter.ID)){              ##fixing random
 misdocumented 1g doses   
  if(vanc$Dose[i] < 10){   
    vanc$Dose[i] <- vanc$Dose[i]*1000    
  }   
}   
test_avgvanc(vanc)                                   ##running test_
avgvanc outputs Test_Average_vanc_dose_list   
avg_vanc<-ldply(Test_Average_vanc_dose_list)         ## list --
> dataframe   
names(avg_vanc)[names(avg_vanc)=='V1']<-
'EID'        ## renaming variables   
names(avg_vanc)[names(avg_vanc)=='V2']<-'avg_daily_vanc_dose'   
   
cvp<-
merge(cvp,avg_vanc, by='EID', all=T)                       ##adding 
average daily doses to the data set   
cvp$avg_daily_vanc_dose<-
as.numeric(cvp$avg_daily_vanc_dose)    ##and converting to number so
 we can do math.   
   
vlabs<-
labs[labs$ITEM_NAME=='Vancomycin Level Trough',]    ##subsetting all
 vanc troughs   
vlabs<-
subset(vlabs, vlabs$ENCNTR_ID %in% cvp$EID)         ##selecting only
 our patients   
vlabs$VAL_NUM<-
as.numeric(vlabs$VAL_NUM)                   ##converting to number (
needed for firstvanc.R to work)   
firstvanc(vlabs)                                           ##output 
is first_vanc_list   
first_vancdf<-ldply(first_vanc_list)                       ##list --
> dataframe   
names(first_vancdf)[names(first_vancdf)=='V1']<-
'EID'      ##renaming variables   
names(first_vancdf)[names(first_vancdf)=='V2']<-




merge(cvp, first_vancdf, by='EID',all=T)              ##first vanc t
rough is added to the dataset   
   
rm(Test_Average_vanc_dose_list, first_vanc_list, first_vancdf, avg_v
anc) ##cleaning RAM   
   
source('f:/Jessica data/Test/maxvanc.R')            ##loads maxvanc 
script which finds the maximum vancomycin trough   
maxvanc(vlabs)                                      ##output is max_
vanc_list   
maxvancdf<-ldply(max_vanc_list)                     ##list--
> dataframe   
names(maxvancdf)[names(maxvancdf)=='V1']<-
'EID'     ##renaming variables   
names(maxvancdf)[names(maxvancdf)=='V2']<-'max_vanc_trough'   
cvp<-
merge(cvp, maxvancdf, by='EID', all=T)         ##adding max_vanc_tro
ugh to dataset   
   
cvp$first_vanc_trough<-as.numeric(cvp$first_vanc_trough)   
cvp$max_vanc_trough<-as.numeric(cvp$max_vanc_trough)   
   
for (i in 1:length(cvp$EID)){                       ##For loop addin
g the vancomycin trough classifications for first vanc trough   
  if (is.na(cvp$first_vanc_trough[i])){   
    cvp$first_vanc_class[i] <-"No levels"   
  }   
  if(is.na(cvp$first_vanc_trough[i])==F){   
    if (cvp$first_vanc_trough[i]<10){   
      cvp$first_vanc_class[i]<- 'subtherapeutic'   
    }   
    if (cvp$first_vanc_trough[i]>=10 & cvp$first_vanc_trough[i]<15){
   
      cvp$first_vanc_class[i]<- 'low_therapeutic'   
    }   
    if (cvp$first_vanc_trough[i]>=15 & cvp$first_vanc_trough[i]<=20)
{   
      cvp$first_vanc_class[i]<- 'high_therapeutic'   
    }   
    if (cvp$first_vanc_trough[i]>20 ){   
      cvp$first_vanc_class[i]<- 'supratherapeutic'   
    }   
  }   
}   
   
for (i in 1:length(cvp$EID)){                      ##For loop adding
 the vancomycin trough classifications for maximum vanc trough   
  if (is.na(cvp$max_vanc_trough[i])){   
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    cvp$max_vanc_class[i] <-"No levels"   
  }   
  if(is.na(cvp$max_vanc_trough[i])==F){   
    if (cvp$max_vanc_trough[i]<10){   
      cvp$max_vanc_class[i]<- 'subtherapeutic'   
    }   
    if (cvp$max_vanc_trough[i]>=10 & cvp$max_vanc_trough[i]<15){   
      cvp$max_vanc_class[i]<- 'low_therapeutic'   
    }   
    if (cvp$max_vanc_trough[i]>=15 & cvp$max_vanc_trough[i]<=20){   
      cvp$max_vanc_class[i]<- 'high_therapeutic'   
    }   
    if (cvp$max_vanc_trough[i]>20 ){   
      cvp$max_vanc_class[i]<- 'supratherapeutic'   
    }   
  }   
}   
   
cvpmeds<-
rbind(cmeds,pmeds)                         ##creating subject specif
ic medication dataset   
source('f:/Jessica data/Test/dot.R')                ##load DoT scrip
t which calculates total DOT, DOT for each drug individually, and in
 combination   
dot(cvpmeds)                                        ##outputs DOT_li
st, takes quite a while, go get some coffee.   
dotdf<-ldply(DOT_list)                              ##list--
> dataframe; unlike the other lists-
>dfs, this has 7 variable names to change   
names(dotdf)[names(dotdf)=='V1']<-"EID"   
names(dotdf)[names(dotdf)=='V2']<-
"Total_DOT"       ##used DOT instead of DoT for ease of typing   
names(dotdf)[names(dotdf)=='V3']<-"Vanc_DOT"   
names(dotdf)[names(dotdf)=='V4']<-"PTZ_DOT"   
names(dotdf)[names(dotdf)=='V5']<-"PTZ_Vanc_DOT"   
names(dotdf)[names(dotdf)=='V6']<-"CFP_DOT"   
names(dotdf)[names(dotdf)=='V7']<-"CFP_Vanc_DOT"   
   
cvp<-
merge(cvp, dotdf, by='EID',all=T)              ##adding DoT informat
ion into dataset   
   
cvp$Total_DOT<-
as.numeric(cvp$Total_DOT)            ##convert character numbers to 
numeric ones for math   
cvp$Vanc_DOT<-as.numeric(cvp$Vanc_DOT)   
cvp$PTZ_DOT<-as.numeric(cvp$PTZ_DOT)   
cvp$PTZ_Vanc_DOT<-as.numeric(cvp$PTZ_Vanc_DOT)   
cvp$CFP_DOT<-as.numeric(cvp$CFP_DOT)   
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cvp$CFP_Vanc_DOT<-as.numeric(cvp$CFP_Vanc_DOT)   
   
rm(DOT_list,max_vanc_list,maxvancdf,dotdf)          ##cleaning   
   
cvp$Combo_DOT<-
cvp$PTZ_Vanc_DOT+cvp$CFP_Vanc_DOT    ##creates composite combination
 tx variable for analysis, needs to be done before next step.   
   
#***** sets 0 values to NA so the 0's don't impact any mean, median 
calculations... but have to add na.rm=T to most *****#   
for(i in 1:length(cvp$EID)){   
  if (cvp$CFP_DOT[i] == 0){   
    cvp$CFP_DOT[i]<-NA   
  }   
}   
   
for(i in 1:length(cvp$EID)){   
  if (cvp$PTZ_DOT[i] == 0){   
    cvp$PTZ_DOT[i]<-NA   
  }   
}   
   
for(i in 1:length(cvp$EID)){   
  if (cvp$PTZ_Vanc_DOT[i] == 0){   
    cvp$PTZ_Vanc_DOT[i]<-NA   
  }   
}   
   
for(i in 1:length(cvp$EID)){   
  if (cvp$CFP_Vanc_DOT[i] == 0){   
    cvp$CFP_Vanc_DOT[i]<-NA   
  }   
}   
   
for(i in 1:length(cvp$EID)){                                        
           ##gives a single Y/N variable for occurence of hypotensio
n   
  ifelse(cvp$MEAN_ARTERIAL_UNDER_60_FLG[i]=='Y'|cvp$HYPOTENSION_FLG[
i]=='Y'|   ##this excludes SBP < 100 mmHg flag as this really isn't 
defensible   
           cvp$VASOPRESSORS_FLG[i]=='Y'|cvp$INOTROPES_FLG[i]=='Y',   
         cvp$hypotension[i]<-'Y',cvp$hypotension[i]<-'N')   
}   
   
for(i in 1:length(cvp$EID)){                                        
         ##Y/N for nephrotoxic drug exposure. Does not give a count.
   
  ifelse(cvp$ACYCLOVIR_FLG[i]=='Y'| cvp$AMINOGLYCOSIDES_FLG[i]=='Y'|
cvp$AMPHOTERICIN_B_FLG[i]=='Y'|   
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           cvp$ANGIOTENSIN_FLG[i]=='Y'| cvp$ANGIOTENSION_FLG[i]=='Y'
|cvp$COLISTIN_FLG[i]=='Y' |    
           cvp$CYCLOSPORINE_FLG[i]=='Y'| cvp$FOSCARNET_FLG[i]=='Y'| 
cvp$LOOP_DIURETICS_FLG[i]=='Y'|   
           cvp$NON_STEROIDAL_ANTI_FLG[i]=='Y'| cvp$SULFONAMIDES_FLG[
i]=='Y'| cvp$TACROLIMUS_FLG[i]=='Y'|   
           cvp$TENOFOVIR_FLG[i]=='Y',cvp$nephrotoxic_drug[i]<-
"Y",cvp$nephrotoxic_drug[i]<-"N")   
}   
   
cvp<-
subset(cvp, is.na(cvp$RIFLE)==F)             ##cleaning up data, for
 some reason patients are added at some point and a bunch of NAs are
 added   
   
for (i in 1:length(cvp$EID)){                     ##Counts all nephr
otoxic drug exposure, dehydration, and dialysis flags   
  n<-
0                                            ##Ignores INTRAV_AGENTS
_FLG because this is Y for all   
  for (y in c(20:21, 23:30, 32:35)){   
    if (cvp[i,y]=='Y'){   
      n<-n+1   
    }   
  }   
  cvp$rf_num[i] <- n   
}   
   
for (i in 1:length(cvp$EID)){                     ##creates new vari
able that includes hypotension as a risk factor, avoids double count
ing    
  if (cvp$hypotension[i]=='Y'){                   ##multiple hypoten
sion exposures   
    cvp$total_rf[i]<-cvp$rf_num[i]+1   
  }   
  else{   
    cvp$total_rf[i]<-cvp$rf_num[i]   
  }   
}   
   
for (i in 1:length(cvp$EID)){                     ##groups # of risk
 factors, 0-3, and 4+, coded as numerical value for math   
  if (cvp$total_rf[i]==0){   
    cvp$rf_group[i]<-0   
  }   
  if (cvp$total_rf[i]==1){   
    cvp$rf_group[i]<-1   
  }   
  if (cvp$total_rf[i]==2){   
115 
 
    cvp$rf_group[i]<-2   
  }   
  if (cvp$total_rf[i]==3){   
    cvp$rf_group[i]<-3   
  }   
  if (cvp$total_rf[i]>=4){   
    cvp$rf_group[i]<-4   
  }   
}   
   
for(i in 1:length(cvp$EID)){                      ##creates Y/N mort
ality variable   
  if (cvp$DISCHRG_DES[i] == 'DEATH <=48 HRS'|cvp$DISCHRG_DES[i] == '
DEATH > 48 HRS'|   
        cvp$DISCHRG_DES[i] == 'HOSPICE HOME'|cvp$DISCHRG_DES[i] == '
HOSPICE TO MED FAC'){   
    cvp$mortality[i]<-'Y'   
  }   
  else{   
    cvp$mortality[i]<-'N'   
  }   
}   
source('f:/Jessica data/Test/dreg.R')            ##loads dreg script
 which finds the PTZ regimen; output = dreg_list   
source('f:/Jessica data/Test/dreg2_cfp.R')       ##loads dreg2 scrip
t which finds the Cefepime regimen; output = dreg2_list   
   
pv<-
subset(cvp, cvp$group=='PV')                             ##creates i
ntermediate subset to recreate the pmeds set   
pmeds<-subset(cvpmeds, cvpmeds$Encounter.ID %in% pv$EID)   
pmeds<-subset(pmeds, pmeds$drug=='PTZ')   
dreg(pmeds)                                      ##calculates the PT
Z regimen based on max number of doses per day,  if >=4 freq=Q6h, if
 <= 3 freq =q8h   
pdf<-ldply(dreg_list)                            ##list--
> dataframe   
pdf2<-
pdf[pdf$V2==1,]                            ## finding patients who o
nly received 1 dose of PTZ per day,   
cvp<-
subset(cvp, !(cvp$EID %in% pdf2$V1))        ##excluding above patien
ts   
pdf3<-
subset(pdf, !(pdf$V1 %in% pdf2$V1))        ##subset of included pati
ents   
names(pdf3)[names(pdf3)=='V1']<-
'EID'            ##renaming variables   
names(pdf3)[names(pdf3)=='V2']<-'NUMBER'   
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names(pdf3)[names(pdf3)=='V3']<-'ptz_dose'   
names(pdf3)[names(pdf3)=='V4']<-'ptz_freq'   
cvp<-
merge(cvp, pdf3, by='EID', all=T)           ##combining datasets   
cvp$ptz_reg<-
paste(cvp$ptz_dose, cvp$ptz_freq)   ##creating ptz_reg (regimen) var
iable for analysis and graphing   
   
cv<-
subset(cvp, cvp$group=='CV')                              ##same ste
ps as above except for cefepime   
cmeds<-subset(cvpmeds, cvpmeds$Encounter.ID %in% cv$EID)   
cmeds<-subset(cmeds, cmeds$drug=="Cefepime")   
dreg2(cmeds)   
cdf<-
ldply(dreg2_list)                           ##Don't check for patien
ts only receiving 1 dose per day as q24h is a valid regimen for cefe
pime   
names(cdf)[names(cdf)=='V1']<-"EID"   
names(cdf)[names(cdf)=='V2']<-"NUMBER"   
names(cdf)[names(cdf)=='V3']<-"cfp_dose"   
names(cdf)[names(cdf)=='V4']<-"cfp_freq"   
cvp<-
merge(cvp, cdf, by="EID", all=T)            ##combining datasets   
cvp$cfp_reg<-
paste(cvp$cfp_dose, cvp$cfp_freq)   ##cfp_reg variable created   
   
cvp$NUMBER.x<-
NULL                               ##NUMBER.x and .y are created fro
m the previous mergers, they are not needed anymore   
cvp$NUMBER.y<-NULL   
   
for (i in 1:length(cvp$EID)){                    ##NA's induced by m
ergers, then pasted together(NA NA) from regimen variable creation. 
Setting to NA.   
  if(cvp$ptz_reg[i]=='NA NA'){   
    cvp$ptz_reg[i]<-NA   
  }   
  if(cvp$cfp_reg[i]=='NA NA'){   
    cvp$cfp_reg[i]<-NA   
  }   
}   
   
library(MatchIt)                                 ##load the MatchIt 
package to perform matching   
library(dplyr)                                   ##load dplyr packag




as.numeric(cvp$TOTAL_CHARLSON_SCORE)  ##Set charlson score to numeri
c value to match on   
   
for(i in 1:length(cvp$EID)){                     ##converting binary
 responses to 0/1 to match on.   
  if(cvp$GENDER[i]=='MALE'){   
    cvp$male[i]<-1   
  }   
  else{   
    cvp$male[i]<-0   
  }   
}   
   
   
for(i in 1:length(cvp$EID)){   
  if(cvp$group[i]=='CV'){   
    cvp$group_num[i]<-1   
  }   
  else{   
    cvp$group_num[i]<-0   
  }   
}   
   
for(i in 1:length(cvp$EID)){   
  if(cvp$hypotension[i]=='Y'){   
    cvp$hypotension_num[i]<-1   
  }   
  else{   
    cvp$hypotension_num[i]<-0   
  }   
}   
   
Matching 
mdf<-
select(cvp, EID, group_num, AGE, TOTAL_CHARLSON_SCORE,              
##subsets variables to match on, since matchit function doesn't   
            Combo_DOT,hypotension_num,baseline_crcl, male, rf_group)
     ##like NAs in the data even if not in the matching variables li
ke in this case   
   
m.out<-
matchit(group_num~AGE+rf_group+Combo_DOT+TOTAL_CHARLSON_SCORE+    ##
running the match on the mdf subset, using nearest neighbor method   
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                 hypotension_num+baseline_crcl+male, data=mdf,      
     ##ratio 3:1   
               method='nearest',exact=c('male','hypotension_num','rf
_group'), ratio=3)   
   
mat_data<-
match.data(m.out)                                 ##setting up a dat
aframe with the matched variables, this contains distances and weigh
ts   
cvp_matched<-
subset(cvp, cvp$EID %in% mat_data$EID)         ##Getting our final 3
:1 matched dataset.   
   
assign("cvp",value=cvp,pos=globalenv())   
assign("m.out",value=m.out,pos=globalenv())   
assign("cvp_matched",value=cvp_matched,pos=globalenv())   
}   
   
library(stargazer)   
library(sjPlot)   
cvp_matched$first_vanc_trough<-
as.numeric(cvp_matched$first_vanc_trough)   
cvp_matched$max_vanc_trough<-
as.numeric(cvp_matched$max_vanc_trough)   
cvp_matched$percent_decrease<-cvp_matched$percent_change   
for( i in 1:length(cvp_matched$EID)){   
  if(cvp_matched$percent_decrease[i]==0){   
    cvp_matched$percent_decrease[i]<-NA   
  }   
}   
   
stargazer(cvp_matched[cvp_matched$group=='PV',],   
          type='text',title='Piperacillin/Tazobactam plus vancomycin
',    
          digits=1, out='pv matched descriptive stats.txt')   
stargazer(cvp_matched[cvp_matched$group=='CV',],   
          type='text',title='Cefepime plus vancomycin',    
          digits=1, out='cv matched descriptive stats.txt')   
stargazer(cvp[cvp$group=='PV',],   
          type='text',title='Piperacillin/Tazobactam plus vancomycin
',    
          digits=1, out='pv unmatched descriptive stats.txt')   
stargazer(cvp[cvp$group=='CV',],   
          type='text',title='Cefepime plus vancomycin',    
          digits=1, out='cv unmatched descriptive stats.txt')   
   
matvanc<-
subset(cvp_matched, cvp_matched$first_vanc_class!='No levels')   
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risk<-table(cvp_matched$RIFLE=='RISK', cvp_matched$group)   
injury<-table(cvp_matched$RIFLE=='INJURY', cvp_matched$group)   
fail<-table(cvp_matched$RIFLE=='Failure', cvp_matched$group)   
any_aki<-table(cvp_matched$RIFLE!='No injury', cvp_matched$group)   
fsub<-
table(matvanc$first_vanc_class=='subtherapeutic', matvanc$group)   
flow<-
table(matvanc$first_vanc_class=='low_therapeutic', matvanc$group)   
fhigh<-
table(matvanc$first_vanc_class=='high_therapeutic', matvanc$group)   
fsup<-
table(matvanc$first_vanc_class=='supratherapeutic', matvanc$group)   
ftx<-table(matvanc$first_vanc_class =='low_therapeutic' |    
             matvanc$first_vanc_class=='high_therapeutic', matvanc$g
roup)   
fv30<-table(matvanc$first_vanc_trough>30,matvanc$group)   
   
matvanc<-
subset(cvp_matched, cvp_matched$max_vanc_class!='No levels')   
   
msub<-
table(matvanc$max_vanc_class=='subtherapeutic', matvanc$group)   
mlow<-
table(matvanc$max_vanc_class=='low_therapeutic', matvanc$group)   
mhigh<-
table(matvanc$max_vanc_class=='high_therapeutic', matvanc$group)   
msup<-
table(matvanc$max_vanc_class=='supratherapeutic', matvanc$group)   
mtx<-table(matvanc$max_vanc_class=='low_therapeutic'|   
             matvanc$max_vanc_class=='high_therapeutic', matvanc$gro
up)   
mv30<-table(matvanc$max_vanc_trough>30,matvanc$group)   
   
attach(cvp_matched)   
Data table generation 
sink('Outcomes and baseline characteristics output.txt')   
print('********* T-test results***********')   
lapply(cvp_matched[,c('AGE','TOTAL_CHARLSON_SCORE','LENGTH_OF_STAY_N
UM',   
                       'baseline_scr','baseline_crcl','min_crcl','pe
rcent_change','percent_decrease',   
                       'avg_daily_vanc_dose','first_vanc_trough','ma
x_vanc_trough',   
                       'Total_DOT','Vanc_DOT', 'Combo_DOT', 'rf_num'
,'total_rf',   
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                       'rf_group','male')], function(x) t.test(x~cvp
_matched$group))   
t.test(CFP_DOT[group=='CV'], PTZ_DOT[group=='PV'])   
   
print('')   
print('')   
print('')   
print('*********Wilcoxon Rank Sum tests for nonparametric analysis**
********')   
lapply(cvp_matched[,c('AGE','TOTAL_CHARLSON_SCORE','LENGTH_OF_STAY_N
UM',   
                      'baseline_scr','baseline_crcl','percent_change
','percent_decrease',   
                      'avg_daily_vanc_dose','first_vanc_trough','max
_vanc_trough',   
                      'Total_DOT','Vanc_DOT','Combo_DOT', 'rf_num','
total_rf',   
                      'rf_group','male')], function(x) wilcox.test(x
~cvp_matched$group))   
wilcox.test(CFP_DOT[group=='CV'], PTZ_DOT[group=='PV'])   
   
print('')   
print('')   
print('')   
print('********Piperacillin/Tazobactam and vancomycin summary result
s*******')   
lapply(cvp_matched[,c('AGE','TOTAL_CHARLSON_SCORE','LENGTH_OF_STAY_N
UM',   
                      'baseline_scr','baseline_crcl','percent_change
','percent_decrease',   
                      'avg_daily_vanc_dose','first_vanc_trough','max
_vanc_trough',   
                      'Total_DOT','Vanc_DOT','Combo_DOT', 'rf_num','
total_rf',   
                      'rf_group','male')], function(x) summary(x[gro
up=='PV']))   
   
print('')   
print('')   
print('')   
print('******Cefepime and vancomycin summary results**********')   
lapply(cvp_matched[,c('AGE','TOTAL_CHARLSON_SCORE','LENGTH_OF_STAY_N
UM',   
                      'baseline_scr','baseline_crcl','percent_change
','percent_decrease',   
                      'avg_daily_vanc_dose','first_vanc_trough','max
_vanc_trough',   
                      'Total_DOT','Vanc_DOT','Combo_DOT', 'rf_num','
total_rf',   
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                      'rf_group','male')], function(x) summary(x[gro
up=='CV']))   
   
print('')   
print('')   
print('')   
print('*******Primary outcomes**********')   
chisq.test(risk)   
risk   
prop.table(risk,2)*100   
chisq.test(injury)   
injury   
prop.table(injury,2)*100   
chisq.test(fail)   
fail   
prop.table(fail,2)*100   
chisq.test(any_aki)   
any_aki   
prop.table(any_aki,2)*100   
   
   
print('')   
print('')   
print('')   
print('*******Baseline matched cohort characteristics*******')   
chisq.test(table(GENDER, group))   
table(GENDER, group)   
prop.table(table(GENDER, group),2)*100   
   
chisq.test(table(mortality, group))   
table(mortality, group)   
prop.table(table(mortality, group),2)*100   
   
chisq.test(table(DIALYSIS_FLG,group))   
table(DIALYSIS_FLG,group)   
prop.table(table(DIALYSIS_FLG,group),2)*100   
   
chisq.test(table(DEHYDRATION_FLG, group))   
table(DEHYDRATION_FLG, group)   
prop.table(table(DEHYDRATION_FLG, group),2)*100   
   
chisq.test(table(hypotension,group))   
table(hypotension,group)   
prop.table(table(hypotension,group),2)*100   
   
chisq.test(table(nephrotoxic_drug,group))   
table(nephrotoxic_drug,group)   
prop.table(table(nephrotoxic_drug,group),2)*100   
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chisq.test(table(ACYCLOVIR_FLG, group))   
table(ACYCLOVIR_FLG, group)   
prop.table(table(ACYCLOVIR_FLG, group),2)*100   
   
chisq.test(table(ANGIOTENSIN_FLG, group))   
table(ANGIOTENSIN_FLG, group)   
prop.table(table(ANGIOTENSIN_FLG, group),2)*100   
   
chisq.test(table(ANGIOTENSION_FLG, group))   
table(ANGIOTENSION_FLG, group)   
prop.table(table(ANGIOTENSION_FLG, group),2)*100   
   
chisq.test(table(AMINOGLYCOSIDES_FLG, group))   
table(AMINOGLYCOSIDES_FLG, group)   
prop.table(table(AMINOGLYCOSIDES_FLG, group),2)*100   
   
chisq.test(table(AMPHOTERICIN_B_FLG, group))   
table(AMPHOTERICIN_B_FLG, group)   
prop.table(table(AMPHOTERICIN_B_FLG, group),2)*100   
   
chisq.test(table(CYCLOSPORINE_FLG, group))   
fisher.test(table(CYCLOSPORINE_FLG, group))   
table(CYCLOSPORINE_FLG, group)   
prop.table(table(CYCLOSPORINE_FLG, group),2)*100   
   
chisq.test(table(FOSCARNET_FLG,group))   
fisher.test(table(FOSCARNET_FLG,group))   
table(FOSCARNET_FLG,group)   
prop.table(table(FOSCARNET_FLG,group),2)*100   
   
chisq.test(table(LOOP_DIURETICS_FLG,group))   
table(LOOP_DIURETICS_FLG,group)   
prop.table(table(LOOP_DIURETICS_FLG,group),2)*100   
   
chisq.test(table(NON_STEROIDAL_ANTI_FLG, group))   
table(NON_STEROIDAL_ANTI_FLG, group)   
prop.table(table(NON_STEROIDAL_ANTI_FLG, group),2)*100   
   
chisq.test(table(SULFONAMIDES_FLG, group))   
table(SULFONAMIDES_FLG, group)   
prop.table(table(SULFONAMIDES_FLG, group),2)*100   
   
chisq.test(table(TACROLIMUS_FLG, group))   
table(TACROLIMUS_FLG, group)   
prop.table(table(TACROLIMUS_FLG, group),2)*100   
   
chisq.test(table(TENOFOVIR_FLG,group))   
fisher.test(table(TENOFOVIR_FLG,group))   
table(TENOFOVIR_FLG,group)   
123 
 
prop.table(table(TENOFOVIR_FLG,group),2)*100   
   
table(rf_group,group)   
chisq.test(rf_group==0,group)   
chisq.test(rf_group==1,group)   
chisq.test(rf_group==2,group)   
chisq.test(rf_group==3,group)   
chisq.test(rf_group==4,group)   
   
print('')   
print('')   
print('')   
print('Vancomycin classifications - first vancomycin trough')   
addmargins(table(cvp_matched$first_vanc_class, cvp_matched$group),1)
   
chisq.test(fsub)   
fsub   
prop.table(fsub,2)*100   
chisq.test(flow)   
flow   
prop.table(flow,2)*100   
chisq.test(fhigh)   
fhigh   
prop.table(fhigh,2)*100   
chisq.test(fsup)   
fsup   
prop.table(fsup, 2)*100   
chisq.test(ftx)   
ftx   
prop.table(ftx, 2)*100   
chisq.test(fv30)   
fv30   
prop.table(fv30,2)*100   
   
   
   
print('')   
print('')   
print('')   
print('Vancomycin classifications - max vancomycin trough')   
print('Table of maximum vanc troughs by group')   
addmargins(table(cvp_matched$max_vanc_class, cvp_matched$group),1)   
   
chisq.test(msub)   
msub   
prop.table(msub,2)*100   
chisq.test(mlow)   
mlow   
prop.table(mlow, 2)*100   
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chisq.test(mhigh)   
mhigh   
prop.table(mhigh, 2)*100   
chisq.test(msup)   
msup   
prop.table(msup,2)*100   
chisq.test(mtx)   
mtx   
prop.table(mtx,2)*100   
chisq.test(mv30)   
mv30   
prop.table(mv30,2)*100   
   
chisq.test(table(avg_daily_vanc_dose<500, group))   
table(avg_daily_vanc_dose<500, group)   
prop.table(table(avg_daily_vanc_dose<500, group),2)*100   
   
chisq.test(table(avg_daily_vanc_dose>=500 & avg_daily_vanc_dose<1000
, group))   
table(avg_daily_vanc_dose>=500 & avg_daily_vanc_dose<1000, group)   
prop.table(table(avg_daily_vanc_dose>=500 & avg_daily_vanc_dose<1000
, group),2)*100   
   
   
chisq.test(table(avg_daily_vanc_dose>=1000 & avg_daily_vanc_dose<150
0, group))   
table(avg_daily_vanc_dose>=1000 & avg_daily_vanc_dose<1500, group)   
prop.table(table(avg_daily_vanc_dose>=1000 & avg_daily_vanc_dose<150
0, group),2)*100   
   
   
chisq.test(table(avg_daily_vanc_dose>=1500 & avg_daily_vanc_dose<200
0, group))   
table(avg_daily_vanc_dose>=1500 & avg_daily_vanc_dose<2000, group)   
prop.table(table(avg_daily_vanc_dose>=1500 & avg_daily_vanc_dose<200
0, group),2)*100   
   
chisq.test(table(avg_daily_vanc_dose>=2000, group))   
table(avg_daily_vanc_dose>=2000, group)   
prop.table(table(avg_daily_vanc_dose>=2000, group),2)*100   
   
chisq.test(table(avg_daily_vanc_dose>=3000, group))   
table(avg_daily_vanc_dose>=3000, group)   
prop.table(table(avg_daily_vanc_dose>=3000, group),2)*100   
   
chisq.test(table(avg_daily_vanc_dose>=4000, group))   
table(avg_daily_vanc_dose>=4000, group)   
prop.table(table(avg_daily_vanc_dose>=4000, group),2)*100   
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sink()   
   
sink('AKI analysis output.txt')   
print('*************AKI t test analysis*******************')   
lapply(cvp_matched[,c('AGE','TOTAL_CHARLSON_SCORE','LENGTH_OF_STAY_N
UM',   
                      'baseline_scr','baseline_crcl','percent_change
','percent_decrease',   
                      'avg_daily_vanc_dose','first_vanc_trough','max
_vanc_trough',   
                      'Total_DOT','Vanc_DOT','Combo_DOT','PTZ_DOT', 
'CFP_DOT', 'CFP_Vanc_DOT',    
                      'PTZ_Vanc_DOT', 'rf_num','total_rf','rf_group'
,'male')],    
       function(x) t.test(x~cvp_matched$AKI))   
print('')   
print('')   
print('')   
print('*********AKI Wilcoxon Rank Sum tests for nonparametric analys
is**********')   
lapply(cvp_matched[,c('AGE','TOTAL_CHARLSON_SCORE','LENGTH_OF_STAY_N
UM',   
                      'baseline_scr','baseline_crcl','percent_change
','percent_decrease',   
                      'avg_daily_vanc_dose','first_vanc_trough','max
_vanc_trough',   
                      'Total_DOT','Vanc_DOT','Combo_DOT','PTZ_DOT', 
'CFP_DOT', 'CFP_Vanc_DOT',    
                      'PTZ_Vanc_DOT', 'rf_num','total_rf','rf_group'
,'male')],   
       function(x) wilcox.test(x~cvp_matched$AKI))   
   
print('')   
print('')   
print('')   
print('********AKI group summary results*******')   
lapply(cvp_matched[,c('AGE','TOTAL_CHARLSON_SCORE','LENGTH_OF_STAY_N
UM',   
                      'baseline_scr','baseline_crcl','percent_change
','percent_decrease',   
                      'avg_daily_vanc_dose','first_vanc_trough','max
_vanc_trough',   
                      'Total_DOT','Vanc_DOT','Combo_DOT','PTZ_DOT', 
'CFP_DOT', 'CFP_Vanc_DOT',    
                      'PTZ_Vanc_DOT', 'rf_num','total_rf','rf_group'
,'male')],    
       function(x) summary(x[AKI=='AKI']))   
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print('')   
print('')   
print('')   
print('******No AKI summary results**********')   
lapply(cvp_matched[,c('AGE','TOTAL_CHARLSON_SCORE','LENGTH_OF_STAY_N
UM',   
                      'baseline_scr','baseline_crcl','percent_change
','percent_decrease',   
                      'avg_daily_vanc_dose','first_vanc_trough','max
_vanc_trough',   
                      'Total_DOT','Vanc_DOT','Combo_DOT','PTZ_DOT', 
'CFP_DOT', 'CFP_Vanc_DOT',    
                      'PTZ_Vanc_DOT', 'rf_num','total_rf','rf_group'
,'male')],    
       function(x) summary(x[AKI=='No AKI']))   
   
   
print('')   
print('')   
print('')   
print('******AKI by nephrotoxin exposure**********')   
addmargins(table(cvp_matched$RIFLE, cvp_matched$nephrotoxic_drug),1)
   
prop.table(table(cvp_matched$RIFLE, cvp_matched$nephrotoxic_drug),2)
*100   
chisq.test(table(cvp_matched$RIFLE=='RISK', cvp_matched$nephrotoxic_
drug))   
chisq.test(table(cvp_matched$RIFLE=='INJURY', cvp_matched$nephrotoxi
c_drug))   
chisq.test(table(cvp_matched$RIFLE=='Failure', cvp_matched$nephrotox
ic_drug))   
chisq.test(table(cvp_matched$RIFLE!='No injury', cvp_matched$nephrot
oxic_drug))   
   
print('')   
print('')   
print('')   
print('******AKI by nephrotoxin exposure**********')   




)   
chisq.test(table(cvp_matched$RIFLE=='INJURY', cvp_matched$hypotensio
n))   
chisq.test(table(cvp_matched$RIFLE=='Failure', cvp_matched$hypotensi
on))   
chisq.test(table(cvp_matched$RIFLE!='No injury', cvp_matched$hypoten
sion))   
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sink()   
   
p3<-
subset(cvp_matched, cvp_matched$ptz_reg =='4.5 Q6H'|cvp_matched$ptz_
reg=='3.375 Q6H')   
detach(cvp_matched)   
attach(p3)   
   
sink('PTZ regimen results.txt')   
   
addmargins(table(RIFLE, ptz_reg))   
prop.table(table(RIFLE, ptz_reg),2)*100   
chisq.test(table(RIFLE=='RISK',ptz_reg))   
chisq.test(table(RIFLE=='INJURY',ptz_reg))   
chisq.test(table(RIFLE=='Failure',ptz_reg))   
chisq.test(table(RIFLE!='No injury',ptz_reg))   
   
sink()   
   
write.table(cvp, row.names=F, 'AKI_dataset_FINAL.txt', sep=',')   
write.table(cvp_matched, row.names=F, 'AKI_matched_dataset_FINAL.txt
', sep=',')   
sink('matching diagnositics.txt')   
m.out   
summary(m.out)   





Appendix B: Chapter 3 code 
Data wrangling 
library(plyr)   
library(dplyr)   
library(data.table)   
dat<-
read.csv('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/cotner_
drugs.csv', sep=',', colClasses='character')   
dem<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/cotner_dem
o.csv',   
           sep=',', colClasses='character')   
dx<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/COTNER_DX2
016-02-17 11-41-11.csv',    
          sep=',', colClasses='character')   
ht<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/COTNER_HT_
WT2016-02-17 11-42-07.csv', sep=',',    
          colClasses='character')   
   
merid<-
unique(dat$ENCNTR_ID[grepl('meropenem', dat$NAME, ignore.case = T)])
   
pipid<-
unique(dat$ENCNTR_ID[grepl('piperacillin', dat$NAME, ignore.case = T
)])   
cfpid<-
unique(dat$ENCNTR_ID[grepl('cefepime', dat$NAME, ignore.case = T)]) 
  
   
cfpmem<-intersect(cfpid, merid)   
cfppip<-intersect(cfpid, pipid)   
cfpmempip<-intersect(cfpmem, cfppip)   
pipmem<-intersect(pipid, merid)   
   
test<-
unique(dat$ENCNTR_ID[dat$ENCNTR_ID %in% merid | dat$ENCNTR_ID %in% p
ipid | dat$ENCNTR_ID %in% cfpid])   
df<-data.frame(EID = test, group = NA)   
   
   
df$group[df$EID %in% cfpid]<-'C'   
df$group[df$EID %in% pipid]<-'P'   
df$group[df$EID %in% merid]<-'M'   
df$group[df$EID %in% cfpmem]<-'CM'   
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df$group[df$EID %in% cfppip]<-'CP'   
df$group[df$EID %in% pipmem]<-'MP'   
df$group[df$EID %in% cfpmempip]<-'CMP'   
   
   
m_final=as.character(df$EID[df$group=='M'])   
p_final=as.character(df$EID[df$group=='P'])   
rm(asid, cfpid, pipid, merid, aspip, ascfp, asmem, cfpmem, cfppip, p
ipmem, aspipmem, ascfpmem, aspipcfp, aspipcfpmem, cfpmempip, test)   
####################################################################
##################################################   
##                           Demographics clean up                  
                                                ##   
####################################################################
##################################################   
dem<-dem[dem$ENCNTR_ID %in% m_final | dem$ENCNTR_ID %in% p_final,]   
dem$drug[dem$ENCNTR_ID %in% m_final]<-'MEM'   
dem$drug[dem$ENCNTR_ID %in% p_final]<-'PTZ'   
dem<-dem[!duplicated(dem$ENCNTR_ID),]   
   
dem$ad_date<-sapply(strsplit(dem$ADMT_DT,' '),'[',1)   
dem$ad_date<-as.Date(dem$ad_date, format='%d-%b-%y')   
   
dem<-dem[dplyr::between(dem$ad_date,    
                        left = as.Date('2006-07-01'),    
                        right = as.Date('2015-09-30')    
                        #incbounds = T   
),]   
dem$COMORBIDITY_SCORE<-as.numeric(dem$COMORBIDITY_SCORE)   
dem$COMORBIDITY_SCORE[is.na(dem$COMORBIDITY_SCORE)]<-0   
dem$AGE<-as.numeric(dem$AGE)   
dem<-dem[dem$AGE >= 18,]   
dem$age_group[dem$AGE<45]<-'18-44'   
dem$age_group[dem$AGE>=45 & dem$AGE <65]<-'45-64'   
dem$age_group[dem$AGE>=65 & dem$AGE <80]<-'65-79'   
dem$age_group[dem$AGE>=80]<-'80+'   
   
dem$LENGTH_OF_STAY_NUM<-as.numeric(dem$LENGTH_OF_STAY_NUM)   
   
pregeid<-
unique(dx$FULL_ENCNTR_ID[grepl('v22',dx$DX_CD, ignore.case = T)])   
dem<-dem[!(dem$ENCNTR_ID %in% pregeid),]   
   
ckdeid<-
unique(dx$FULL_ENCNTR_ID[grepl('585\\.[12349]', dx$DX_CD, ignore.cas
e = T)])   
dem<-dem[!(dem$ENCNTR_ID %in% ckdeid),]   




unique(dx$FULL_ENCNTR_ID[grepl('277\\.', dx$DX_CD, ignore.case = T)]
)   
dem$CF[dem$ENCNTR_ID %in% cf]<-1   
dem$CF[is.na(dem$CF)]<-0   
   
htn<-
unique(dx$FULL_ENCNTR_ID[grepl('401\\.', dx$DX_CD, ignore.case = T)]
)   
dem$HTN[dem$ENCNTR_ID %in% htn]<-1   
dem$HTN[is.na(dem$HTN)]<-0   
   
dm<-
unique(dx$FULL_ENCNTR_ID[grepl('250\\.', dx$DX_CD, ignore.case = T)]
)   
dem$dm[dem$ENCNTR_ID %in% dm]<-1   
dem$dm[is.na(dem$dm)]<-0   
   
hf<-
unique(dx$FULL_ENCNTR_ID[grepl('428\\.', dx$DX_CD, ignore.case = T)]
)   
dem$hf[dem$ENCNTR_ID %in% hf]<-1   
dem$hf[is.na(dem$hf)]<-0   
   
ht<-ht[ht$ENCNTR_ID %in% dem$ENCNTR_ID,]   
ht$INIT_WT<-as.numeric(ht$INIT_WT)   
ht$HT<-as.numeric(ht$HT)   
ht$WT<-as.numeric(ht$WT)   
ht$INIT_WT[is.na(ht$INIT_WT)]<-ht$WT[is.na(ht$INIT_WT)]   
ht2<-select(ht, ENCNTR_ID, INIT_WT, HT)   
   
dem<-merge(dem, ht2, by='ENCNTR_ID', all=T)   
dem$INIT_WT[dem$INIT_WT==0]<-NA   
dem$HT[dem$HT==0]<-NA   
   
wtcut<-mean(dem$INIT_WT, na.rm=T)+4*sd(dem$INIT_WT, na.rm=T)   
dem<-dem[dem$INIT_WT<=wtcut | is.na(dem$INIT_WT),]   
htcut<-mean(dem$HT, na.rm=T)+4*sd(dem$HT, na.rm=T)   
dem<-dem[dem$HT<=htcut | is.na(dem$HT),]   
dem<-dem[dem$HT>27 | is.na(dem$HT),]   
   
dem$BMI<-dem$INIT_WT/((dem$HT/100)**2)   
rm(ckdeid, pregeid, ht, ht2, wtcut, htcut, dm, hf, htn,a_final, p_fi
nal, cf, df, crcl_cut)   
####################################################################
##################################################   
##                           Medications clean up                   




##################################################   
meds<-dat   
rm(dat)   
meds<-meds[meds$ENCNTR_ID %in% dem$ENCNTR_ID,]   
abx<-
meds[grepl('meropenem', meds$NAME, ignore.case = T) | grepl('piperac
illin', meds$NAME, ignore.case = T),]   
abx$admin_date<-
sapply(strsplit(abx$PERFRMD_FROM_DT_TM, ' '),'[',1)   
abx$admin_date<-as.Date(abx$admin_date, format = '%d-%b-%y')   
   
dem$tx_index<-NA   
dem$tx_end<-NA   
dem$DOT<-NA   
   
abx2<-select(abx, ENCNTR_ID, admin_date)   
abx2<-unique(abx2)   
   
for(i in 1:nrow(dem)){                                        ##~1.2
 hrs to complete   
  dem$tx_index[i] = min(abx2$admin_date[abx2$ENCNTR_ID == dem$ENCNTR
_ID[i]])   
  dem$tx_end[i] = max(abx2$admin_date[abx2$ENCNTR_ID == dem$ENCNTR_I
D[i]])   
  dem$DOT[i]<-
length(unique(abx2$admin_date[abx2$ENCNTR_ID == dem$ENCNTR_ID[i]])) 
  
}   
dem$tx_index<-as.Date(dem$tx_index, origin='1970-01-01')   
dem$tx_end<-as.Date(dem$tx_end, origin='1970-01-01')   
   
dem<-dem[dem$DOT>=2,]   
   
dem$caucasian[dem$RACE_CD_DES=='WHITE']<-1   
dem$caucasian[is.na(dem$caucasian)]<-0   
   
dem$ad_year<-sapply(strsplit(as.character(dem$ad_date), '-
'),'[',1)   
dem<-dem[dem$GENDR_CD_DES !='UNKNOWN',]   
####################################################################
##################################################   
##                           labs                                   
                                                ##   
####################################################################
##################################################   
labs<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/labs.txt',
 sep='\t',header=T, colClasses='character')   
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labs<-labs[labs$ENCNTR_ID %in% dem$ENCNTR_ID]   
scr<-labs[labs$ITM_NM =='Creatinine Level',]   
scr$date<-as.POSIXct(scr$ENTRD_DT_TM, format='%d-%b-%y %H:%M:%S')   
scr$VAL_NUM<-as.numeric(scr$VAL_NUM)   
scr<-scr[!is.na(scr$VAL_NUM),]   
   
   
dem<-dem[dem$ENCNTR_ID %in% scr$ENCNTR_ID,]   
for(i in 1:nrow(dem)){   
  x<- scr[scr$ENCNTR_ID == dem$ENCNTR_ID[i],]   
  dem$baseline_scr[i]<-x$VAL_NUM[x$date==min(x$date)]   
  dem$baseline_scr_date[i]<-min(x$date)   
}   
   
dem$baseline_crcl<-(140-dem$AGE)/dem$baseline_scr   
dem$baseline_crcl[dem$GENDR_CD_DES=='FEMALE']<-
dem$baseline_crcl[dem$GENDR_CD_DES=='FEMALE']*0.85   
   
dem<-dem[!is.na(dem$baseline_scr),]   
dem<-dem[dem$baseline_crcl>=30,]   
crclcut<-
mean(dem$baseline_crcl, na.rm = T)+4*sd(dem$baseline_crcl)   
dem<-dem[dem$baseline_crcl<=crclcut,]   
   
scr$date2<-sapply(strsplit(as.character(scr$date),' '),'[',1)   
scr$date2<-as.Date(scr$date2)   
   
for(i in 1:nrow(dem)){   
  x<- scr[scr$ENCNTR_ID == dem$ENCNTR_ID[i] & scr$date2 >= dem$tx_in
dex[i]+2 & scr$date2<dem$tx_end[i]+7,]   
  dem$max_scr[i]<-max(x$VAL_NUM)[1]   
  dem$max_scr_date[i]<-x$date2[x$VAL_NUM==max(x$VAL_NUM)][1]   
}   
   
dem$min_crcl<-(140-dem$AGE)/dem$max_scr   
dem$min_crcl[dem$GENDR_CD_DES=='FEMALE']<-
dem$min_crcl[dem$GENDR_CD_DES=='FEMALE']*0.85   
dem$percent_change<-(dem$min_crcl/dem$baseline_crcl-1)*100    
dem<-dem[!is.infinite(dem$max_scr),]   
   
dem$RIFLE[dem$percent_change <= -25 & dem$percent_change >-50]<-
'risk'   
dem$RIFLE[dem$percent_change <= -50 & dem$percent_change >-75]<-
'injury'   
dem$RIFLE[dem$percent_change <= -75| dem$max_scr>4]<-'failure'   
   
dem$aki[is.na(dem$RIFLE)]<-0   
dem$aki[!is.na(dem$RIFLE)]<-1   
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dem$baseline_crcl_cat[dem$baseline_crcl <60]<-1   
dem$baseline_crcl_cat[dem$baseline_crcl >=60 & dem$baseline_crcl<90]
<-2   
dem$baseline_crcl_cat[dem$baseline_crcl >=90]<-3   
####################################################################
##################################################   
##                           Nephrotoxin info                       
                                                ##   
####################################################################
##################################################   
library(stringr)   
neph<-
read.csv('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/COTNER_
NEPHROTOXIN.csv', colClasses='character')   
   
# vid<-
unique(meds$ENCNTR_ID[grepl('vancomycin', meds$NAME, ignore.case = T
)])   
# dem<- dem[!(dem$ENCNTR_ID %in% vid),]   
   
vanc<-meds[grepl('vanco', meds$NAME, ignore.case = T),]   
vanc<-vanc[grepl('v', vanc$TASK_ROUT_CD, ignore.case = T),]   
# vanc$NAME<-gsub('zzz','',vanc$NAME)   
# vanc$NAME<-gsub('inj','',vanc$NAME, ignore.case = T)   
# vanc$NAME<-gsub('\\.','',vanc$NAME)   
# vanc$NAME<-gsub('-','',vanc$NAME)   
# vanc$NAME<-gsub('\\(pediatric\\)','',vanc$NAME, ignore.case = T)   
# vanc$NAME<-str_trim(vanc$NAME)   
vanc$date<-sapply(strsplit(vanc$PERFRMD_FROM_DT_TM, ' '),'[',1)   
vanc$date<-as.Date(vanc$date,  format = '%d-%b-%y')   
   
ag<-
meds[grepl('aminogly', meds$THERPUTC_CATGRY, ignore.case = T),]   
ag<-ag[!grepl('inhal', ag$NAME, ignore.case = T),]   
ag<-ag[!grepl('irrigat', ag$NAME, ignore.case = T),]   
ag<-ag[!grepl('neomycin', ag$NAME, ignore.case = T),]   
# ag$NAME<-gsub('zzz','',ag$NAME)   
# ag$NAME<-gsub('inj','',ag$NAME, ignore.case = T)   
# ag$NAME<-gsub('\\.','',ag$NAME)   
# ag$NAME<-gsub('-','',ag$NAME)   
# ag$NAME<-gsub('\\(pediatric\\)','',ag$NAME, ignore.case = T)   
# ag$NAME<-str_trim(ag$NAME)   
ag$date<-sapply(strsplit(ag$PERFRMD_FROM_DT_TM, ' '),'[',1)   
ag$date<-as.Date(ag$date, format = '%d-%b-%y')   
   
   
amphb<-meds[grepl('amphote', meds$NAME, ignore.case = T),]   
amphb<-amphb[!grepl('inhal', amphb$NAME, ignore.case = T),]   
amphb<-amphb[!grepl('irrigat', amphb$NAME, ignore.case = T),]   
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# amphb$NAME<-gsub('zzz','',amphb$NAME)   
# amphb$NAME<-gsub('inj','',amphb$NAME, ignore.case = T)   
# amphb$NAME<-gsub('\\.','',amphb$NAME)   
# amphb$NAME<-gsub('-','',amphb$NAME)   
# amphb$NAME<-
gsub('\\(pediatric\\)','',amphb$NAME, ignore.case = T)   
# amphb$NAME<-str_trim(amphb$NAME)   
amphb$date<-sapply(strsplit(amphb$PERFRMD_FROM_DT_TM, ' '),'[',1)   
amphb$date<-as.Date(amphb$date, format = '%d-%b-%y')   
   
cont<-neph[neph$NAME =='(ADM Override)',]   
cont<-
cont[grepl('gado', cont$TASK_NM, ignore.case = T) | grepl('iodix', c
ont$TASK_NM, ignore.case = T)|   
             grepl('iohex', cont$TASK_NM, ignore.case = T)| grepl('i
othal', cont$TASK_NM, ignore.case = T),]   
cont<-cont[!grepl('oral', cont$TASK_NM, ignore.case = T),]   
cont$date<-sapply(strsplit(cont$PERFRMD_FROM_DT_TM, ' '),'[',1)   
cont$date<-as.Date(cont$date)#, format = '%d-%b-%y')   
cont<-cont[!is.na(cont$date),]   
   
nsaids<-
meds[grepl('ibuprofen', meds$NAME, ignore.case=T)|grepl('naproxen', 
meds$NAME, ignore.case=T)|   
               grepl('indomethacin', meds$NAME, ignore.case=T)|grepl
('ketorolac', meds$NAME, ignore.case=T)|   
               grepl('meloxicam', meds$NAME, ignore.case=T)|grepl('c
elecoxib', meds$NAME, ignore.case=T)|   
               grepl('diclofenac', meds$NAME, ignore.case=T)|grepl('
etodolac', meds$NAME, ignore.case=T)|   
               grepl('nabumetone', meds$NAME, ignore.case=T)|grepl('
piroxicam', meds$NAME, ignore.case=T)|   
               grepl('sulindac', meds$NAME, ignore.case=T),]     
nsaids$date<-
sapply(strsplit(nsaids$PERFRMD_FROM_DT_TM, ' '),'[',1)   
nsaids$date<-as.Date(nsaids$date, format = '%d-%b-%y')   
   
#Need to follow up with Andrew   
calc<-neph[neph$DRUG_KEY %in% c('d03752','d00079'),]   
calc$date<-sapply(strsplit(calc$PERFRMD_FROM_DT_TM, ' '),'[',1)   
calc$date<-as.Date(calc$date)#, format = '%d-%b-%y')   
calc<-calc[!is.na(calc$date),]   
   
loop<-
meds[grepl('furosemide', meds$NAME, ignore.case=T)|grepl('bumetanide
', meds$NAME, ignore.case=T)|   
             grepl('torsemide', meds$NAME, ignore.case=T)|grepl('eth
acryn', meds$NAME, ignore.case=T),]   
loop$date<-sapply(strsplit(loop$PERFRMD_FROM_DT_TM, ' '),'[',1)   
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loop$date<-as.Date(loop$date, format = '%d-%b-%y')   
   
vaso<-
meds[grepl('norepinephrine', meds$NAME, ignore.case=T)|grepl('epinep
hrine', meds$NAME, ignore.case=T)|   
             grepl('phenylephrine', meds$NAME, ignore.case=T)|grepl(
'vasopressin', meds$NAME, ignore.case=T)|   
             grepl('dopamine', meds$NAME, ignore.case=T),]   
vaso$date<-sapply(strsplit(vaso$PERFRMD_FROM_DT_TM, ' '),'[',1)   
vaso$date<-as.Date(vaso$date, format = '%d-%b-%y')   
   
iono<-
meds[grepl('Dobutamine', meds$NAME, ignore.case=T)|grepl('milrinone'
, meds$NAME, ignore.case=T),]   
iono$date<-sapply(strsplit(iono$PERFRMD_FROM_DT_TM, ' '),'[',1)   
iono$date<-as.Date(iono$date, format = '%d-%b-%y')   
   
acei<-neph[grepl('pril', neph$NAME, ignore.case=T),]   
acei$date<-sapply(strsplit(acei$PERFRMD_FROM_DT_TM, ' '),'[',1)   
acei$date<-as.Date(acei$date)#, format = '%d-%b-%y')   
acei<-acei[complete.cases(acei),]   
   
# NEed to follow up with Andrew   
arb<-
neph[neph$DRUG_KEY  %in% c('d03821','d04322','d04113','d04222','d043
64','d04801'),]   
arb$date<-sapply(strsplit(arb$PERFRMD_FROM_DT_TM, ' '),'[',1)   
arb$date<-as.Date(arb$date)#, format = '%m/%d/%Y')   
arb<-arb[!is.na(arb$date),]   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% vanc$ENCNTR_ID)){   
    dem$vanc_exp[i]<-0   
    next   
  }   
  else{   
    x<-vanc[vanc$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$vanc_exp[i]<-1   
    }   
    else{   
      dem$vanc_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
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  if(!(dem$ENCNTR_ID [i] %in% ag$ENCNTR_ID)){   
    dem$aminoglycoside_exp[i]<-0   
    next   
  }   
  else{   
    x<-ag[ag$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$aminoglycoside_exp[i]<-1   
    }   
    else{   
      dem$aminoglycoside_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% amphb$ENCNTR_ID)){   
    dem$amphb_exp[i]<-0   
    next   
  }   
  else{   
    x<-amphb[amphb$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$amphb_exp[i]<-1   
    }   
    else{   
      dem$amphb_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% cont$ENCNTR_ID)){   
    dem$cont_exp[i]<-0   
    next   
  }   
  else{   
    x<-cont[cont$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]#   
    ),]   
    if(dim(x)[1]>0){   
      dem$cont_exp[i]<-1   
    }   
    else{   
137 
 
      dem$cont_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% nsaids$ENCNTR_ID)){   
    dem$nsaids_exp[i]<-0   
    next   
  }   
  else{   
    x<-nsaids[nsaids$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$nsaids_exp[i]<-1   
    }   
    else{   
      dem$nsaids_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% calc$ENCNTR_ID)){   
    dem$calc_exp[i]<-0   
    next   
  }   
  else{   
    x<-calc[calc$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]#   
    ),]   
    if(dim(x)[1]>0){   
      dem$calc_exp[i]<-1   
    }   
    else{   
      dem$calc_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% loop$ENCNTR_ID)){   
    dem$loop_exp[i]<-0   
    next   
  }   
  else{   
    x<-loop[loop$ENCNTR_ID == dem$ENCNTR_ID[i],]   
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    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$loop_exp[i]<-1   
    }   
    else{   
      dem$loop_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% vaso$ENCNTR_ID)){   
    dem$vaso_exp[i]<-0   
    next   
  }   
  else{   
    x<-vaso[vaso$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$vaso_exp[i]<-1   
    }   
    else{   
      dem$vaso_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% iono$ENCNTR_ID)){   
    dem$iono_exp[i]<-0   
    next   
  }   
  else{   
    x<-iono[iono$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$iono_exp[i]<-1   
    }   
    else{   
      dem$iono_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% acei$ENCNTR_ID)){   
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    dem$acei_exp[i]<-0   
    next   
  }   
  else{   
    x<-acei[acei$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$acei_exp[i]<-1   
    }   
    else{   
      dem$acei_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% arb$ENCNTR_ID)){   
    dem$arb_exp[i]<-0   
    next   
  }   
  else{   
    x<-arb[arb$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]#   
    ),]   
    if(dim(x)[1]>0){   
      dem$arb_exp[i]<-1   
    }   
    else{   
      dem$arb_exp[i]<-0   
    }   
  }   
}   
####################################################################
##################################################   
##                           Vital signs clean up                   
                                                ##   
####################################################################
##################################################   
vit<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/cotner_vit
als.csv', sep=',', colClasses='character')   
vit<-vit[vit$ENCNTR_ID %in% dem$ENCNTR_ID,]   
bp<-
vit[grepl('Systolic', vit$LEFT_LABEL, ignore.case = T)| grepl('diast
olic', vit$LEFT_LABEL, ignore.case = T),]   
bp$VAL_TXT<-as.numeric(bp$VAL_TXT)   




dcast.data.table(ENCNTR_ID+RECRD_DT_TM~LEFT_LABEL, value.var = 'VAL_
TXT', data=bp, fun.aggregate = min)   
bpcast$dbp[is.infinite(bpcast$'Direct Arterial Blood Pressure (Diast
olic)')]<-bpcast$Diastolic   
bpcast$sbp[is.infinite(bpcast$'Direct Arterial Blood Pressure (Systo
lic)')]<-bpcast$Systolic   
bpcast$dbp[is.infinite(bpcast$Diastolic)]<-
bpcast$'Direct Arterial Blood Pressure (Diastolic)'   
bpcast$sbp[is.infinite(bpcast$Systolic)]<-
bpcast$'Direct Arterial Blood Pressure (Systolic)'   
bpcast$dbp[is.infinite(bpcast$'Direct Arterial Blood Pressure (Diast
olic)')& is.infinite(bpcast$Diastolic)]<-NA   
bpcast$sbp[is.infinite(bpcast$'Direct Arterial Blood Pressure (Systo
lic)')& is.infinite(bpcast$Systolic)]<-NA   
bpcast$dbp[is.infinite(bpcast$dbp)]<-NA   
bpcast$sbp[is.infinite(bpcast$sbp)]<-NA   
bp<-dplyr::select(bpcast, ENCNTR_ID, RECRD_DT_TM, dbp, sbp)   
   
bp<-bp[complete.cases(bp),]   
bp$date<-sapply(strsplit(bp$RECRD_DT_TM, ' '),'[',1)   
bp$date<-as.Date(bp$date, format = '%d-%b-%y')   
bp$RECRD_DT_TM<-as.POSIXct(bp$RECRD_DT_TM, format='%d-%b-
%y %H:%M:%S')   
   
bp$map<-round((2*bp$dbp +bp$sbp)/3,2)   
sbpcut<-mean(bp$sbp)+4*sd(bp$sbp)   
dbpcut<-mean(bp$dbp)+4*sd(bp$dbp)   
mapcut<-mean(bp$map)+4*sd(bp$map)   
bp<-bp[bp$sbp<=sbpcut & bp$dbp <= dbpcut & bp$map<=mapcut,]   
   
dem$hypotension<-0   
   
for(i in 1:nrow(dem)){   
  if(min(bp$map[bp$ENCNTR_ID == dem$ENCNTR_ID[i] & dplyr::between(bp
$date,    
                                                                  le
ft = dem$tx_index[i]-1,   
                                                                  ri
ght = dem$tx_end[i])])<65){   
    dem$hypotension[i]<-1   
    next   
  }   
  if(min(sbp<-
bp$sbp[bp$ENCNTR_ID == dem$ENCNTR_ID[i] & dplyr::between(bp$date,    
                                                                    
   left = dem$tx_index[i]-1,   
                                                                    
   right = dem$tx_end[i])])<90){   
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    dem$hypotension[i]<-1   
    next   
  }   
  if(dem$vaso_exp[i]==1){   
    dem$hypotension[i]<-1   
  }   
}   
 
Inverse probability of treatment weights, model, and plots 
dat<-dem[dem$vanc_exp==1,]   
rm(list=setdiff(ls(), c('dat','dem','akitab','restab')))   
   
dem_back<-dem   
dem<-dat   
#run restab results and AKI tab   
   
library(ipw)   
dat$pv[dat$drug=='PTZ']<-1   
dat$pv[is.na(dat$pv)]<-0   
temp<-ipwpoint(exposure = pv, family ='binomial', link='logit',   
               numerator = ~1,    
               denominator = ~GENDR_CD_DES+dm +COMORBIDITY_SCORE+   
                 as.factor(baseline_crcl_cat) + amphb_exp + cont_exp
 +   
                 calc_exp + vaso_exp + hypotension,    
               data= dat)   
   
summary(temp$ipw.weights)   
   
   
   
ipwplot(weights = temp$ipw.weights, logscale = F)   
summary(temp$den.mod)   
   
dat$sw<-temp$ipw.weights   
   
library(survey)   
msm<-
(svyglm(aki~pv, family=quasibinomial(), design=svydesign(~1, weights
 = ~sw, data=dat)))   
msm2<-
(svyglm(aki~pv, family=binomial(), design=svydesign(~1, weights = ~s
w, data=dat)))   
   
cbind(msm1=exp(coef(msm)), msm2=exp(coef(msm2)))   
cbind(msm1=exp(confint(msm)),msm2=exp(confint(msm2)))   
summary(msm)   
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msm_test<-
(svyglm(aki~male, family=quasibinomial(), design=svydesign(~1, weigh
ts = ~sw, data=dat)))   
summary(msm_test)   
   
   
####################################################################
   
library(ggplot2)   
table(dat$aki, dat$drug)   
table(dat$RIFLE, dat$drug)   
   
x<-data.frame(drug = c('pv','pv','pv','pv',   
                       'cv','cv','cv','cv'),   
              class = c('n','r','i','f',   
                        'n','r','i','f'),   
              n = c(7185, 1516, 777, 420,   
                    286, 33, 12, 7))   
   
pv<-sum(x$n[x$drug=='pv'])   
x$perc[x$drug=='pv']<-(x$n[x$drug=='pv']/pv)*100   
   
   
cv<-sum(x$n[x$drug=='cv'])   
x$perc[x$drug=='cv']<-(x$n[x$drug=='cv']/cv)*100   
   
xadd<-data.frame(drug = c('pv',   
                          'cv'),   
                 class = c('aki',   
                           'aki'),   
                 n = c(pv-x$n[x$class=='n' & x$drug=='pv'],   
                       cv-x$n[x$class=='n' & x$drug=='cv']),   
                 perc = c(100-x$perc[x$class=='n' & x$drug=='pv'],   
                          100-x$perc[x$class=='n' & x$drug=='cv'])   
)   
   
x<-rbind(x,xadd)   
x<-x[x$class!='n',]   
#########################################################   
library(ggplot2)   
   
x$drug<-as.factor(x$drug)   
x$drug<-relevel(x$drug, ref='pv')   
   
p<-ggplot(x, aes(x=class, y=perc, fill=drug))   
   
p + geom_bar(stat='identity', position= position_dodge(), color='bla
ck') +   
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  xlab('AKI classification') +   
  ylab('Incidence (%)')+   
  scale_x_discrete(limits = c('aki','r','i','f'),   
                   labels = c('Any AKI','Risk','Injury','Failure')) 
+   
  scale_fill_grey(labels = c('TZP+VAN', 'MEM+VAN')) +    
  scale_y_continuous(expand = c(0,0),   
                     limits = c(0,30),   
                     breaks = seq(0,30, by = 5))+   
  theme_bw() +   
  annotate('text', x=0.8, y = 28.4, label = '27.4%', color ='black',
 size = 3) +   
  annotate('text', x=1.25, y = 16.4, label = '15.4%', color ='black'
, size = 3) +   
  annotate('text', x=1.8, y = 16.3, label = '15.3%', color ='black',
 size = 3) +   
  annotate('text', x=2.25, y = 10.8, label = '9.8%', color ='black',
 size = 3) +   
  annotate('text', x=2.8, y = 8.8, label = '7.8%', color ='black', s
ize = 3) +   
  annotate('text', x=3.25, y = 4.5, label = '3.5%', color ='black', 
size = 3) +   
  annotate('text', x=3.8, y = 5.2, label = '4.2%', color ='black', s
ize = 3) +   
  annotate('text', x=4.25, y = 3.1, label = '2.1%', color ='black', 
size = 3) +   
  theme(legend.position = 'bottom',    
        legend.title = element_blank(),   
        legend.text = element_text(color = 'black'),   
        axis.text = element_text(color = 'black'),   
        axis.title = element_text(color = 'black'),   
        axis.ticks = element_blank())   
ggsave('AKI plot.png', width = 4, height = 3, units ='in', dpi = 120
0)   
####################################################################
###########################   
   
dat$dc_date<-sapply(strsplit(dat$DISCHRG_DT,' '),'[',1)   
dat$dc_date<-as.Date(dat$dc_date, format= '%d-%b-%y')   
dat$LENGTH_OF_STAY_NUM[is.na(dat$LENGTH_OF_STAY_NUM)]<- as.numeric(d
at$dc_date[is.na(dat$LENGTH_OF_STAY_NUM)] -    
                                                                    
 dat$ad_date[is.na(dat$LENGTH_OF_STAY_NUM)])   
   
quantiles_95 <- function(x) {   
  r <- quantile(x, probs=c(0.05, 0.25, 0.5, 0.75, 0.95))   
  names(r) <- c("ymin", "lower", "middle", "upper", "ymax")   
  r   
}   
144 
 
   
q<-ggplot(data=dat, aes(x = LENGTH_OF_STAY_NUM, fill=drug))   
   
los_summary<-data.frame(drug = c('MEM','PTZ'),   
                        mean = c(15.8, 14.5),   
                        sd = c(27.6, 15.5),   
                        median = c(9, 10),   
                        l25 = c(6, 5),   
                        u25 = c(15, 18),   
                        l5 = c(3,3),   
                        u95 = c(48.15, 41)   
)   
   
   
q+geom_boxplot(aes(middle = median, lower = l25, upper =u25, ymin = 
l5, ymax = u95), stat='identity') +   
  scale_y_continuous(limits=c(0,50), breaks = seq(0,50, by=10), expa
nd = c(0,0)) +   
  scale_x_discrete( labels = c('MEM+VAN','TZP+VAN'))+   
  guides(fill=F) +   
  stat_summary(fun.y = mean, geom='point', shape=18, size =4, na.rm=
T)+   
  scale_fill_manual(values='light gray') +   
  ylab('Length of stay (days)') +   
  xlab('Drug therapy') +   
  theme_bw()+   
  theme(axis.ticks = element_blank(),   
        axis.text = element_text(color = 'black'),   
        axis.title = element_text(color='black', face='bold'))   
q<-ggplot(los_summary, aes(x = drug, y=mean, fill='gray'))   
   
q+geom_boxplot(aes(middle = median, lower = l25, upper =u25, ymin = 
l5, ymax = u95), stat='identity') +   
  scale_y_continuous(limits=c(0,50), breaks = seq(0,50, by=10), expa
nd = c(0,0)) +   
  scale_x_discrete( labels = c('MEM+VAN','TZP+VAN'))+   
  guides(fill=F) +   
  stat_summary(fun.y = mean, geom='point', shape=18, size =4, na.rm=
T)+   
  scale_fill_manual(values='light gray') +   
  ylab('Length of stay (days)') +   
  xlab('Drug therapy') +   
  theme_bw()+   
  theme(axis.ticks = element_blank(),   
        axis.text = element_text(color = 'black'),   




Data table generation 
restab<-
data.frame(variable = rep(NA,100), MEM= NA, PTZ = NA, p=NA)   
restab$variable[1] = 'N'   
restab$MEM[1] = paste(nrow(dem[dem$drug=='MEM',]), " (", (round(nrow
(dem[dem$drug=='MEM',])/nrow(dem),3)*100),'%)', sep='')   
restab$PTZ[1] = paste(nrow(dem[dem$drug=='PTZ',]), " (", (round(nrow
(dem[dem$drug=='PTZ',])/nrow(dem),3)*100),'%)', sep='')   
   
attach(dem)   
   
restab$variable[2]<-'Age (mean[SD])'   
restab$MEM[2]<-
paste(round(mean(AGE[drug=='MEM'], na.rm = T),2), ' (', round(sd(AGE
[drug=='MEM'], na.rm = T),2),')', sep='')   
restab$PTZ[2]<-
paste(round(mean(AGE[drug=='PTZ'], na.rm = T),2), ' (', round(sd(AGE
[drug=='PTZ'], na.rm = T),2),')', sep='')   
restab$p[2]<-t.test(AGE~drug)$p.value   
   
restab$variable[3]<-'Age (median [IQR])'   
restab$MEM[3]<-
paste(median(AGE[drug=='MEM'], na.rm=T), " (", quantile(AGE[drug=='M
EM'], probs=0.25, na.rm = T),'-',   
                    quantile(AGE[drug=='MEM'], probs=0.75, na.rm = T
),')', sep='')   
restab$PTZ[3]<-
paste(median(AGE[drug=='PTZ'], na.rm=T), " (", quantile(AGE[drug=='P
TZ'], probs=0.25, na.rm = T),'-',   
                     quantile(AGE[drug=='PTZ'], probs=0.75, na.rm = 
T),')', sep='')   
restab$p[3]<-wilcox.test(AGE~drug)$p.value   
   
restab$variable[4]<-'Gender'   
restab$variable[5]<-'Male'   
restab$MEM[5]<-
paste(nrow(dem[dem$GENDR_CD_DES=='MALE' & dem$drug=='MEM',]), ' (', 
   
                    round((nrow(dem[dem$GENDR_CD_DES=='MALE' & dem$d
rug=='MEM',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[5]<-
paste(nrow(dem[dem$GENDR_CD_DES=='MALE' & dem$drug=='PTZ',]), ' (', 
   
                     round((nrow(dem[dem$GENDR_CD_DES=='MALE' & dem$
drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   




paste(nrow(dem[dem$GENDR_CD_DES=='FEMALE' & dem$drug=='MEM',]), ' ('
,    
                    round((nrow(dem[dem$GENDR_CD_DES=='FEMALE' & dem
$drug=='MEM',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[6]<-
paste(nrow(dem[dem$GENDR_CD_DES=='FEMALE' & dem$drug=='PTZ',]), ' ('
,    
                     round((nrow(dem[dem$GENDR_CD_DES=='FEMALE' & de
m$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='') 
  
restab$p[4]<-chisq.test(table(GENDR_CD_DES, drug))$p.value   
   
restab$variable[7]<-'caucasian'   
restab$MEM[7]<-
paste(nrow(dem[dem$caucasian==1 & dem$drug=='MEM',]), ' (',    
                    round((nrow(dem[dem$caucasian==1 & dem$drug=='ME
M',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[7]<-
paste(nrow(dem[dem$caucasian==1 & dem$drug=='PTZ',]), ' (',    
                     round((nrow(dem[dem$caucasian==1 & dem$drug=='P
TZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[7]<-chisq.test(table(caucasian, drug))$p.value   
   
restab$variable[8]<-'WT (mean[SD])'   
restab$MEM[8]<-
paste(round(mean(INIT_WT[drug=='MEM'], na.rm = T),2), ' (', round(sd
(INIT_WT[drug=='MEM'], na.rm = T),2),')', sep='')   
restab$PTZ[8]<-
paste(round(mean(INIT_WT[drug=='PTZ'], na.rm = T),2), ' (', round(sd
(INIT_WT[drug=='PTZ'], na.rm = T),2),')', sep='')   
restab$p[8]<-t.test(INIT_WT~drug)$p.value   
   
restab$variable[9]<-'WT (median [IQR])'   
restab$MEM[9]<-
paste(median(INIT_WT[drug=='MEM'], na.rm=T), " (", quantile(INIT_WT[
drug=='MEM'], probs=0.25, na.rm = T),'-',   
                    quantile(INIT_WT[drug=='MEM'], probs=0.75, na.rm
 = T),')', sep='')   
restab$PTZ[9]<-
paste(median(INIT_WT[drug=='PTZ'], na.rm=T), " (", quantile(INIT_WT[
drug=='PTZ'], probs=0.25, na.rm = T),'-',   
                     quantile(INIT_WT[drug=='PTZ'], probs=0.75, na.r
m = T),')', sep='')   
restab$p[9]<-wilcox.test(INIT_WT~drug)$p.value   
   




paste(round(mean(BMI[drug=='MEM'], na.rm = T),2), ' (', round(sd(BMI
[drug=='MEM'], na.rm = T),2),')', sep='')   
restab$PTZ[10]<-
paste(round(mean(BMI[drug=='PTZ'], na.rm = T),2), ' (', round(sd(BMI
[drug=='PTZ'], na.rm = T),2),')', sep='')   
restab$p[10]<-t.test(BMI~drug)$p.value   
   
restab$variable[11]<-'BMI (median [IQR])'   
restab$MEM[11]<-
paste(round(median(BMI[drug=='MEM'], na.rm=T),2), " (", round(quanti
le(BMI[drug=='MEM'], probs=0.25, na.rm = T),2),'-',   
                     round(quantile(BMI[drug=='MEM'], probs=0.75, na
.rm = T),2),')', sep='')   
restab$PTZ[11]<-
paste(round(median(BMI[drug=='PTZ'], na.rm=T),2), " (", round(quanti
le(BMI[drug=='PTZ'], probs=0.25, na.rm = T),2),'-',   
                      round(quantile(BMI[drug=='PTZ'], probs=0.75, n
a.rm = T),2),')', sep='')   
restab$p[11]<-wilcox.test(BMI~drug)$p.value   
   
restab$variable[12]<-'COMORBIDITY_SCORE (mean[SD])'   
restab$MEM[12]<-
paste(round(mean(dem$COMORBIDITY_SCORE[drug=='MEM'], na.rm = T),2), 
' (', round(sd(dem$COMORBIDITY_SCORE[drug=='MEM'], na.rm = T),2),')'
, sep='')   
restab$PTZ[12]<-
paste(round(mean(dem$COMORBIDITY_SCORE[drug=='PTZ'], na.rm = T),2), 
' (', round(sd(dem$COMORBIDITY_SCORE[drug=='PTZ'], na.rm = T),2),')'
, sep='')   
restab$p[12]<-t.test(dem$COMORBIDITY_SCORE~drug)$p.value   
   
restab$variable[13]<-'COMORBIDITY_SCORE (median [IQR])'   
restab$MEM[13]<-
paste(median(dem$COMORBIDITY_SCORE[drug=='MEM'], na.rm=T), " (", qua
ntile(dem$COMORBIDITY_SCORE[drug=='MEM'], probs=0.25, na.rm = T),'-
',   
                     quantile(dem$COMORBIDITY_SCORE[drug=='MEM'], pr
obs=0.75, na.rm = T),')', sep='')   
restab$PTZ[13]<-
paste(median(dem$COMORBIDITY_SCORE[drug=='PTZ'], na.rm=T), " (", qua
ntile(dem$COMORBIDITY_SCORE[drug=='PTZ'], probs=0.25, na.rm = T),'-
',   
                      quantile(dem$COMORBIDITY_SCORE[drug=='PTZ'], p
robs=0.75, na.rm = T),')', sep='')   
restab$p[13]<-wilcox.test(dem$COMORBIDITY_SCORE~drug)$p.value   
   




paste(round(mean(dem$baseline_crcl[drug=='MEM'], na.rm = T),2), ' ('
, round(sd(dem$baseline_crcl[drug=='MEM'], na.rm = T),2),')', sep=''
)   
restab$PTZ[14]<-
paste(round(mean(dem$baseline_crcl[drug=='PTZ'], na.rm = T),2), ' ('
, round(sd(dem$baseline_crcl[drug=='PTZ'], na.rm = T),2),')', sep=''
)   
restab$p[14]<-t.test(dem$baseline_crcl~drug)$p.value   
   
restab$variable[15]<-'baseline crcl (median [IQR])'   
restab$MEM[15]<-
paste(round(median(dem$baseline_crcl[drug=='MEM'], na.rm=T),2), " ("
,    
                     round(quantile(dem$baseline_crcl[drug=='MEM'], 
probs=0.25, na.rm = T),2),'-',   
                     round(quantile(dem$baseline_crcl[drug=='MEM'], 
probs=0.75, na.rm = T),2),')', sep='')   
restab$PTZ[15]<-
paste(round(median(dem$baseline_crcl[drug=='PTZ'], na.rm=T),2), " ("
,    
                      round(quantile(dem$baseline_crcl[drug=='PTZ'],
 probs=0.25, na.rm = T),2),'-',   
                      round(quantile(dem$baseline_crcl[drug=='PTZ'],
 probs=0.75, na.rm = T),2),')', sep='')   
restab$p[15]<-wilcox.test(dem$baseline_crcl~drug)$p.value   
   
restab$variable[16]<-'baseline crcl drug'   
restab$variable[17]<-'30-59 mL/min'   
restab$MEM[17]<-
paste(nrow(dem[dem$baseline_crcl_cat == 1 & dem$drug=='MEM',]), ' ('
,    
                     round((nrow(dem[dem$baseline_crcl_cat == 1 & de
m$drug=='MEM',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='') 
  
restab$PTZ[17]<-
paste(nrow(dem[dem$baseline_crcl_cat == 1 & dem$drug=='PTZ',]), ' ('
,    
                      round((nrow(dem[dem$baseline_crcl_cat == 1 & d
em$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')
   
restab$variable[18]<-'60-89 mL/min'   
restab$MEM[18]<-
paste(nrow(dem[dem$baseline_crcl_cat == 2 & dem$drug=='MEM',]), ' ('
,    
                     round((nrow(dem[dem$baseline_crcl_cat == 2 & de





paste(nrow(dem[dem$baseline_crcl_cat == 2 & dem$drug=='PTZ',]), ' ('
,    
                      round((nrow(dem[dem$baseline_crcl_cat == 2 & d
em$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')
   
restab$variable[19]<-'>=90 mL/min'   
restab$MEM[19]<-
paste(nrow(dem[dem$baseline_crcl_cat == 3 & dem$drug=='MEM',]), ' ('
,    
                     round((nrow(dem[dem$baseline_crcl_cat == 3 & de
m$drug=='MEM',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='') 
  
restab$PTZ[19]<-
paste(nrow(dem[dem$baseline_crcl_cat == 3 & dem$drug=='PTZ',]), ' ('
,    
                      round((nrow(dem[dem$baseline_crcl_cat == 3 & d
em$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')
   
restab$p[16]<-chisq.test(table(baseline_crcl_cat, drug))$p.value   
   
restab$variable[20]<-'Concomitant nephrotoxins'   
restab$variable[21]<-'Aminoglycosides'   
restab$MEM[21]<-
paste(nrow(dem[dem$aminoglycoside_exp == 1 & dem$drug=='MEM',]), ' (
',    
                     round((nrow(dem[dem$aminoglycoside_exp == 1 & d
em$drug=='MEM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
                     '%)', sep='')   
restab$PTZ[21]<-
paste(nrow(dem[dem$aminoglycoside_exp == 1 & dem$drug=='PTZ',]), ' (
',    
                      round((nrow(dem[dem$aminoglycoside_exp == 1 & 
dem$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                      '%)', sep='')   
restab$p[21]<-chisq.test(table(aminoglycoside_exp, drug))$p.value   
   
restab$variable[22]<-'amphb'   
restab$MEM[22]<-
paste(nrow(dem[dem$amphb_exp == 1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$amphb_exp == 1 & dem$drug==
'MEM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
                     '%)', sep='')   
restab$PTZ[22]<-
paste(nrow(dem[dem$amphb_exp == 1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$amphb_exp == 1 & dem$drug=
='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                      '%)', sep='')   
restab$p[22]<-chisq.test(table(amphb_exp, drug))$p.value   
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restab$variable[23]<-'acei'   
restab$MEM[23]<-
paste(nrow(dem[dem$acei_exp == 1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$acei_exp == 1 & dem$drug=='
MEM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
                     '%)', sep='')   
restab$PTZ[23]<-
paste(nrow(dem[dem$acei_exp == 1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$acei_exp == 1 & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                      '%)', sep='')   
restab$p[23]<-chisq.test(table(acei_exp, drug))$p.value   
   
restab$variable[24]<-'arb'   
restab$MEM[24]<-
paste(nrow(dem[dem$arb_exp == 1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$arb_exp == 1 & dem$drug=='M
EM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
                     '%)', sep='')   
restab$PTZ[24]<-
paste(nrow(dem[dem$arb_exp == 1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$arb_exp == 1 & dem$drug=='
PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                      '%)', sep='')   
restab$p[24]<-chisq.test(table(arb_exp, drug))$p.value   
   
   
restab$variable[25]<-'cont'   
restab$MEM[25]<-
paste(nrow(dem[dem$cont_exp == 1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$cont_exp == 1 & dem$drug=='
MEM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
                     '%)', sep='')   
restab$PTZ[25]<-
paste(nrow(dem[dem$cont_exp == 1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$cont_exp == 1 & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                      '%)', sep='')   
restab$p[25]<-chisq.test(table(cont_exp, drug))$p.value   
   
restab$variable[26]<-'loop'   
restab$MEM[26]<-
paste(nrow(dem[dem$loop_exp == 1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$loop_exp == 1 & dem$drug=='
MEM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
                     '%)', sep='')   
restab$PTZ[26]<-
paste(nrow(dem[dem$loop_exp == 1 & dem$drug=='PTZ',]), ' (',    
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                      round((nrow(dem[dem$loop_exp == 1 & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                      '%)', sep='')   
restab$p[26]<-chisq.test(table(loop_exp, drug))$p.value   
   
restab$variable[27]<-'nsaids'   
restab$MEM[27]<-
paste(nrow(dem[dem$nsaids_exp == 1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$nsaids_exp == 1 & dem$drug=
='MEM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
                     '%)', sep='')   
restab$PTZ[27]<-
paste(nrow(dem[dem$nsaids_exp == 1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$nsaids_exp == 1 & dem$drug
=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                      '%)', sep='')   
restab$p[27]<-chisq.test(table(nsaids_exp, drug))$p.value   
   
restab$variable[28]<-'calc'   
restab$MEM[28]<-
paste(nrow(dem[dem$calc_exp == 1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$calc_exp == 1 & dem$drug=='
MEM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
                     '%)', sep='')   
restab$PTZ[28]<-
paste(nrow(dem[dem$calc_exp == 1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$calc_exp == 1 & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                      '%)', sep='')   
restab$p[28]<-chisq.test(table(calc_exp, drug))$p.value   
   
restab$variable[29]<-'vanc'   
restab$MEM[29]<-
paste(nrow(dem[dem$vanc_exp == 1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$vanc_exp == 1 & dem$drug=='
MEM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
                     '%)', sep='')   
restab$PTZ[29]<-
paste(nrow(dem[dem$vanc_exp == 1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$vanc_exp == 1 & dem$drug
=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[29]<-chisq.test(table(vanc_exp, drug))$p.value   
   
restab$variable[30]<-'vaso'   
restab$MEM[30]<-
paste(nrow(dem[dem$vaso_exp == 1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$vaso_exp == 1 & dem$drug=='
MEM',])/nrow(dem[dem$drug=='MEM',])*100),2),    
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                     '%)', sep='')   
restab$PTZ[30]<-
paste(nrow(dem[dem$vaso_exp == 1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$vaso_exp == 1 & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                      '%)', sep='')   
restab$p[30]<-chisq.test(table(vaso_exp, drug))$p.value   
   
restab$variable[31]<-'Comorbidities'   
restab$variable[32]<-'DM'   
restab$MEM[32]<-
paste(nrow(dem[dem$dm==1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$dm==1 & dem$drug=='MEM',])/
nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[32]<-
paste(nrow(dem[dem$dm==1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$dm==1 & dem$drug=='PTZ',])
/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[32]<-chisq.test(table(dem$dm, drug))$p.value   
   
restab$variable[33]<-'HF'   
restab$MEM[33]<-
paste(nrow(dem[dem$hf==1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$hf==1 & dem$drug=='MEM',])/
nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[33]<-
paste(nrow(dem[dem$hf==1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$hf==1 & dem$drug=='PTZ',])
/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[33]<-chisq.test(table(dem$hf, drug))$p.value   
   
restab$variable[34]<-'HTN'   
restab$MEM[34]<-
paste(nrow(dem[dem$HTN==1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$HTN==1 & dem$drug=='MEM',])
/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[34]<-
paste(nrow(dem[dem$HTN==1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$HTN==1 & dem$drug=='PTZ',]
)/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[34]<-chisq.test(table(HTN, drug))$p.value   
   
restab$variable[35]<-'CF'   
restab$MEM[35]<-
paste(nrow(dem[dem$CF==1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$CF==1 & dem$drug=='MEM',])/
nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[35]<-
paste(nrow(dem[dem$CF==1 & dem$drug=='PTZ',]), ' (',    
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                      round((nrow(dem[dem$CF==1 & dem$drug=='PTZ',])
/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[35]<-chisq.test(table(CF, drug))$p.value   
   
restab$variable[36]<-'LOS (mean[SD])'   
restab$MEM[36]<-
paste(round(mean(dem$LENGTH_OF_STAY_NUM[drug=='MEM'], na.rm = T),2),
 ' (', round(sd(dem$LENGTH_OF_STAY_NUM[drug=='MEM'], na.rm = T),2),'
)', sep='')   
restab$PTZ[36]<-
paste(round(mean(dem$LENGTH_OF_STAY_NUM[drug=='PTZ'], na.rm = T),2),
 ' (', round(sd(dem$LENGTH_OF_STAY_NUM[drug=='PTZ'], na.rm = T),2),'
)', sep='')   
restab$p[36]<-t.test(dem$LENGTH_OF_STAY_NUM~drug)$p.value   
   
restab$variable[37]<-'LOS (median [IQR])'   
restab$MEM[37]<-
paste(median(dem$LENGTH_OF_STAY_NUM[drug=='MEM'], na.rm=T), " (", qu
antile(dem$LENGTH_OF_STAY_NUM[drug=='MEM'], probs=0.25, na.rm = T),'
-',   
                     quantile(dem$LENGTH_OF_STAY_NUM[drug=='MEM'], p
robs=0.75, na.rm = T),')', sep='')   
restab$PTZ[37]<-
paste(median(dem$LENGTH_OF_STAY_NUM[drug=='PTZ'], na.rm=T), " (", qu
antile(dem$LENGTH_OF_STAY_NUM[drug=='PTZ'], probs=0.25, na.rm = T),'
-',   
                      quantile(dem$LENGTH_OF_STAY_NUM[drug=='PTZ'], 
probs=0.75, na.rm = T),')', sep='')   
restab$p[37]<-wilcox.test(dem$LENGTH_OF_STAY_NUM~drug)$p.value   
   
# restab$variable[38]<-'icu_admit'   
# restab$MEM[38]<-
paste(nrow(dem[dem$icu_admit==1 & dem$drug=='MEM',]), ' (',    
#                      round((nrow(dem[dem$icu_admit==1 & dem$drug==
'MEM',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
# restab$PTZ[38]<-
paste(nrow(dem[dem$icu_admit==1 & dem$drug=='PTZ',]), ' (',    
#                         round((nrow(dem[dem$icu_admit==1 & dem$dru
g=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
# restab$p[38]<-chisq.test(table(icu_admit, drug))$p.value   
   
# restab$variable[39]<-'Drug'   
# restab$variable[40]<-'PTZ'   
# restab$MEM[40]<-
paste(nrow(dem[dem$drug=='P' & dem$drug=='MEM',]), ' (',    
#                      round((nrow(dem[dem$drug=='P' & dem$drug=='ME
M',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
# restab$PTZ[40]<-
paste(nrow(dem[dem$drug=='P' & dem$drug=='PTZ',]), ' (',    
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#                         round((nrow(dem[dem$drug=='P' & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
# restab$variable[41]<-'CFP'   
# restab$MEM[41]<-
paste(nrow(dem[dem$drug=='C' & dem$drug=='MEM',]), ' (',    
#                      round((nrow(dem[dem$drug=='C' & dem$drug=='ME
M',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
# restab$PTZ[41]<-
paste(nrow(dem[dem$drug=='C' & dem$drug=='PTZ',]), ' (',    
#                         round((nrow(dem[dem$drug=='C' & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
# restab$variable[42]<-'MEM'   
# restab$MEM[42]<-
paste(nrow(dem[dem$drug=='M' & dem$drug=='MEM',]), ' (',    
#                      round((nrow(dem[dem$drug=='M' & dem$drug=='ME
M',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
# restab$PTZ[42]<-
paste(nrow(dem[dem$drug=='M' & dem$drug=='PTZ',]), ' (',    
#                         round((nrow(dem[dem$drug=='M' & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
#    
# restab$p[39]<-chisq.test(table(drug, drug))$p.value   
   
restab$variable[45]<-'AKI'   
restab$variable[46]<-'Any'   
restab$MEM[46]<-
paste(nrow(dem[dem$aki==1 & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$aki==1 & dem$drug=='MEM',])
/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[46]<-
paste(nrow(dem[dem$aki==1 & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$aki==1 & dem$drug=='PTZ',]
)/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[46]<-chisq.test(table(aki, drug))$p.value   
   
restab$variable[47]<-'Risk'   
restab$MEM[47]<-
paste(nrow(dem[dem$RIFLE=='risk' & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$RIFLE=='risk' & dem$drug=='
MEM',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[47]<-
paste(nrow(dem[dem$RIFLE=='risk' & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$RIFLE=='risk' & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$variable[48]<-'injury'   
restab$MEM[48]<-
paste(nrow(dem[dem$RIFLE=='injury' & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$RIFLE=='injury' & dem$drug=




paste(nrow(dem[dem$RIFLE=='injury' & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$RIFLE=='injury' & dem$drug
=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
   
restab$variable[49]<-'failure'   
restab$MEM[49]<-
paste(nrow(dem[dem$RIFLE=='failure' & dem$drug=='MEM',]), ' (',    
                     round((nrow(dem[dem$RIFLE=='failure' & dem$drug
=='MEM',])/nrow(dem[dem$drug=='MEM',])*100),2), '%)', sep='')   
restab$PTZ[49]<-
paste(nrow(dem[dem$RIFLE=='failure' & dem$drug=='PTZ',]), ' (',    
                      round((nrow(dem[dem$RIFLE=='failure' & dem$dru
g=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
   
restab<-restab[!is.na(restab$variable),]   
restab$p[restab$p <=0.00001]<-0.00001   
restab$p<-round(restab$p, 5)   
write.csv(restab,'unmatched_results_table.csv', row.names=F)   




Appendix C: Chapter 4 code 
Data wrangling 
library(plyr)   
library(dplyr)   
library(data.table)   
dat<-
read.csv('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/cotner_
drugs.csv', sep=',', colClasses='character')   
dem<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/cotner_dem
o.csv',   
           sep=',', colClasses='character')   
dx<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/COTNER_DX2
016-02-17 11-41-11.csv',    
          sep=',', colClasses='character')   
ht<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/COTNER_HT_
WT2016-02-17 11-42-07.csv', sep=',',    
          colClasses='character')   
asid<-
unique(dat$ENCNTR_ID[grepl('sulbactam', dat$NAME, ignore.case = T)])
   
merid<-
unique(dat$ENCNTR_ID[grepl('meropenem', dat$NAME, ignore.case = T)])
   
pipid<-
unique(dat$ENCNTR_ID[grepl('piperacillin', dat$NAME, ignore.case = T
)])   
cfpid<-
unique(dat$ENCNTR_ID[grepl('cefepime', dat$NAME, ignore.case = T)]) 
  
aspip<-intersect(asid, pipid)   
ascfp<-intersect(asid, cfpid)   
asmem<-intersect(asid, merid)   
aspipcfp<-intersect(aspip, ascfp)   
aspipmem<-intersect(aspip, asmem)   
ascfpmem<-intersect(ascfp, asmem)   
aspipcfpmem<-intersect(ascfpmem, aspipmem)   
cfpmem<-intersect(cfpid, merid)   
cfppip<-intersect(cfpid, pipid)   
cfpmempip<-intersect(cfpmem, cfppip)   
pipmem<-intersect(pipid, merid)   




unique(dat$ENCNTR_ID[dat$ENCNTR_ID %in% asid | dat$ENCNTR_ID %in% me
rid | dat$ENCNTR_ID %in% pipid | dat$ENCNTR_ID %in% cfpid])   
df<-data.frame(EID = test, group = NA)   
   
df$group[df$EID %in% asid]<-'A'   
df$group[df$EID %in% cfpid]<-'C'   
df$group[df$EID %in% pipid]<-'P'   
df$group[df$EID %in% merid]<-'M'   
df$group[df$EID %in% aspip]<-'AP'   
df$group[df$EID %in% ascfp]<-'AC'   
df$group[df$EID %in% asmem]<-'AM'   
df$group[df$EID %in% cfpmem]<-'CM'   
df$group[df$EID %in% cfppip]<-'CP'   
df$group[df$EID %in% pipmem]<-'MP'   
df$group[df$EID %in% aspipmem]<-'AMP'   
df$group[df$EID %in% ascfpmem]<-'ACM'   
df$group[df$EID %in% aspipcfp]<-'ACP'   
df$group[df$EID %in% cfpmempip]<-'CMP'   
df$group[df$EID %in% aspipcfpmem]<-'ACMP'   
   
a_final=as.character(df$EID[df$group=='A'])   
p_final=as.character(df$EID[df$group=='P'])   
rm(asid, cfpid, pipid, merid, aspip, ascfp, asmem, cfpmem, cfppip, p
ipmem, aspipmem, ascfpmem, aspipcfp, aspipcfpmem, cfpmempip, test)   
####################################################################
##################################################   
##                           Demographics clean up                  
                                                ##   
####################################################################
##################################################   
dem<-dem[dem$ENCNTR_ID %in% a_final | dem$ENCNTR_ID %in% p_final,]   
dem$drug[dem$ENCNTR_ID %in% a_final]<-'AS'   
dem$drug[dem$ENCNTR_ID %in% p_final]<-'PTZ'   
dem<-dem[!duplicated(dem$ENCNTR_ID),]   
   
dem$ad_date<-sapply(strsplit(dem$ADMT_DT,' '),'[',1)   
dem$ad_date<-as.Date(dem$ad_date, format='%d-%b-%y')   
   
dem<-dem[dplyr::between(dem$ad_date,    
                        left = as.Date('2006-07-01'),    
                        right = as.Date('2015-09-30')    
                        #incbounds = T   
),]   
dem$COMORBIDITY_SCORE<-as.numeric(dem$COMORBIDITY_SCORE)   
dem$COMORBIDITY_SCORE[is.na(dem$COMORBIDITY_SCORE)]<-0   
dem$AGE<-as.numeric(dem$AGE)   
dem<-dem[dem$AGE >= 18,]   
dem$age_group[dem$AGE<45]<-'18-44'   
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dem$age_group[dem$AGE>=45 & dem$AGE <65]<-'45-64'   
dem$age_group[dem$AGE>=65 & dem$AGE <80]<-'65-79'   
dem$age_group[dem$AGE>=80]<-'80+'   
   
dem$LENGTH_OF_STAY_NUM<-as.numeric(dem$LENGTH_OF_STAY_NUM)   
   
pregeid<-
unique(dx$FULL_ENCNTR_ID[grepl('v22',dx$DX_CD, ignore.case = T)])   
dem<-dem[!(dem$ENCNTR_ID %in% pregeid),]   
   
ckdeid<-
unique(dx$FULL_ENCNTR_ID[grepl('585\\.[12349]', dx$DX_CD, ignore.cas
e = T)])   
dem<-dem[!(dem$ENCNTR_ID %in% ckdeid),]   
   
cf<-
unique(dx$FULL_ENCNTR_ID[grepl('277\\.', dx$DX_CD, ignore.case = T)]
)   
dem$CF[dem$ENCNTR_ID %in% cf]<-1   
dem$CF[is.na(dem$CF)]<-0   
dem<-dem[dem$CF==0,]   
   
htn<-
unique(dx$FULL_ENCNTR_ID[grepl('401\\.', dx$DX_CD, ignore.case = T)]
)   
dem$HTN[dem$ENCNTR_ID %in% htn]<-1   
dem$HTN[is.na(dem$HTN)]<-0   
   
dm<-
unique(dx$FULL_ENCNTR_ID[grepl('250\\.', dx$DX_CD, ignore.case = T)]
)   
dem$dm[dem$ENCNTR_ID %in% dm]<-1   
dem$dm[is.na(dem$dm)]<-0   
   
hf<-
unique(dx$FULL_ENCNTR_ID[grepl('428\\.', dx$DX_CD, ignore.case = T)]
)   
dem$hf[dem$ENCNTR_ID %in% hf]<-1   
dem$hf[is.na(dem$hf)]<-0   
   
ht<-ht[ht$ENCNTR_ID %in% dem$ENCNTR_ID,]   
ht$INIT_WT<-as.numeric(ht$INIT_WT)   
ht$HT<-as.numeric(ht$HT)   
ht$WT<-as.numeric(ht$WT)   
ht$INIT_WT[is.na(ht$INIT_WT)]<-ht$WT[is.na(ht$INIT_WT)]   
ht2<-select(ht, ENCNTR_ID, INIT_WT, HT)   
   
dem<-merge(dem, ht2, by='ENCNTR_ID', all=T)   
dem$INIT_WT[dem$INIT_WT==0]<-NA   
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dem$HT[dem$HT==0]<-NA   
   
wtcut<-mean(dem$INIT_WT, na.rm=T)+4*sd(dem$INIT_WT, na.rm=T)   
dem<-dem[dem$INIT_WT<=wtcut | is.na(dem$INIT_WT),]   
htcut<-mean(dem$HT, na.rm=T)+4*sd(dem$HT, na.rm=T)   
dem<-dem[dem$HT<=htcut | is.na(dem$HT),]   
dem<-dem[dem$HT>27 | is.na(dem$HT),]   
   
dem$BMI<-dem$INIT_WT/((dem$HT/100)**2)   
rm(ckdeid, pregeid, ht, ht2, wtcut, htcut, dm, hf, htn,a_final, p_fi
nal, cf, df, crcl_cut)   
####################################################################
##################################################   
##                           Medications clean up                   
                                                ##   
####################################################################
##################################################   
meds<-dat   
rm(dat)   
meds<-meds[meds$ENCNTR_ID %in% dem$ENCNTR_ID,]   
abx<-
meds[grepl('sulbactam', meds$NAME, ignore.case = T) | grepl('piperac
illin', meds$NAME, ignore.case = T),]   
abx$admin_date<-
sapply(strsplit(abx$PERFRMD_FROM_DT_TM, ' '),'[',1)   
abx$admin_date<-as.Date(abx$admin_date, format = '%d-%b-%y')   
   
dem$tx_index<-NA   
dem$tx_end<-NA   
dem$DOT<-NA   
   
abx2<-select(abx, ENCNTR_ID, admin_date)   
abx2<-unique(abx2)   
   
for(i in 1:nrow(dem)){                                        ##~1.2
 hrs to complete   
  dem$tx_index[i] = min(abx2$admin_date[abx2$ENCNTR_ID == dem$ENCNTR
_ID[i]])   
  dem$tx_end[i] = max(abx2$admin_date[abx2$ENCNTR_ID == dem$ENCNTR_I
D[i]])   
  dem$DOT[i]<-
length(unique(abx2$admin_date[abx2$ENCNTR_ID == dem$ENCNTR_ID[i]])) 
  
}   
   
dem$tx_index<-as.Date(dem$tx_index, origin='1970-01-01')   
dem$tx_end<-as.Date(dem$tx_end, origin='1970-01-01')   
   
dem<-dem[dem$DOT>=2,]   
160 
 
   
dem$caucasian[dem$RACE_CD_DES=='WHITE']<-1   
dem$caucasian[is.na(dem$caucasian)]<-0   
   
dem$ad_year<-sapply(strsplit(as.character(dem$ad_date), '-
'),'[',1)   
dem<-dem[dem$GENDR_CD_DES !='UNKNOWN',]   
####################################################################
##################################################   
##                           labs                                   
                                                ##   
####################################################################
##################################################   
labs<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/labs.txt',
 sep='\t',header=T, colClasses='character')   
labs<-labs[labs$ENCNTR_ID %in% dem$ENCNTR_ID]   
scr<-labs[labs$ITM_NM =='Creatinine Level',]   
scr$date<-as.POSIXct(scr$ENTRD_DT_TM, format='%d-%b-%y %H:%M:%S')   
scr$VAL_NUM<-as.numeric(scr$VAL_NUM)   
scr<-scr[!is.na(scr$VAL_NUM),]   
   
   
dem<-dem[dem$ENCNTR_ID %in% scr$ENCNTR_ID,]   
for(i in 1:nrow(dem)){   
  x<- scr[scr$ENCNTR_ID == dem$ENCNTR_ID[i],]   
  dem$baseline_scr[i]<-x$VAL_NUM[x$date==min(x$date)]   
  dem$baseline_scr_date[i]<-min(x$date)   
}   
   
dem$baseline_crcl<-(140-dem$AGE)/dem$baseline_scr   
dem$baseline_crcl[dem$GENDR_CD_DES=='FEMALE']<-
dem$baseline_crcl[dem$GENDR_CD_DES=='FEMALE']*0.85   
   
dem<-dem[!is.na(dem$baseline_scr),]   
dem<-dem[dem$baseline_crcl>=30,]   
crclcut<-
mean(dem$baseline_crcl, na.rm = T)+4*sd(dem$baseline_crcl)   
dem<-dem[dem$baseline_crcl<=crclcut,]   
   
scr$date2<-sapply(strsplit(as.character(scr$date),' '),'[',1)   
scr$date2<-as.Date(scr$date2)   
   
for(i in 1:nrow(dem)){   
  x<- scr[scr$ENCNTR_ID == dem$ENCNTR_ID[i] & scr$date2 >= dem$tx_in
dex[i]+2 & scr$date2<dem$tx_end[i]+7,]   
  dem$max_scr[i]<-max(x$VAL_NUM)[1]   
  dem$max_scr_date[i]<-x$date2[x$VAL_NUM==max(x$VAL_NUM)][1]   
}   
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dem$min_crcl<-(140-dem$AGE)/dem$max_scr   
dem$min_crcl[dem$GENDR_CD_DES=='FEMALE']<-
dem$min_crcl[dem$GENDR_CD_DES=='FEMALE']*0.85   
dem$percent_change<-(dem$min_crcl/dem$baseline_crcl-1)*100    
dem<-dem[!is.infinite(dem$max_scr),]   
   
dem$RIFLE[dem$percent_change <= -25 & dem$percent_change >-50]<-
'risk'   
dem$RIFLE[dem$percent_change <= -50 & dem$percent_change >-75]<-
'injury'   
dem$RIFLE[dem$percent_change <= -75| dem$max_scr>4]<-'failure'   
   
dem$aki[is.na(dem$RIFLE)]<-0   
dem$aki[!is.na(dem$RIFLE)]<-1   
   
dem$baseline_crcl_cat[dem$baseline_crcl <60]<-1   
dem$baseline_crcl_cat[dem$baseline_crcl >=60 & dem$baseline_crcl<90]
<-2   
dem$baseline_crcl_cat[dem$baseline_crcl >=90]<-3   
   
####################################################################
##################################################   
##                           Nephrotoxin info                       
                                                ##   
####################################################################
##################################################   
library(stringr)   
neph<-
read.csv('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/COTNER_
NEPHROTOXIN.csv', colClasses='character')   
   
vid<-
unique(meds$ENCNTR_ID[grepl('vancomycin', meds$NAME, ignore.case = T
)])   
dem<- dem[!(dem$ENCNTR_ID %in% vid),]   
   
ag<-
meds[grepl('aminogly', meds$THERPUTC_CATGRY, ignore.case = T),]   
ag<-ag[!grepl('inhal', ag$NAME, ignore.case = T),]   
ag<-ag[!grepl('irrigat', ag$NAME, ignore.case = T),]   
ag$NAME<-gsub('zzz','',ag$NAME)   
ag$NAME<-gsub('inj','',ag$NAME, ignore.case = T)   
ag$NAME<-gsub('\\.','',ag$NAME)   
ag$NAME<-gsub('-','',ag$NAME)   
ag$NAME<-gsub('\\(pediatric\\)','',ag$NAME, ignore.case = T)   
ag$NAME<-str_trim(ag$NAME)   
ag$date<-sapply(strsplit(ag$PERFRMD_FROM_DT_TM, ' '),'[',1)   
ag$date<-as.Date(ag$date, format = '%d-%b-%y')   
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ag<-ag[!grepl('neomycin', ag$NAME, ignore.case = T),]   
   
amphb<-meds[grepl('amphote', meds$NAME, ignore.case = T),]   
amphb<-amphb[!grepl('inhal', amphb$NAME, ignore.case = T),]   
amphb<-amphb[!grepl('irrigat', amphb$NAME, ignore.case = T),]   
amphb$NAME<-gsub('zzz','',amphb$NAME)   
amphb$NAME<-gsub('inj','',amphb$NAME, ignore.case = T)   
amphb$NAME<-gsub('\\.','',amphb$NAME)   
amphb$NAME<-gsub('-','',amphb$NAME)   
amphb$NAME<-gsub('\\(pediatric\\)','',amphb$NAME, ignore.case = T)   
amphb$NAME<-str_trim(amphb$NAME)   
amphb$date<-sapply(strsplit(amphb$PERFRMD_FROM_DT_TM, ' '),'[',1)   
amphb$date<-as.Date(amphb$date, format = '%d-%b-%y')   
   
cont<-neph[neph$NAME =='(ADM Override)',]   
cont<-
cont[grepl('gado', cont$TASK_NM, ignore.case = T) | grepl('iodix', c
ont$TASK_NM, ignore.case = T)|   
             grepl('iohex', cont$TASK_NM, ignore.case = T)| grepl('i
othal', cont$TASK_NM, ignore.case = T),]   
cont<-cont[!grepl('oral', cont$TASK_NM, ignore.case = T),]   
cont$date<-sapply(strsplit(cont$PERFRMD_FROM_DT_TM, ' '),'[',1)   
cont$date<-as.Date(cont$date)#, format = '%d-%b-%y')   
cont<-cont[!is.na(cont$date),]   
   
nsaids<-
meds[grepl('ibuprofen', meds$NAME, ignore.case=T)|grepl('naproxen', 
meds$NAME, ignore.case=T)|   
               grepl('indomethacin', meds$NAME, ignore.case=T)|grepl
('ketorolac', meds$NAME, ignore.case=T)|   
               grepl('meloxicam', meds$NAME, ignore.case=T)|grepl('c
elecoxib', meds$NAME, ignore.case=T)|   
               grepl('diclofenac', meds$NAME, ignore.case=T)|grepl('
etodolac', meds$NAME, ignore.case=T)|   
               grepl('nabumetone', meds$NAME, ignore.case=T)|grepl('
piroxicam', meds$NAME, ignore.case=T)|   
               grepl('sulindac', meds$NAME, ignore.case=T),]     
nsaids$date<-
sapply(strsplit(nsaids$PERFRMD_FROM_DT_TM, ' '),'[',1)   
nsaids$date<-as.Date(nsaids$date, format = '%d-%b-%y')   
   
#Need to follow up with Andrew   
calc<-neph[neph$DRUG_KEY %in% c('d03752','d00079'),]   
calc$date<-sapply(strsplit(calc$PERFRMD_FROM_DT_TM, ' '),'[',1)   
calc$date<-as.Date(calc$date)#, format = '%d-%b-%y')   
calc<-calc[!is.na(calc$date),]   





', meds$NAME, ignore.case=T)|   
             grepl('torsemide', meds$NAME, ignore.case=T)|grepl('eth
acryn', meds$NAME, ignore.case=T),]   
loop$date<-sapply(strsplit(loop$PERFRMD_FROM_DT_TM, ' '),'[',1)   
loop$date<-as.Date(loop$date, format = '%d-%b-%y')   
   
vaso<-
meds[grepl('norepinephrine', meds$NAME, ignore.case=T)|grepl('epinep
hrine', meds$NAME, ignore.case=T)|   
             grepl('phenylephrine', meds$NAME, ignore.case=T)|grepl(
'vasopressin', meds$NAME, ignore.case=T)|   
             grepl('dopamine', meds$NAME, ignore.case=T),]   
vaso$date<-sapply(strsplit(vaso$PERFRMD_FROM_DT_TM, ' '),'[',1)   
vaso$date<-as.Date(vaso$date, format = '%d-%b-%y')   
   
iono<-
meds[grepl('Dobutamine', meds$NAME, ignore.case=T)|grepl('milrinone'
, meds$NAME, ignore.case=T),]   
iono$date<-sapply(strsplit(iono$PERFRMD_FROM_DT_TM, ' '),'[',1)   
iono$date<-as.Date(iono$date, format = '%d-%b-%y')   
   
acei<-neph[grepl('pril', neph$NAME, ignore.case=T),]   
acei$date<-sapply(strsplit(acei$PERFRMD_FROM_DT_TM, ' '),'[',1)   
acei$date<-as.Date(acei$date)#, format = '%d-%b-%y')   
acei<-acei[complete.cases(acei),]   
   
# NEed to follow up with Andrew   
arb<-
neph[neph$DRUG_KEY  %in% c('d03821','d04322','d04113','d04222','d043
64','d04801'),]   
arb$date<-sapply(strsplit(arb$PERFRMD_FROM_DT_TM, ' '),'[',1)   
arb$date<-as.Date(arb$date)#, format = '%m/%d/%Y')   
arb<-arb[!is.na(arb$date),]   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% ag$ENCNTR_ID)){   
    dem$aminoglycoside_exp[i]<-0   
    next   
  }   
  else{   
    x<-ag[ag$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$aminoglycoside_exp[i]<-1   
    }   
    else{   
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      dem$aminoglycoside_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% amphb$ENCNTR_ID)){   
    dem$amphb_exp[i]<-0   
    next   
  }   
  else{   
    x<-amphb[amphb$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$amphb_exp[i]<-1   
    }   
    else{   
      dem$amphb_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% cont$ENCNTR_ID)){   
    dem$cont_exp[i]<-0   
    next   
  }   
  else{   
    x<-cont[cont$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]#   
    ),]   
    if(dim(x)[1]>0){   
      dem$cont_exp[i]<-1   
    }   
    else{   
      dem$cont_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% nsaids$ENCNTR_ID)){   
    dem$nsaids_exp[i]<-0   
    next   
  }   
  else{   
    x<-nsaids[nsaids$ENCNTR_ID == dem$ENCNTR_ID[i],]   
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    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$nsaids_exp[i]<-1   
    }   
    else{   
      dem$nsaids_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% calc$ENCNTR_ID)){   
    dem$calc_exp[i]<-0   
    next   
  }   
  else{   
    x<-calc[calc$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]#   
    ),]   
    if(dim(x)[1]>0){   
      dem$calc_exp[i]<-1   
    }   
    else{   
      dem$calc_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% loop$ENCNTR_ID)){   
    dem$loop_exp[i]<-0   
    next   
  }   
  else{   
    x<-loop[loop$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$loop_exp[i]<-1   
    }   
    else{   
      dem$loop_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
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  if(!(dem$ENCNTR_ID [i] %in% vaso$ENCNTR_ID)){   
    dem$vaso_exp[i]<-0   
    next   
  }   
  else{   
    x<-vaso[vaso$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$vaso_exp[i]<-1   
    }   
    else{   
      dem$vaso_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% iono$ENCNTR_ID)){   
    dem$iono_exp[i]<-0   
    next   
  }   
  else{   
    x<-iono[iono$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$iono_exp[i]<-1   
    }   
    else{   
      dem$iono_exp[i]<-0   
    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% acei$ENCNTR_ID)){   
    dem$acei_exp[i]<-0   
    next   
  }   
  else{   
    x<-acei[acei$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]),]   
    if(dim(x)[1]>0){   
      dem$acei_exp[i]<-1   
    }   
    else{   
      dem$acei_exp[i]<-0   
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    }   
  }   
}   
   
for(i in 1:nrow(dem)){   
  if(!(dem$ENCNTR_ID [i] %in% arb$ENCNTR_ID)){   
    dem$arb_exp[i]<-0   
    next   
  }   
  else{   
    x<-arb[arb$ENCNTR_ID == dem$ENCNTR_ID[i],]   
    x<-x[dplyr::between(x = x$date, left = dem$tx_index[i]-
1, right = dem$tx_end[i]#   
    ),]   
    if(dim(x)[1]>0){   
      dem$arb_exp[i]<-1   
    }   
    else{   
      dem$arb_exp[i]<-0   
    }   
  }   
}   
   
rm(ag, amphb, cont, nsaids, calc, loop, vaso, iono, acei, arb)   
####################################################################
##################################################   
##                           Vital signs clean up                   
                                                ##   
####################################################################
##################################################   
vit<-
fread('//file2/crutter/UKHC - Cotner, Sarah - 2016/Cotner/cotner_vit
als.csv', sep=',', colClasses='character')   
vit<-vit[vit$ENCNTR_ID %in% dem$ENCNTR_ID,]   
bp<-
vit[grepl('Systolic', vit$LEFT_LABEL, ignore.case = T)| grepl('diast
olic', vit$LEFT_LABEL, ignore.case = T),]   
bp$VAL_TXT<-as.numeric(bp$VAL_TXT)   
   
bpcast<-
dcast.data.table(ENCNTR_ID+RECRD_DT_TM~LEFT_LABEL, value.var = 'VAL_
TXT', data=bp, fun.aggregate = min)   
bpcast$dbp[is.infinite(bpcast$'Direct Arterial Blood Pressure (Diast
olic)')]<-bpcast$Diastolic   
bpcast$sbp[is.infinite(bpcast$'Direct Arterial Blood Pressure (Systo
lic)')]<-bpcast$Systolic   
bpcast$dbp[is.infinite(bpcast$Diastolic)]<-




bpcast$'Direct Arterial Blood Pressure (Systolic)'   
bpcast$dbp[is.infinite(bpcast$'Direct Arterial Blood Pressure (Diast
olic)')& is.infinite(bpcast$Diastolic)]<-NA   
bpcast$sbp[is.infinite(bpcast$'Direct Arterial Blood Pressure (Systo
lic)')& is.infinite(bpcast$Systolic)]<-NA   
bpcast$dbp[is.infinite(bpcast$dbp)]<-NA   
bpcast$sbp[is.infinite(bpcast$sbp)]<-NA   
bp<-dplyr::select(bpcast, ENCNTR_ID, RECRD_DT_TM, dbp, sbp)   
   
bp<-bp[complete.cases(bp),]   
bp$date<-sapply(strsplit(bp$RECRD_DT_TM, ' '),'[',1)   
bp$date<-as.Date(bp$date, format = '%d-%b-%y')   
bp$RECRD_DT_TM<-as.POSIXct(bp$RECRD_DT_TM, format='%d-%b-
%y %H:%M:%S')   
   
bp$map<-round((2*bp$dbp +bp$sbp)/3,2)   
sbpcut<-mean(bp$sbp)+4*sd(bp$sbp)   
dbpcut<-mean(bp$dbp)+4*sd(bp$dbp)   
mapcut<-mean(bp$map)+4*sd(bp$map)   
bp<-bp[bp$sbp<=sbpcut & bp$dbp <= dbpcut & bp$map<=mapcut,]   
   
dem$hypotension<-0   
   
for(i in 1:nrow(dem)){   
  if(min(bp$map[bp$ENCNTR_ID == dem$ENCNTR_ID[i] & dplyr::between(bp
$date,    
                                                                  le
ft = dem$tx_index[i]-1,   
                                                                  ri
ght = dem$tx_end[i])])<65){   
    dem$hypotension[i]<-1   
    next   
  }   
  if(min(sbp<-
bp$sbp[bp$ENCNTR_ID == dem$ENCNTR_ID[i] & dplyr::between(bp$date,    
                                                                    
   left = dem$tx_index[i]-1,   
                                                                    
   right = dem$tx_end[i])])<90){   
    dem$hypotension[i]<-1   
    next   
  }   
  if(dem$vaso_exp[i]==1){   
    dem$hypotension[i]<-1   
  }   
}   
   





library(dplyr)   
library(MatchIt)   
library(data.table)   
mat<-
dplyr::select(dem, ENCNTR_ID, age_group, GENDR_CD_DES, COMORBIDITY_S
CORE, baseline_crcl_cat, hypotension, drug)   
   
mat$drug[mat$drug=='AS']<-1   
mat$drug[mat$drug=='PTZ']<-0   
   
mdf<-
matchit(drug~age_group+ GENDR_CD_DES+ COMORBIDITY_SCORE+ baseline_cr
cl_cat+ hypotension,    
             data=mat, ratio =3, exact = c('GENDR_CD_DES','age_group
'))   
   
summary(mdf)   
m.out<-match.data(mdf)   
matdem<-dem[dem$ENCNTR_ID %in% m.out$ENCNTR_ID,]   
 
Modeling 
mat<-matdem   
mat$aki<-as.numeric(mat$aki)   
attach(mat)   
x<-'binomial'   
library(sjPlot)   
age<-glm(aki~factor(age_group), family=x, data=mat)   
sjt.glm(age)   
   
sex<-glm(aki~factor(GENDR_CD_DES), x, mat)   
sjt.glm(sex)   
race<-glm(aki~factor(caucasian), x, mat)   
sjt.glm(race)   
cci<-glm(aki~as.numeric(COMORBIDITY_SCORE), x, mat)   
sjt.glm(cci)   
crcl<-glm(aki~factor(baseline_crcl_cat), x, mat)   
sjt.glm(crcl)   
ag<-glm(aki~aminoglycoside_exp,x, mat)   
sjt.glm(ag)   
ab<-glm(aki~amphb_exp,x,mat)   
sjt.glm(ab)   
ac<-glm(aki~acei_exp, x, mat)   
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sjt.glm(ac)   
loop<-glm(aki~loop_exp,x, mat)   
sjt.glm(loop)   
ns<-glm(aki~nsaids_exp, x, mat)   
sjt.glm(ns)   
van<-glm(aki~vanc_exp, x, mat)   
sjt.glm(van)   
vas<-glm(aki~vaso_exp, x, mat)   
sjt.glm(vas)   
cf<-glm(aki~CF, x, mat)   
sjt.glm(cf)   
dm<-glm(aki~dm, x, mat)   
sjt.glm(dm)   
htn<-glm(aki~HTN,x,mat)   
sjt.glm(htn)   
hf<-glm(aki~hf, x, mat)   
sjt.glm(hf)   
icu<-glm(aki~icu_admit, x, mat)   
sjt.glm(icu)   
drug<-glm(aki~factor(drug), x, mat)   
sjt.glm(drug)   
hy<-glm(aki~hypotension, x, mat)   
sjt.glm(hy)   
pi<-glm(aki~group, x, mat)   
sjt.glm(pi)   
   
detach(mat)   
attach(mat)   
arb<-glm(aki~arb_exp, x, mat)   
sjt.glm(arb)   
cont<-glm(aki~cont_exp,x,mat)   
sjt.glm(cont)   
calc<-glm(aki~calc_exp, x,mat)   
sjt.glm(calc)   
   
mod<-
glm(aki~drug+GENDR_CD_DES+aminoglycoside_exp+amphb_exp+acei_exp+calc
_exp+cont_exp+loop_exp+vaso_exp+dm+hf+nsaids_exp   
         , x, mat)   
sjt.glm(mod, showAIC = T)   
   
modstep<-step(mod)   
   
mod2<-
glm(formula = aki ~ drug+ GENDR_CD_DES + aminoglycoside_exp + amphb_
exp +    
            calc_exp + cont_exp + loop_exp, family = x, data = mat) 
  
sjt.glm(mod2, showAIC = T)   
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library(ResourceSelection)   
hoslem.test(mod2$y, fitted(mod2), g = 100)   
hoslem.test(mod$y, fitted(mod), g = 100)   
   
library(rms)   
modlrm<-
lrm(aki~group+age_group+GENDR_CD_DES+as.numeric(COMORBIDITY_SCORE)+b
aseline_crcl_cat+aminoglycoside_exp+   
              amphb_exp+acei_exp+calc_exp+loop_exp+nsaids_exp+vanc_e
xp+vaso_exp+CF+dm+HTN+hf+icu_admit+drug+hypotension, data = mat)   
mod2lrm<-
lrm(formula = aki ~ group + age_group + as.numeric(COMORBIDITY_SCORE
) +    
               baseline_crcl_cat + aminoglycoside_exp + amphb_exp + 
calc_exp +    
               loop_exp + nsaids_exp + vanc_exp + vaso_exp + CF + dm
 + hf +    
               drug + hypotension, data = mat)   
   
   
mod2i<-
glm(formula = aki ~ group + age_group + as.numeric(COMORBIDITY_SCORE
) +    
             baseline_crcl_cat + aminoglycoside_exp + amphb_exp + ca
lc_exp +    
             loop_exp + nsaids_exp + vanc_exp + vaso_exp + CF + dm +
 hf +    
             drug*vanc_exp + hypotension, family = x, data = mat)   
 
Data table generation 
restab<-data.frame(variable = rep(NA,100), AS= NA, PTZ = NA, p=NA)   
restab$variable[1] = 'N'   
restab$AS[1] = paste(nrow(dem[dem$drug=='AS',]), " (", (round(nrow(d
em[dem$drug=='AS',])/nrow(dem),3)*100),'%)', sep='')   
restab$PTZ[1] = paste(nrow(dem[dem$drug=='PTZ',]), " (", (round(nrow
(dem[dem$drug=='PTZ',])/nrow(dem),3)*100),'%)', sep='')   
   
attach(dem)   
   
restab$variable[2]<-'Age (mean[SD])'   
restab$AS[2]<-
paste(round(mean(AGE[drug=='AS'], na.rm = T),2), ' (', round(sd(AGE[




paste(round(mean(AGE[drug=='PTZ'], na.rm = T),2), ' (', round(sd(AGE
[drug=='PTZ'], na.rm = T),2),')', sep='')   
restab$p[2]<-t.test(AGE~drug)$p.value   
   
restab$variable[3]<-'Age (median [IQR])'   
restab$AS[3]<-
paste(median(AGE[drug=='AS'], na.rm=T), " (", quantile(AGE[drug=='AS
'], probs=0.25, na.rm = T),'-',   
                    quantile(AGE[drug=='AS'], probs=0.75, na.rm = T)
,')', sep='')   
restab$PTZ[3]<-
paste(median(AGE[drug=='PTZ'], na.rm=T), " (", quantile(AGE[drug=='P
TZ'], probs=0.25, na.rm = T),'-',   
                       quantile(AGE[drug=='PTZ'], probs=0.75, na.rm 
= T),')', sep='')   
restab$p[3]<-wilcox.test(AGE~drug)$p.value   
   
restab$variable[4]<-'Gender'   
restab$variable[5]<-'Male'   
restab$AS[5]<-
paste(nrow(dem[dem$GENDR_CD_DES=='MALE' & dem$drug=='AS',]), ' (',  
  
                    round((nrow(dem[dem$GENDR_CD_DES=='MALE' & dem$d
rug=='AS',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[5]<-
paste(nrow(dem[dem$GENDR_CD_DES=='MALE' & dem$drug=='PTZ',]), ' (', 
   
                       round((nrow(dem[dem$GENDR_CD_DES=='MALE' & de
m$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='') 
  
restab$variable[6]<-'Female'   
restab$AS[6]<-
paste(nrow(dem[dem$GENDR_CD_DES=='FEMALE' & dem$drug=='AS',]), ' (',
    
                    round((nrow(dem[dem$GENDR_CD_DES=='FEMALE' & dem
$drug=='AS',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[6]<-
paste(nrow(dem[dem$GENDR_CD_DES=='FEMALE' & dem$drug=='PTZ',]), ' ('
,    
                       round((nrow(dem[dem$GENDR_CD_DES=='FEMALE' & 
dem$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep=''
)   
restab$p[4]<-chisq.test(table(GENDR_CD_DES, drug))$p.value   
   
restab$variable[7]<-'caucasian'   
restab$AS[7]<-
paste(nrow(dem[dem$caucasian==1 & dem$drug=='AS',]), ' (',    
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                    round((nrow(dem[dem$caucasian==1 & dem$drug=='AS
',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[7]<-
paste(nrow(dem[dem$caucasian==1 & dem$drug=='PTZ',]), ' (',    
                       round((nrow(dem[dem$caucasian==1 & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[7]<-chisq.test(table(caucasian, drug))$p.value   
   
restab$variable[8]<-'WT (mean[SD])'   
restab$AS[8]<-
paste(round(mean(INIT_WT[drug=='AS'], na.rm = T),2), ' (', round(sd(
INIT_WT[drug=='AS'], na.rm = T),2),')', sep='')   
restab$PTZ[8]<-
paste(round(mean(INIT_WT[drug=='PTZ'], na.rm = T),2), ' (', round(sd
(INIT_WT[drug=='PTZ'], na.rm = T),2),')', sep='')   
restab$p[8]<-t.test(INIT_WT~drug)$p.value   
   
restab$variable[9]<-'WT (median [IQR])'   
restab$AS[9]<-
paste(median(INIT_WT[drug=='AS'], na.rm=T), " (", quantile(INIT_WT[d
rug=='AS'], probs=0.25, na.rm = T),'-',   
                    quantile(INIT_WT[drug=='AS'], probs=0.75, na.rm 
= T),')', sep='')   
restab$PTZ[9]<-
paste(median(INIT_WT[drug=='PTZ'], na.rm=T), " (", quantile(INIT_WT[
drug=='PTZ'], probs=0.25, na.rm = T),'-',   
                       quantile(INIT_WT[drug=='PTZ'], probs=0.75, na
.rm = T),')', sep='')   
restab$p[9]<-wilcox.test(INIT_WT~drug)$p.value   
   
restab$variable[10]<-'BMI (mean[SD])'   
restab$AS[10]<-
paste(round(mean(BMI[drug=='AS'], na.rm = T),2), ' (', round(sd(BMI[
drug=='AS'], na.rm = T),2),')', sep='')   
restab$PTZ[10]<-
paste(round(mean(BMI[drug=='PTZ'], na.rm = T),2), ' (', round(sd(BMI
[drug=='PTZ'], na.rm = T),2),')', sep='')   
restab$p[10]<-t.test(BMI~drug)$p.value   
   
restab$variable[11]<-'BMI (median [IQR])'   
restab$AS[11]<-
paste(round(median(BMI[drug=='AS'], na.rm=T),2), " (", round(quantil
e(BMI[drug=='AS'], probs=0.25, na.rm = T),2),'-',   
                     round(quantile(BMI[drug=='AS'], probs=0.75, na.
rm = T),2),')', sep='')   
restab$PTZ[11]<-
paste(round(median(BMI[drug=='PTZ'], na.rm=T),2), " (", round(quanti
le(BMI[drug=='PTZ'], probs=0.25, na.rm = T),2),'-',   
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                        round(quantile(BMI[drug=='PTZ'], probs=0.75,
 na.rm = T),2),')', sep='')   
restab$p[11]<-wilcox.test(BMI~drug)$p.value   
   
restab$variable[12]<-'COMORBIDITY_SCORE (mean[SD])'   
restab$AS[12]<-
paste(round(mean(dem$COMORBIDITY_SCORE[drug=='AS'], na.rm = T),2), '
 (', round(sd(dem$COMORBIDITY_SCORE[drug=='AS'], na.rm = T),2),')', 
sep='')   
restab$PTZ[12]<-
paste(round(mean(dem$COMORBIDITY_SCORE[drug=='PTZ'], na.rm = T),2), 
' (', round(sd(dem$COMORBIDITY_SCORE[drug=='PTZ'], na.rm = T),2),')'
, sep='')   
restab$p[12]<-t.test(dem$COMORBIDITY_SCORE~drug)$p.value   
   
restab$variable[13]<-'COMORBIDITY_SCORE (median [IQR])'   
restab$AS[13]<-
paste(median(dem$COMORBIDITY_SCORE[drug=='AS'], na.rm=T), " (", quan
tile(dem$COMORBIDITY_SCORE[drug=='AS'], probs=0.25, na.rm = T),'-
',   
                     quantile(dem$COMORBIDITY_SCORE[drug=='AS'], pro
bs=0.75, na.rm = T),')', sep='')   
restab$PTZ[13]<-
paste(median(dem$COMORBIDITY_SCORE[drug=='PTZ'], na.rm=T), " (", qua
ntile(dem$COMORBIDITY_SCORE[drug=='PTZ'], probs=0.25, na.rm = T),'-
',   
                        quantile(dem$COMORBIDITY_SCORE[drug=='PTZ'],
 probs=0.75, na.rm = T),')', sep='')   
restab$p[13]<-wilcox.test(dem$COMORBIDITY_SCORE~drug)$p.value   
   
restab$variable[14]<-'baseline crcl (mean[SD])'   
restab$AS[14]<-
paste(round(mean(dem$baseline_crcl[drug=='AS'], na.rm = T),2), ' (',
 round(sd(dem$baseline_crcl[drug=='AS'], na.rm = T),2),')', sep='') 
  
restab$PTZ[14]<-
paste(round(mean(dem$baseline_crcl[drug=='PTZ'], na.rm = T),2), ' ('
, round(sd(dem$baseline_crcl[drug=='PTZ'], na.rm = T),2),')', sep=''
)   
restab$p[14]<-t.test(dem$baseline_crcl~drug)$p.value   
   
restab$variable[15]<-'baseline crcl (median [IQR])'   
restab$AS[15]<-
paste(round(median(dem$baseline_crcl[drug=='AS'], na.rm=T),2), " (",
    
                     round(quantile(dem$baseline_crcl[drug=='AS'], p
robs=0.25, na.rm = T),2),'-',   
                     round(quantile(dem$baseline_crcl[drug=='AS'], p




paste(round(median(dem$baseline_crcl[drug=='PTZ'], na.rm=T),2), " ("
,    
                        round(quantile(dem$baseline_crcl[drug=='PTZ'
], probs=0.25, na.rm = T),2),'-',   
                        round(quantile(dem$baseline_crcl[drug=='PTZ'
], probs=0.75, na.rm = T),2),')', sep='')   
restab$p[15]<-wilcox.test(dem$baseline_crcl~drug)$p.value   
   
restab$variable[16]<-'baseline crcl drug'   
restab$variable[17]<-'30-59 mL/min'   
restab$AS[17]<-
paste(nrow(dem[dem$baseline_crcl_cat == 1 & dem$drug=='AS',]), ' (',
    
                     round((nrow(dem[dem$baseline_crcl_cat == 1 & de
m$drug=='AS',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[17]<-
paste(nrow(dem[dem$baseline_crcl_cat == 1 & dem$drug=='PTZ',]), ' ('
,    
                        round((nrow(dem[dem$baseline_crcl_cat == 1 &
 dem$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='
')   
restab$variable[18]<-'60-89 mL/min'   
restab$AS[18]<-
paste(nrow(dem[dem$baseline_crcl_cat == 2 & dem$drug=='AS',]), ' (',
    
                     round((nrow(dem[dem$baseline_crcl_cat == 2 & de
m$drug=='AS',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[18]<-
paste(nrow(dem[dem$baseline_crcl_cat == 2 & dem$drug=='PTZ',]), ' ('
,    
                        round((nrow(dem[dem$baseline_crcl_cat == 2 &
 dem$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='
')   
restab$variable[19]<-'>=90 mL/min'   
restab$AS[19]<-
paste(nrow(dem[dem$baseline_crcl_cat == 3 & dem$drug=='AS',]), ' (',
    
                     round((nrow(dem[dem$baseline_crcl_cat == 3 & de
m$drug=='AS',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[19]<-
paste(nrow(dem[dem$baseline_crcl_cat == 3 & dem$drug=='PTZ',]), ' ('
,    
                        round((nrow(dem[dem$baseline_crcl_cat == 3 &
 dem$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='
')   
restab$p[16]<-chisq.test(table(baseline_crcl_cat, drug))$p.value   
   
restab$variable[20]<-'Concomitant nephrotoxins'   
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restab$variable[21]<-'Aminoglycosides'   
restab$AS[21]<-
paste(nrow(dem[dem$aminoglycoside_exp == 1 & dem$drug=='AS',]), ' ('
,    
                     round((nrow(dem[dem$aminoglycoside_exp == 1 & d
em$drug=='AS',])/nrow(dem[dem$drug=='AS',])*100),2),    
                     '%)', sep='')   
restab$PTZ[21]<-
paste(nrow(dem[dem$aminoglycoside_exp == 1 & dem$drug=='PTZ',]), ' (
',    
                        round((nrow(dem[dem$aminoglycoside_exp == 1 
& dem$drug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[21]<-chisq.test(table(aminoglycoside_exp, drug))$p.value   
   
restab$variable[22]<-'amphb'   
restab$AS[22]<-
paste(nrow(dem[dem$amphb_exp == 1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$amphb_exp == 1 & dem$drug==
'AS',])/nrow(dem[dem$drug=='AS',])*100),2),    
                     '%)', sep='')   
restab$PTZ[22]<-
paste(nrow(dem[dem$amphb_exp == 1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$amphb_exp == 1 & dem$dru
g=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[22]<-chisq.test(table(amphb_exp, drug))$p.value   
   
restab$variable[23]<-'acei'   
restab$AS[23]<-
paste(nrow(dem[dem$acei_exp == 1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$acei_exp == 1 & dem$drug=='
AS',])/nrow(dem[dem$drug=='AS',])*100),2),    
                     '%)', sep='')   
restab$PTZ[23]<-
paste(nrow(dem[dem$acei_exp == 1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$acei_exp == 1 & dem$drug
=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[23]<-chisq.test(table(acei_exp, drug))$p.value   
   
restab$variable[24]<-'arb'   
restab$AS[24]<-
paste(nrow(dem[dem$arb_exp == 1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$arb_exp == 1 & dem$drug=='A
S',])/nrow(dem[dem$drug=='AS',])*100),2),    
                     '%)', sep='')   
restab$PTZ[24]<-
paste(nrow(dem[dem$arb_exp == 1 & dem$drug=='PTZ',]), ' (',    
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                        round((nrow(dem[dem$arb_exp == 1 & dem$drug=
='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[24]<-chisq.test(table(arb_exp, drug))$p.value   
   
   
restab$variable[25]<-'cont'   
restab$AS[25]<-
paste(nrow(dem[dem$cont_exp == 1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$cont_exp == 1 & dem$drug=='
AS',])/nrow(dem[dem$drug=='AS',])*100),2),    
                     '%)', sep='')   
restab$PTZ[25]<-
paste(nrow(dem[dem$cont_exp == 1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$cont_exp == 1 & dem$drug
=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[25]<-chisq.test(table(cont_exp, drug))$p.value   
   
restab$variable[26]<-'loop'   
restab$AS[26]<-
paste(nrow(dem[dem$loop_exp == 1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$loop_exp == 1 & dem$drug=='
AS',])/nrow(dem[dem$drug=='AS',])*100),2),    
                     '%)', sep='')   
restab$PTZ[26]<-
paste(nrow(dem[dem$loop_exp == 1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$loop_exp == 1 & dem$drug
=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[26]<-chisq.test(table(loop_exp, drug))$p.value   
   
restab$variable[27]<-'nsaids'   
restab$AS[27]<-
paste(nrow(dem[dem$nsaids_exp == 1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$nsaids_exp == 1 & dem$drug=
='AS',])/nrow(dem[dem$drug=='AS',])*100),2),    
                     '%)', sep='')   
restab$PTZ[27]<-
paste(nrow(dem[dem$nsaids_exp == 1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$nsaids_exp == 1 & dem$dr
ug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[27]<-chisq.test(table(nsaids_exp, drug))$p.value   
   
restab$variable[28]<-'calc'   
restab$AS[28]<-
paste(nrow(dem[dem$calc_exp == 1 & dem$drug=='AS',]), ' (',    
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                     round((nrow(dem[dem$calc_exp == 1 & dem$drug=='
AS',])/nrow(dem[dem$drug=='AS',])*100),2),    
                     '%)', sep='')   
restab$PTZ[28]<-
paste(nrow(dem[dem$calc_exp == 1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$calc_exp == 1 & dem$drug
=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[28]<-chisq.test(table(calc_exp, drug))$p.value   
   
# restab$variable[29]<-'vanc'   
# restab$AS[29]<-
paste(nrow(dem[dem$vanc_exp == 1 & dem$drug=='AS',]), ' (',    
#                      round((nrow(dem[dem$vanc_exp == 1 & dem$drug=
='AS',])/nrow(dem[dem$drug=='AS',])*100),2),    
#                      '%)', sep='')   
# restab$PTZ[29]<-
paste(nrow(dem[dem$vanc_exp == 1 & dem$drug=='PTZ',]), ' (',    
#                         round((nrow(dem[dem$vanc_exp == 1 & dem$dr
ug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
#                         '%)', sep='')   
# restab$p[29]<-chisq.test(table(vanc_exp, drug))$p.value   
   
restab$variable[30]<-'vaso'   
restab$AS[30]<-
paste(nrow(dem[dem$vaso_exp == 1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$vaso_exp == 1 & dem$drug=='
AS',])/nrow(dem[dem$drug=='AS',])*100),2),    
                     '%)', sep='')   
restab$PTZ[30]<-
paste(nrow(dem[dem$vaso_exp == 1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$vaso_exp == 1 & dem$drug
=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
restab$p[30]<-chisq.test(table(vaso_exp, drug))$p.value   
   
restab$variable[31]<-'Comorbidities'   
restab$variable[32]<-'DM'   
restab$AS[32]<-
paste(nrow(dem[dem$dm==1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$dm==1 & dem$drug=='AS',])/n
row(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[32]<-
paste(nrow(dem[dem$dm==1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$dm==1 & dem$drug=='PTZ',
])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[32]<-chisq.test(table(dem$dm, drug))$p.value   
   




paste(nrow(dem[dem$hf==1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$hf==1 & dem$drug=='AS',])/n
row(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[33]<-
paste(nrow(dem[dem$hf==1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$hf==1 & dem$drug=='PTZ',
])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[33]<-chisq.test(table(dem$hf, drug))$p.value   
   
restab$variable[34]<-'HTN'   
restab$AS[34]<-
paste(nrow(dem[dem$HTN==1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$HTN==1 & dem$drug=='AS',])/
nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[34]<-
paste(nrow(dem[dem$HTN==1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$HTN==1 & dem$drug=='PTZ'
,])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[34]<-chisq.test(table(HTN, drug))$p.value   
   
restab$variable[35]<-'CF'   
restab$AS[35]<-
paste(nrow(dem[dem$CF==1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$CF==1 & dem$drug=='AS',])/n
row(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[35]<-
paste(nrow(dem[dem$CF==1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$CF==1 & dem$drug=='PTZ',
])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[35]<-chisq.test(table(CF, drug))$p.value   
   
restab$variable[36]<-'LOS (mean[SD])'   
restab$AS[36]<-
paste(round(mean(dem$LENGTH_OF_STAY_NUM[drug=='AS'], na.rm = T),2), 
' (', round(sd(dem$LENGTH_OF_STAY_NUM[drug=='AS'], na.rm = T),2),')'
, sep='')   
restab$PTZ[36]<-
paste(round(mean(dem$LENGTH_OF_STAY_NUM[drug=='PTZ'], na.rm = T),2),
 ' (', round(sd(dem$LENGTH_OF_STAY_NUM[drug=='PTZ'], na.rm = T),2),'
)', sep='')   
restab$p[36]<-t.test(dem$LENGTH_OF_STAY_NUM~drug)$p.value   
   
restab$variable[37]<-'LOS (median [IQR])'   
restab$AS[37]<-
paste(median(dem$LENGTH_OF_STAY_NUM[drug=='AS'], na.rm=T), " (", qua
ntile(dem$LENGTH_OF_STAY_NUM[drug=='AS'], probs=0.25, na.rm = T),'-
',   
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                     quantile(dem$LENGTH_OF_STAY_NUM[drug=='AS'], pr
obs=0.75, na.rm = T),')', sep='')   
restab$PTZ[37]<-
paste(median(dem$LENGTH_OF_STAY_NUM[drug=='PTZ'], na.rm=T), " (", qu
antile(dem$LENGTH_OF_STAY_NUM[drug=='PTZ'], probs=0.25, na.rm = T),'
-',   
                        quantile(dem$LENGTH_OF_STAY_NUM[drug=='PTZ']
, probs=0.75, na.rm = T),')', sep='')   
restab$p[37]<-wilcox.test(dem$LENGTH_OF_STAY_NUM~drug)$p.value   
   
# restab$variable[38]<-'icu_admit'   
# restab$AS[38]<-
paste(nrow(dem[dem$icu_admit==1 & dem$drug=='AS',]), ' (',    
#                      round((nrow(dem[dem$icu_admit==1 & dem$drug==
'AS',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
# restab$PTZ[38]<-
paste(nrow(dem[dem$icu_admit==1 & dem$drug=='PTZ',]), ' (',    
#                         round((nrow(dem[dem$icu_admit==1 & dem$dru
g=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
# restab$p[38]<-chisq.test(table(icu_admit, drug))$p.value   
   
# restab$variable[39]<-'Drug'   
# restab$variable[40]<-'PTZ'   
# restab$AS[40]<-
paste(nrow(dem[dem$drug=='P' & dem$drug=='AS',]), ' (',    
#                      round((nrow(dem[dem$drug=='P' & dem$drug=='AS
',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
# restab$PTZ[40]<-
paste(nrow(dem[dem$drug=='P' & dem$drug=='PTZ',]), ' (',    
#                         round((nrow(dem[dem$drug=='P' & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
# restab$variable[41]<-'CFP'   
# restab$AS[41]<-
paste(nrow(dem[dem$drug=='C' & dem$drug=='AS',]), ' (',    
#                      round((nrow(dem[dem$drug=='C' & dem$drug=='AS
',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
# restab$PTZ[41]<-
paste(nrow(dem[dem$drug=='C' & dem$drug=='PTZ',]), ' (',    
#                         round((nrow(dem[dem$drug=='C' & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
# restab$variable[42]<-'MEM'   
# restab$AS[42]<-
paste(nrow(dem[dem$drug=='M' & dem$drug=='AS',]), ' (',    
#                      round((nrow(dem[dem$drug=='M' & dem$drug=='AS
',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
# restab$PTZ[42]<-
paste(nrow(dem[dem$drug=='M' & dem$drug=='PTZ',]), ' (',    
#                         round((nrow(dem[dem$drug=='M' & dem$drug==
'PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
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#    
# restab$p[39]<-chisq.test(table(drug, drug))$p.value   
   
restab$variable[45]<-'AKI'   
restab$variable[46]<-'Any'   
restab$AS[46]<-
paste(nrow(dem[dem$aki==1 & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$aki==1 & dem$drug=='AS',])/
nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[46]<-
paste(nrow(dem[dem$aki==1 & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$aki==1 & dem$drug=='PTZ'
,])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$p[46]<-chisq.test(table(aki, drug))$p.value   
   
restab$variable[47]<-'Risk'   
restab$AS[47]<-
paste(nrow(dem[dem$RIFLE=='risk' & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$RIFLE=='risk' & dem$drug=='
AS',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[47]<-
paste(nrow(dem[dem$RIFLE=='risk' & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$RIFLE=='risk' & dem$drug
=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
restab$variable[48]<-'injury'   
restab$AS[48]<-
paste(nrow(dem[dem$RIFLE=='injury' & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$RIFLE=='injury' & dem$drug=
='AS',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[48]<-
paste(nrow(dem[dem$RIFLE=='injury' & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$RIFLE=='injury' & dem$dr
ug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
   
restab$variable[49]<-'failure'   
restab$AS[49]<-
paste(nrow(dem[dem$RIFLE=='failure' & dem$drug=='AS',]), ' (',    
                     round((nrow(dem[dem$RIFLE=='failure' & dem$drug
=='AS',])/nrow(dem[dem$drug=='AS',])*100),2), '%)', sep='')   
restab$PTZ[49]<-
paste(nrow(dem[dem$RIFLE=='failure' & dem$drug=='PTZ',]), ' (',    
                        round((nrow(dem[dem$RIFLE=='failure' & dem$d
rug=='PTZ',])/nrow(dem[dem$drug=='PTZ',])*100),2), '%)', sep='')   
   
restab<-restab[!is.na(restab$variable),]   
restab$p[restab$p <=0.00001]<-0.00001   
restab$p<-round(restab$p, 5)   
write.csv(restab,'unmatched_results_table.csv', row.names=F)   







data.frame(variable = rep(NA,100), AS = NA, PTZ = NA, p=NA)   
mattab$variable[1] = 'N'   
mattab$AS[1] = paste(nrow(matdem[matdem$drug=='AS',]), " (", (round(
nrow(matdem[matdem$drug=='AS',])/nrow(matdem),3)*100),'%)', sep='') 
  
mattab$PTZ[1] = paste(nrow(matdem[matdem$drug=='PTZ',]), " (", (roun
d(nrow(matdem[matdem$drug=='PTZ',])/nrow(matdem),3)*100),'%)', sep='
')   
   
attach(matdem)   
   
mattab$variable[2]<-'Age (mean[SD])'   
mattab$AS[2]<-
paste(round(mean(AGE[drug=='AS'], na.rm = T),2), ' (', round(sd(AGE[
drug=='AS'], na.rm = T),2),')', sep='')   
mattab$PTZ[2]<-
paste(round(mean(AGE[drug=='PTZ'], na.rm = T),2), ' (', round(sd(AGE
[drug=='PTZ'], na.rm = T),2),')', sep='')   
mattab$p[2]<-t.test(AGE~drug)$p.value   
   
mattab$variable[3]<-'Age (median [IQR])'   
mattab$AS[3]<-
paste(median(AGE[drug=='AS'], na.rm=T), " (", quantile(AGE[drug=='AS
'], probs=0.25, na.rm = T),'-',   
                    quantile(AGE[drug=='AS'], probs=0.75, na.rm = T)
,')', sep='')   
mattab$PTZ[3]<-
paste(median(AGE[drug=='PTZ'], na.rm=T), " (", quantile(AGE[drug=='P
TZ'], probs=0.25, na.rm = T),'-',   
                       quantile(AGE[drug=='PTZ'], probs=0.75, na.rm 
= T),')', sep='')   
mattab$p[3]<-wilcox.test(AGE~drug)$p.value   
   
mattab$variable[4]<-'Gender'   
mattab$variable[5]<-'Male'   
mattab$AS[5]<-
paste(nrow(matdem[matdem$GENDR_CD_DES=='MALE' & matdem$drug=='AS',])
, ' (',    
                    round((nrow(matdem[matdem$GENDR_CD_DES=='MALE' &
 matdem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)'
, sep='')   
mattab$PTZ[5]<-
paste(nrow(matdem[matdem$GENDR_CD_DES=='MALE' & matdem$drug=='PTZ',]
), ' (',    
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                       round((nrow(matdem[matdem$GENDR_CD_DES=='MALE
' & matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),
 '%)', sep='')   
mattab$variable[6]<-'Female'   
mattab$AS[6]<-
paste(nrow(matdem[matdem$GENDR_CD_DES=='FEMALE' & matdem$drug=='AS',
]), ' (',    
                    round((nrow(matdem[matdem$GENDR_CD_DES=='FEMALE'
 & matdem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%
)', sep='')   
mattab$PTZ[6]<-
paste(nrow(matdem[matdem$GENDR_CD_DES=='FEMALE' & matdem$drug=='PTZ'
,]), ' (',    
                       round((nrow(matdem[matdem$GENDR_CD_DES=='FEMA
LE' & matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2
), '%)', sep='')   
mattab$p[4]<-chisq.test(table(GENDR_CD_DES, drug))$p.value   
   
mattab$variable[7]<-'caucasian'   
mattab$AS[7]<-
paste(nrow(matdem[matdem$caucasian==1 & matdem$drug=='AS',]), ' (', 
   
                    round((nrow(matdem[matdem$caucasian==1 & matdem$
drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep=''
)   
mattab$PTZ[7]<-
paste(nrow(matdem[matdem$caucasian==1 & matdem$drug=='PTZ',]), ' (',
    
                       round((nrow(matdem[matdem$caucasian==1 & matd
em$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)', s
ep='')   
mattab$p[7]<-chisq.test(table(caucasian, drug))$p.value   
   
mattab$variable[8]<-'WT (mean[SD])'   
mattab$AS[8]<-
paste(round(mean(INIT_WT[drug=='AS'], na.rm = T),2), ' (', round(sd(
INIT_WT[drug=='AS'], na.rm = T),2),')', sep='')   
mattab$PTZ[8]<-
paste(round(mean(INIT_WT[drug=='PTZ'], na.rm = T),2), ' (', round(sd
(INIT_WT[drug=='PTZ'], na.rm = T),2),')', sep='')   
mattab$p[8]<-t.test(INIT_WT~drug)$p.value   
   
mattab$variable[9]<-'WT (median [IQR])'   
mattab$AS[9]<-
paste(median(INIT_WT[drug=='AS'], na.rm=T), " (", quantile(INIT_WT[d
rug=='AS'], probs=0.25, na.rm = T),'-',   
                    quantile(INIT_WT[drug=='AS'], probs=0.75, na.rm 




paste(median(INIT_WT[drug=='PTZ'], na.rm=T), " (", quantile(INIT_WT[
drug=='PTZ'], probs=0.25, na.rm = T),'-',   
                       quantile(INIT_WT[drug=='PTZ'], probs=0.75, na
.rm = T),')', sep='')   
mattab$p[9]<-wilcox.test(INIT_WT~drug)$p.value   
   
mattab$variable[10]<-'BMI (mean[SD])'   
mattab$AS[10]<-
paste(round(mean(BMI[drug=='AS'], na.rm = T),2), ' (', round(sd(BMI[
drug=='AS'], na.rm = T),2),')', sep='')   
mattab$PTZ[10]<-
paste(round(mean(BMI[drug=='PTZ'], na.rm = T),2), ' (', round(sd(BMI
[drug=='PTZ'], na.rm = T),2),')', sep='')   
mattab$p[10]<-t.test(BMI~drug)$p.value   
   
mattab$variable[11]<-'BMI (median [IQR])'   
mattab$AS[11]<-
paste(round(median(BMI[drug=='AS'], na.rm=T),2), " (", round(quantil
e(BMI[drug=='AS'], probs=0.25, na.rm = T),2),'-',   
                     round(quantile(BMI[drug=='AS'], probs=0.75, na.
rm = T),2),')', sep='')   
mattab$PTZ[11]<-
paste(round(median(BMI[drug=='PTZ'], na.rm=T),2), " (", round(quanti
le(BMI[drug=='PTZ'], probs=0.25, na.rm = T),2),'-',   
                        round(quantile(BMI[drug=='PTZ'], probs=0.75,
 na.rm = T),2),')', sep='')   
mattab$p[11]<-wilcox.test(BMI~drug)$p.value   
   
mattab$variable[12]<-'COMORBIDITY_SCORE (mean[SD])'   
mattab$AS[12]<-
paste(round(mean(matdem$COMORBIDITY_SCORE[drug=='AS'], na.rm = T),2)
, ' (', round(sd(matdem$COMORBIDITY_SCORE[drug=='AS'], na.rm = T),2)
,')', sep='')   
mattab$PTZ[12]<-
paste(round(mean(matdem$COMORBIDITY_SCORE[drug=='PTZ'], na.rm = T),2
), ' (', round(sd(matdem$COMORBIDITY_SCORE[drug=='PTZ'], na.rm = T),
2),')', sep='')   
mattab$p[12]<-t.test(matdem$COMORBIDITY_SCORE~drug)$p.value   
   
mattab$variable[13]<-'COMORBIDITY_SCORE (median [IQR])'   
mattab$AS[13]<-
paste(median(matdem$COMORBIDITY_SCORE[drug=='AS'], na.rm=T), " (", q
uantile(matdem$COMORBIDITY_SCORE[drug=='AS'], probs=0.25, na.rm = T)
,'-',   
                     quantile(matdem$COMORBIDITY_SCORE[drug=='AS'], 
probs=0.75, na.rm = T),')', sep='')   
mattab$PTZ[13]<-
paste(median(matdem$COMORBIDITY_SCORE[drug=='PTZ'], na.rm=T), " (", 
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quantile(matdem$COMORBIDITY_SCORE[drug=='PTZ'], probs=0.25, na.rm = 
T),'-',   
                        quantile(matdem$COMORBIDITY_SCORE[drug=='PTZ
'], probs=0.75, na.rm = T),')', sep='')   
mattab$p[13]<-wilcox.test(matdem$COMORBIDITY_SCORE~drug)$p.value   
   
mattab$variable[14]<-'baseline crcl (mean[SD])'   
mattab$AS[14]<-
paste(round(mean(matdem$baseline_crcl[drug=='AS'], na.rm = T),2), ' 
(', round(sd(matdem$baseline_crcl[drug=='AS'], na.rm = T),2),')', se
p='')   
mattab$PTZ[14]<-
paste(round(mean(matdem$baseline_crcl[drug=='PTZ'], na.rm = T),2), '
 (', round(sd(matdem$baseline_crcl[drug=='PTZ'], na.rm = T),2),')', 
sep='')   
mattab$p[14]<-t.test(matdem$baseline_crcl~drug)$p.value   
   
mattab$variable[15]<-'baseline crcl (median [IQR])'   
mattab$AS[15]<-
paste(round(median(matdem$baseline_crcl[drug=='AS'], na.rm=T),2), " 
(",    
                     round(quantile(matdem$baseline_crcl[drug=='AS']
, probs=0.25, na.rm = T),2),'-',   
                     round(quantile(matdem$baseline_crcl[drug=='AS']
, probs=0.75, na.rm = T),2),')', sep='')   
mattab$PTZ[15]<-
paste(round(median(matdem$baseline_crcl[drug=='PTZ'], na.rm=T),2), "
 (",    
                        round(quantile(matdem$baseline_crcl[drug=='P
TZ'], probs=0.25, na.rm = T),2),'-',   
                        round(quantile(matdem$baseline_crcl[drug=='P
TZ'], probs=0.75, na.rm = T),2),')', sep='')   
mattab$p[15]<-wilcox.test(matdem$baseline_crcl~drug)$p.value   
   
mattab$variable[16]<-'baseline crcl drug'   
mattab$variable[17]<-'30-59 mL/min'   
mattab$AS[17]<-
paste(nrow(matdem[matdem$baseline_crcl_cat == 1 & matdem$drug=='AS',
]), ' (',    
                     round((nrow(matdem[matdem$baseline_crcl_cat == 
1 & matdem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '
%)', sep='')   
mattab$PTZ[17]<-
paste(nrow(matdem[matdem$baseline_crcl_cat == 1 & matdem$drug=='PTZ'
,]), ' (',    
                        round((nrow(matdem[matdem$baseline_crcl_cat 
== 1 & matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),
2), '%)', sep='')   




paste(nrow(matdem[matdem$baseline_crcl_cat == 2 & matdem$drug=='AS',
]), ' (',    
                     round((nrow(matdem[matdem$baseline_crcl_cat == 
2 & matdem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '
%)', sep='')   
mattab$PTZ[18]<-
paste(nrow(matdem[matdem$baseline_crcl_cat == 2 & matdem$drug=='PTZ'
,]), ' (',    
                        round((nrow(matdem[matdem$baseline_crcl_cat 
== 2 & matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),
2), '%)', sep='')   
mattab$variable[19]<-'>=90 mL/min'   
mattab$AS[19]<-
paste(nrow(matdem[matdem$baseline_crcl_cat == 3 & matdem$drug=='AS',
]), ' (',    
                     round((nrow(matdem[matdem$baseline_crcl_cat == 
3 & matdem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '
%)', sep='')   
mattab$PTZ[19]<-
paste(nrow(matdem[matdem$baseline_crcl_cat == 3 & matdem$drug=='PTZ'
,]), ' (',    
                        round((nrow(matdem[matdem$baseline_crcl_cat 
== 3 & matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),
2), '%)', sep='')   
mattab$p[16]<-chisq.test(table(baseline_crcl_cat, drug))$p.value   
   
mattab$variable[20]<-'Concomitant nephrotoxins'   
mattab$variable[21]<-'Aminoglycosides'   
mattab$AS[21]<-
paste(nrow(matdem[matdem$aminoglycoside_exp == 1 & matdem$drug=='AS'
,]), ' (',    
                     round((nrow(matdem[matdem$aminoglycoside_exp ==
 1 & matdem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), 
   
                     '%)', sep='')   
mattab$PTZ[21]<-
paste(nrow(matdem[matdem$aminoglycoside_exp == 1 & matdem$drug=='PTZ
',]), ' (',    
                        round((nrow(matdem[matdem$aminoglycoside_exp
 == 1 & matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100)
,2),    
                        '%)', sep='')   
mattab$p[21]<-chisq.test(table(aminoglycoside_exp, drug))$p.value   
   
mattab$variable[22]<-'amphb'   
mattab$AS[22]<-
paste(nrow(matdem[matdem$amphb_exp == 1 & matdem$drug=='AS',]), ' ('
,    
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                     round((nrow(matdem[matdem$amphb_exp == 1 & matd
em$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2),    
                     '%)', sep='')   
mattab$PTZ[22]<-
paste(nrow(matdem[matdem$amphb_exp == 1 & matdem$drug=='PTZ',]), ' (
',    
                        round((nrow(matdem[matdem$amphb_exp == 1 & m
atdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
mattab$p[22]<-chisq.test(table(amphb_exp, drug))$p.value   
   
mattab$variable[23]<-'acei'   
mattab$AS[23]<-
paste(nrow(matdem[matdem$acei_exp == 1 & matdem$drug=='AS',]), ' (',
    
                     round((nrow(matdem[matdem$acei_exp == 1 & matde
m$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2),    
                     '%)', sep='')   
mattab$PTZ[23]<-
paste(nrow(matdem[matdem$acei_exp == 1 & matdem$drug=='PTZ',]), ' ('
,    
                        round((nrow(matdem[matdem$acei_exp == 1 & ma
tdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
mattab$p[23]<-chisq.test(table(acei_exp, drug))$p.value   
   
mattab$variable[24]<-'arb'   
mattab$AS[24]<-
paste(nrow(matdem[matdem$arb_exp == 1 & matdem$drug=='AS',]), ' (', 
   
                     round((nrow(matdem[matdem$arb_exp == 1 & matdem
$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2),    
                     '%)', sep='')   
mattab$PTZ[24]<-
paste(nrow(matdem[matdem$arb_exp == 1 & matdem$drug=='PTZ',]), ' (',
    
                        round((nrow(matdem[matdem$arb_exp == 1 & mat
dem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
mattab$p[24]<-chisq.test(table(arb_exp, drug))$p.value   
   
   
mattab$variable[25]<-'cont'   
mattab$AS[25]<-
paste(nrow(matdem[matdem$cont_exp == 1 & matdem$drug=='AS',]), ' (',
    
                     round((nrow(matdem[matdem$cont_exp == 1 & matde
m$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2),    




paste(nrow(matdem[matdem$cont_exp == 1 & matdem$drug=='PTZ',]), ' ('
,    
                        round((nrow(matdem[matdem$cont_exp == 1 & ma
tdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
mattab$p[25]<-chisq.test(table(cont_exp, drug))$p.value   
   
mattab$variable[26]<-'loop'   
mattab$AS[26]<-
paste(nrow(matdem[matdem$loop_exp == 1 & matdem$drug=='AS',]), ' (',
    
                     round((nrow(matdem[matdem$loop_exp == 1 & matde
m$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2),    
                     '%)', sep='')   
mattab$PTZ[26]<-
paste(nrow(matdem[matdem$loop_exp == 1 & matdem$drug=='PTZ',]), ' ('
,    
                        round((nrow(matdem[matdem$loop_exp == 1 & ma
tdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
mattab$p[26]<-chisq.test(table(loop_exp, drug))$p.value   
   
mattab$variable[27]<-'nsaids'   
mattab$AS[27]<-
paste(nrow(matdem[matdem$nsaids_exp == 1 & matdem$drug=='AS',]), ' (
',    
                     round((nrow(matdem[matdem$nsaids_exp == 1 & mat
dem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2),    
                     '%)', sep='')   
mattab$PTZ[27]<-
paste(nrow(matdem[matdem$nsaids_exp == 1 & matdem$drug=='PTZ',]), ' 
(',    
                        round((nrow(matdem[matdem$nsaids_exp == 1 & 
matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
mattab$p[27]<-chisq.test(table(nsaids_exp, drug))$p.value   
   
mattab$variable[28]<-'calc'   
mattab$AS[28]<-
paste(nrow(matdem[matdem$calc_exp == 1 & matdem$drug=='AS',]), ' (',
    
                     round((nrow(matdem[matdem$calc_exp == 1 & matde
m$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2),    
                     '%)', sep='')   
mattab$PTZ[28]<-
paste(nrow(matdem[matdem$calc_exp == 1 & matdem$drug=='PTZ',]), ' ('
,    
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                        round((nrow(matdem[matdem$calc_exp == 1 & ma
tdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
mattab$p[28]<-chisq.test(table(calc_exp, drug))$p.value   
   
# mattab$variable[29]<-'vanc'   
# mattab$AS[29]<-
paste(nrow(matdem[matdem$vanc_exp == 1 & matdem$drug=='AS',]), ' (',
    
#                      round((nrow(matdem[matdem$vanc_exp == 1 & mat
dem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2),    
#                      '%)', sep='')   
# mattab$PTZ[29]<-
paste(nrow(matdem[matdem$vanc_exp == 1 & matdem$drug=='PTZ',]), ' ('
,    
#                         round((nrow(matdem[matdem$vanc_exp == 1 & 
matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),    
#                         '%)', sep='')   
# mattab$p[29]<-chisq.test(table(vanc_exp, drug))$p.value   
   
mattab$variable[30]<-'vaso'   
mattab$AS[30]<-
paste(nrow(matdem[matdem$vaso_exp == 1 & matdem$drug=='AS',]), ' (',
    
                     round((nrow(matdem[matdem$vaso_exp == 1 & matde
m$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2),    
                     '%)', sep='')   
mattab$PTZ[30]<-
paste(nrow(matdem[matdem$vaso_exp == 1 & matdem$drug=='PTZ',]), ' ('
,    
                        round((nrow(matdem[matdem$vaso_exp == 1 & ma
tdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2),    
                        '%)', sep='')   
mattab$p[30]<-chisq.test(table(vaso_exp, drug))$p.value   
   
mattab$variable[31]<-'Comorbidities'   
mattab$variable[32]<-'DM'   
mattab$AS[32]<-
paste(nrow(matdem[matdem$dm==1 & matdem$drug=='AS',]), ' (',    
                     round((nrow(matdem[matdem$dm==1 & matdem$drug==
'AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep='')   
mattab$PTZ[32]<-
paste(nrow(matdem[matdem$dm==1 & matdem$drug=='PTZ',]), ' (',    
                        round((nrow(matdem[matdem$dm==1 & matdem$dru
g=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)', sep='')
   
mattab$p[32]<-chisq.test(table(matdem$dm, drug))$p.value   
   




paste(nrow(matdem[matdem$hf==1 & matdem$drug=='AS',]), ' (',    
                     round((nrow(matdem[matdem$hf==1 & matdem$drug==
'AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep='')   
mattab$PTZ[33]<-
paste(nrow(matdem[matdem$hf==1 & matdem$drug=='PTZ',]), ' (',    
                        round((nrow(matdem[matdem$hf==1 & matdem$dru
g=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)', sep='')
   
mattab$p[33]<-chisq.test(table(matdem$hf, drug))$p.value   
   
mattab$variable[34]<-'HTN'   
mattab$AS[34]<-
paste(nrow(matdem[matdem$HTN==1 & matdem$drug=='AS',]), ' (',    
                     round((nrow(matdem[matdem$HTN==1 & matdem$drug=
='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep='')   
mattab$PTZ[34]<-
paste(nrow(matdem[matdem$HTN==1 & matdem$drug=='PTZ',]), ' (',    
                        round((nrow(matdem[matdem$HTN==1 & matdem$dr
ug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)', sep=''
)   
mattab$p[34]<-chisq.test(table(HTN, drug))$p.value   
   
mattab$variable[35]<-'CF'   
mattab$AS[35]<-
paste(nrow(matdem[matdem$CF==1 & matdem$drug=='AS',]), ' (',    
                     round((nrow(matdem[matdem$CF==1 & matdem$drug==
'AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep='')   
mattab$PTZ[35]<-
paste(nrow(matdem[matdem$CF==1 & matdem$drug=='PTZ',]), ' (',    
                        round((nrow(matdem[matdem$CF==1 & matdem$dru
g=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)', sep='')
   
mattab$p[35]<-chisq.test(table(CF, drug))$p.value   
   
mattab$variable[36]<-'LOS (mean[SD])'   
mattab$AS[36]<-
paste(round(mean(matdem$LENGTH_OF_STAY_NUM[drug=='AS'], na.rm = T),2
), ' (', round(sd(matdem$LENGTH_OF_STAY_NUM[drug=='AS'], na.rm = T),
2),')', sep='')   
mattab$PTZ[36]<-
paste(round(mean(matdem$LENGTH_OF_STAY_NUM[drug=='PTZ'], na.rm = T),
2), ' (', round(sd(matdem$LENGTH_OF_STAY_NUM[drug=='PTZ'], na.rm = T
),2),')', sep='')   
mattab$p[36]<-t.test(matdem$LENGTH_OF_STAY_NUM~drug)$p.value   
   
mattab$variable[37]<-'LOS (median [IQR])'   
mattab$AS[37]<-
paste(median(matdem$LENGTH_OF_STAY_NUM[drug=='AS'], na.rm=T), " (", 
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quantile(matdem$LENGTH_OF_STAY_NUM[drug=='AS'], probs=0.25, na.rm = 
T),'-',   
                     quantile(matdem$LENGTH_OF_STAY_NUM[drug=='AS'],
 probs=0.75, na.rm = T),')', sep='')   
mattab$PTZ[37]<-
paste(median(matdem$LENGTH_OF_STAY_NUM[drug=='PTZ'], na.rm=T), " (",
 quantile(matdem$LENGTH_OF_STAY_NUM[drug=='PTZ'], probs=0.25, na.rm 
= T),'-',   
                        quantile(matdem$LENGTH_OF_STAY_NUM[drug=='PT
Z'], probs=0.75, na.rm = T),')', sep='')   
mattab$p[37]<-wilcox.test(matdem$LENGTH_OF_STAY_NUM~drug)$p.value   
   
# mattab$variable[38]<-'icu_admit'   
# mattab$AS[38]<-
paste(nrow(matdem[matdem$icu_admit==1 & matdem$drug=='AS',]), ' (', 
   
#                      round((nrow(matdem[matdem$icu_admit==1 & matd
em$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep
='')   
# mattab$PTZ[38]<-
paste(nrow(matdem[matdem$icu_admit==1 & matdem$drug=='PTZ',]), ' (',
    
#                         round((nrow(matdem[matdem$icu_admit==1 & m
atdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)'
, sep='')   
# mattab$p[38]<-chisq.test(table(icu_admit, drug))$p.value   
   
# mattab$variable[39]<-'Drug'   
# mattab$variable[40]<-'PTZ'   
# mattab$AS[40]<-
paste(nrow(matdem[matdem$drug=='P' & matdem$drug=='AS',]), ' (',    
#                      round((nrow(matdem[matdem$drug=='P' & matdem$
drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep=''
)   
# mattab$PTZ[40]<-
paste(nrow(matdem[matdem$drug=='P' & matdem$drug=='PTZ',]), ' (',    
#                         round((nrow(matdem[matdem$drug=='P' & matd
em$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)', s
ep='')   
# mattab$variable[41]<-'CFP'   
# mattab$AS[41]<-
paste(nrow(matdem[matdem$drug=='C' & matdem$drug=='AS',]), ' (',    
#                      round((nrow(matdem[matdem$drug=='C' & matdem$
drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep=''
)   
# mattab$PTZ[41]<-
paste(nrow(matdem[matdem$drug=='C' & matdem$drug=='PTZ',]), ' (',    
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#                         round((nrow(matdem[matdem$drug=='C' & matd
em$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)', s
ep='')   
# mattab$variable[42]<-'MEM'   
# mattab$AS[42]<-
paste(nrow(matdem[matdem$drug=='M' & matdem$drug=='AS',]), ' (',    
#                      round((nrow(matdem[matdem$drug=='M' & matdem$
drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep=''
)   
# mattab$PTZ[42]<-
paste(nrow(matdem[matdem$drug=='M' & matdem$drug=='PTZ',]), ' (',    
#                         round((nrow(matdem[matdem$drug=='M' & matd
em$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)', s
ep='')   
#    
# mattab$p[39]<-chisq.test(table(drug, drug))$p.value   
   
   
mattab$variable[45]<-'AKI'   
mattab$variable[46]<-'Any'   
mattab$AS[46]<-
paste(nrow(matdem[matdem$aki==1 & matdem$drug=='AS',]), ' (',    
                     round((nrow(matdem[matdem$aki==1 & matdem$drug=
='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep='')   
mattab$PTZ[46]<-
paste(nrow(matdem[matdem$aki==1 & matdem$drug=='PTZ',]), ' (',    
                        round((nrow(matdem[matdem$aki==1 & matdem$dr
ug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)', sep=''
)   
mattab$p[46]<-chisq.test(table(aki, drug))$p.value   
   
mattab$variable[47]<-'Risk'   
mattab$AS[47]<-
paste(nrow(matdem[matdem$RIFLE=='risk' & matdem$drug=='AS',]), ' (',
    
                     round((nrow(matdem[matdem$RIFLE=='risk' & matde
m$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', sep=
'')   
mattab$PTZ[47]<-
paste(nrow(matdem[matdem$RIFLE=='risk' & matdem$drug=='PTZ',]), ' ('
,    
                        round((nrow(matdem[matdem$RIFLE=='risk' & ma
tdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)',
 sep='')   
mattab$variable[48]<-'injury'   
mattab$AS[48]<-
paste(nrow(matdem[matdem$RIFLE=='injury' & matdem$drug=='AS',]), ' (
',    
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                     round((nrow(matdem[matdem$RIFLE=='injury' & mat
dem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', se
p='')   
mattab$PTZ[48]<-
paste(nrow(matdem[matdem$RIFLE=='injury' & matdem$drug=='PTZ',]), ' 
(',    
                        round((nrow(matdem[matdem$RIFLE=='injury' & 
matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%)
', sep='')   
   
mattab$variable[49]<-'failure'   
mattab$AS[49]<-
paste(nrow(matdem[matdem$RIFLE=='failure' & matdem$drug=='AS',]), ' 
(',    
                     round((nrow(matdem[matdem$RIFLE=='failure' & ma
tdem$drug=='AS',])/nrow(matdem[matdem$drug=='AS',])*100),2), '%)', s
ep='')   
mattab$PTZ[49]<-
paste(nrow(matdem[matdem$RIFLE=='failure' & matdem$drug=='PTZ',]), '
 (',    
                        round((nrow(matdem[matdem$RIFLE=='failure' &
 matdem$drug=='PTZ',])/nrow(matdem[matdem$drug=='PTZ',])*100),2), '%
)', sep='')   
   
mattab<-mattab[!is.na(mattab$variable),]   
mattab$p[mattab$p <=0.00001]<-0.00001   
mattab$p<-round(mattab$p, 5)   




Appendix D: Chapter 5 code 
R code used to clean data 
library(data.table)   
dat<-
fread('d:/Dissertation Data/crcl_data.csv', colClasses='character') 
  
head(dat)   
dat$V1=NULL   
dat$date = as.Date(dat$date)   
dat$crcl = as.numeric(dat$crcl)   
   
eids = unique(dat$ENCNTR_ID)   
   
#dat_b = dat   
#dat=dat[1:100]   
#dat = dat_b   
   
for(i in eids){   
  x = dat[dat$ENCNTR_ID == i,]   
  dat$baseline_crcl[dat$ENCNTR_ID==i] = x$crcl[1]   
}   
base_crcls = dat[,c('ENCNTR_ID','baseline_crcl')]   
base_crcls = unique(base_crcls)   
   
dat$pct_change = (dat$crcl/dat$baseline_crcl)-1   
head(dat)   
table(dat$pct_change < -0.25)   
   
demo = fread('D:/Dissertation Data/RUTTER_846_ENCOUNTERS.csv', colCl
asses='character')   
head(demo)   
demo = demo[demo$ENCNTR_ID %in% eids,]   
demo$ad_date = sapply(strsplit(demo$ADMT_DT,' '),'[',1)   
demo$ad_date = as.Date(demo$ad_date)   
demo$dc_date = sapply(strsplit(demo$DISCHRG_DT,' '),'[', 1)   
demo$dc_date = as.Date(demo$dc_date)   
demo$los = as.numeric(demo$dc_date - demo$ad_date)   
summary(demo$los)   
demo = demo[demo$los >=2,]   
   
dup_eids = demo[duplicated(demo$ENCNTR_ID)]   
demo_dups = demo[demo$ENCNTR_ID %in% dup_eids$ENCNTR_ID,]   
   
demo = demo[!demo$ENCNTR_ID %in% demo_dups$ENCNTR_ID,]   
for(i in unique(demo_dups$ENCNTR_ID)){   
  x = demo_dups[demo_dups$ENCNTR_ID==i,]   
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  x = x[x$ad_date == min(x$ad_date)]   
  demo = rbind(demo, x)   
}   
rm(demo_dups, dup_eids, x, tmp_list)   
   
demo = merge(demo, base_crcls, by = 'ENCNTR_ID', all=T)   
demo$F_NAME<-NULL   
demo$L_NAME= NULL   
head(demo)   
   
demo$AGE<-as.numeric(demo$AGE)   
   
dat$AKI[dat$pct_change <=-0.25]=1   
dat$AKI[is.na(dat$AKI)]=0   
aki_eids = dat$ENCNTR_ID[dat$AKI==1]   
aki_eids = unique(aki_eids)   
   
dat$RIFLE[dat$pct_change <=-0.25 & dat$pct_change >-0.5]<-'risk'   
dat$RIFLE[dat$pct_change <=-0.5 & dat$pct_change >-0.75]<-'injury'   
dat$RIFLE[dat$pct_change <=-0.75]<-'failure'   
dat$RIFLE[is.na(dat$RIFLE)]<-'none'   
table(dat$RIFLE, dat$AKI)   
   
demo$AKI[demo$ENCNTR_ID %in% aki_eids]=1   
demo$AKI[is.na(demo$AKI)]=0   
table(demo$AKI  )   
   
demo = demo[demo$GENDR_CD_DES !='UNKNOWN',]   
table(demo$GENDR_CD_DES)   
   
for(i in aki_eids){   
  x = dat[dat$ENCNTR_ID == i,]   
  x = x[x$AKI==1,]   
  aki_date = min(x$date)   
  demo$aki_date[demo$ENCNTR_ID == i]=aki_date   
}   
   
demo$aki_date = as.Date(demo$aki_date, origin = '1970-01-01')   
head(demo)   
   
cbtx = fread('R codes/first_combo_tx_date.csv', colClasses='characte
r')   
cbtx = cbtx[cbtx$Vancomycin==1,]   
cbtx = cbtx[cbtx$ENCNTR_ID %in% demo$ENCNTR_ID]   
demo = demo[demo$ENCNTR_ID %in% cbtx$ENCNTR_ID]   
str(cbtx)   
   
combo_dates = cbtx[,c('ENCNTR_ID','date')]   
names(combo_dates)[2]<-'combo_tx_date'   
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demo = merge(demo, combo_dates, by='ENCNTR_ID', all=T)   
head(demo)   
demo$combo_tx_date<-as.Date(demo$combo_tx_date)   
table(demo$aki_date>= demo$combo_tx_date+2)   
str(demo)   
   
demo$index_date = demo$combo_tx_date+2   
eid_dates = demo[,c('ENCNTR_ID','index_date')]   
write.csv(eid_dates, 'R codes/eid_index_dates.csv',row.names=F)   
#####################   
#dat_b<-dat   
#dat<-dat_b   
dat<-merge(dat, eid_dates, by='ENCNTR_ID', all=T)   
dat$tx_aki[dat$AKI == 1 & dat$date >= dat$index_date]=1   
dat$tx_aki[is.na(dat$tx_aki)]<-0   
   
aki_eids=unique(dat$ENCNTR_ID[dat$tx_aki==1])   
table(demo$AKI)   
demo$AKI=0   
demo$AKI[demo$ENCNTR_ID %in% aki_eids]=1   
table(demo$AKI)   
head(demo)   
   
demo<-demo[demo$index_date>=demo$ad_date,]   
study_days = data.frame(ENCNTR_ID =NA, date=NA)   
for(i in 1:nrow(demo)){   
  date_range = seq(demo$ad_date[i], demo$index_date[i], by=1)   
  study_days = rbind(study_days, data.frame(ENCNTR_ID= demo$ENCNTR_I
D[i], date=date_range))   
}   
study_days = study_days[!is.na(study_days$date),]   
study_days$date = as.Date(study_days$date, origin= '1970-01-01')   
View(tail(study_days, 1000))   
   
new_study_days = data.frame()   
for(i in unique(study_days$ENCNTR_ID)){   
  x = study_days[study_days$ENCNTR_ID==i,]   
  x$day = seq(nrow(x)-1, 0, by = -1)   
  new_study_days = rbind(new_study_days, x)   
}   
rm(study_days)   
summary(new_study_days$day)   
   
max_days = data.frame()   
for(i in unique(new_study_days$ENCNTR_ID)){   
  x = new_study_days[new_study_days$ENCNTR_ID == i,]   
  x = max(x$day)   
  max_days = rbind(max_days,x)   
}   
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hist(max_days$X2, breaks = 100) # shows small % of max_days > 60 mos
t <30   
summary(max_days)   
rm(max_days)   
   
new_study_days = new_study_days[new_study_days$day<=30,]   
summary(new_study_days)   
table(demo$ENCNTR_ID %in% new_study_days$ENCNTR_ID)   
write.csv(demo, 'pt_demo.csv', row.names=F)   
write.csv(new_study_days, 'study_days.csv', row.names=F)   
   
rm(list= setdiff(ls(), c('demo','new_study_days')))   
#########################################################   
labs = fread('labs 21618.csv', colClasses='character')   
labs = labs[labs$ENCNTR_ID %in% new_study_days$ENCNTR_ID,]   
labs$date = sapply(strsplit(labs$ENTERED,' '),'[',1)   
labs = merge(new_study_days, labs, by=c('ENCNTR_ID', 'date'), all.x=
T)   
head(labs)   
labs$V1=NULL   
   
labs$val_num=as.numeric(labs$VAL_NUM)   
labs_num = labs[!is.na(labs$val_num),]   
labs_cat = labs[is.na(labs$val_num),]   
nrow(labs) == nrow(labs_num) + nrow(labs_cat) #all obs kept   
rm(labs)   
head(labs_num)   
lab_limits = as.data.frame(labs_num[,c('CODE','REFERENCE_LOWER_LIMIT
','REFERENCE_UPPER_LIMIT')])   
lab_limits = unique(lab_limits)   
#lab_limits$ITEM_NAME<-
gsub(pattern = 'zzz', lab_limits$ITEM_NAME, replacement = '')   
lab_limits$REFERENCE_LOWER_LIMIT = as.numeric(lab_limits$REFERENCE_L
OWER_LIMIT)   
lab_limits$REFERENCE_UPPER_LIMIT = as.numeric(lab_limits$REFERENCE_U
PPER_LIMIT)   
lab_dups <- lab_limits$CODE[duplicated(lab_limits$CODE)]   
lab_limits$flg[lab_limits$CODE %in% lab_dups & (is.na(lab_limits$REF
ERENCE_LOWER_LIMIT) |   
                                                  is.na(lab_limits$R
EFERENCE_UPPER_LIMIT))] = 1   
lab_limits$flg[is.na(lab_limits$flg)]=0   
lab_limits=lab_limits[lab_limits$flg==0,]   
lab_dups <- lab_limits$CODE[duplicated(lab_limits$CODE)]   
lab_dups = lab_limits[lab_limits$CODE %in% lab_dups,]   
lab_dups = lab_dups[order(lab_dups$CODE),]   
   
for(i in 1:nrow(lab_limits)){   
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  x = labs_num[labs_num$CODE == lab_limits$CODE[i],]   
  x = x[x$REFERENCE_LOWER_LIMIT == lab_limits$REFERENCE_LOWER_LIMIT[
i],]   
  x = x[x$REFERENCE_UPPER_LIMIT == lab_limits$REFERENCE_UPPER_LIMIT[
i],]   
  lab_limits$ct[i] = nrow(x)   
}   
summary(lab_limits$ct)   
new_lab_lim=data.frame()   
for(i in unique(lab_limits$CODE)){   
  x = lab_limits[lab_limits$CODE == i,]   
  x = x[x$ct==max(x$ct),]   
  new_lab_lim = rbind(new_lab_lim, x)   
}   
names(new_lab_lim) = c('CODE','LL','UL','flg','ct')   
new_lab_lim$flg=NULL   
new_lab_lim$ct = NULL   
labs_num$REFERENCE_LOWER_LIMIT=NULL   
labs_num$REFERENCE_UPPER_LIMIT=NULL   
labs_num = merge(labs_num, new_lab_lim, by='CODE', all=T)   
   
# View(table(labs_num$ITEM_NAME[is.na(labs_num$REFERENCE_LOWER_LIMIT
)]))   
   
names(labs_num)   
labs_num$val[labs_num$val_num < labs_num$LL]<-'low'   
labs_num$val[labs_num$val_num > labs_num$UL]<-'high'   
labs_num$val[labs_num$val_num >= labs_num$LL &    
               labs_num$val_num <= labs_num$UL] = 'norm'   
labs_num$val[is.na(labs_num$val)]='perf'   
table(labs_num$val)   
   
keep_vars = c('ENCNTR_ID','day','CODE','val')   
labs_num = labs_num[,keep_vars]   
labs_num$var = paste('L_',labs_num$CODE,'_D',labs_num$day,sep='')   
head(labs_num$var)   
class(labs_num)   
labs_num<-as.data.table(labs_num)   
labs_num$val_n = as.numeric(factor(labs_num$val, levels = c('perf','
low','norm','high'), ordered = T))   
labs_num_cast = dcast(labs_num, ENCNTR_ID~var, value.var = 'val_n', 
fun.aggregate = max)   
#View(head(labs_num_cast[,100:200]))  # lots if -
inf need to replace with NA or 0?   
labs_num_cast<-as.data.frame(labs_num_cast)   
for( i in 1:ncol(labs_num_cast)) set(labs_num_cast, which(is.infinit
e(labs_num_cast[[i]])), i , 0)   
   
demo = merge(demo, labs_num_cast, by='ENCNTR_ID', all.y=T)   
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#View(head(demo[1:100]))   
rm(labs_num_cast, labs_num, lab_limits, lab_dups, new_lab_lim)   
   
#####   
# Now that numeric labs are added we can look at the categorical lab
s    
# IE did they perform lab without numeric returns   
#   
####   
head(labs_cat)   
labs_cat$var = paste('L_',labs_cat$CODE,'_D',labs_cat$day,sep='')   
labs_cat = as.data.table(labs_cat)   
labs_cat$n = 1   
summary(labs_cat$day)   
labs_cat_cast = dcast(labs_cat, ENCNTR_ID ~ var, value.var = 'n')   
head(labs_cat_cast[,1:100],5)   
   
keep_vars = names(labs_cat_cast)[!(names(labs_cat_cast) %in% names(d
emo))]   
keep_vars = c('ENCNTR_ID', keep_vars)   
labs_cat_cast = labs_cat_cast[,keep_vars]   
demo=merge(demo, labs_cat_cast, by='ENCNTR_ID',all=T)   
#####   
rm(list=setdiff(ls(),c('demo','new_study_days')))   
meds = fread('RUTTER_MEDS.txt', colClasses='character', sep='\t')   
meds = meds[meds$ENCNTR_ID %in% demo$ENCNTR_ID,]   
head(meds)   
keep_vars = c('ENCNTR_ID','DRUG_KEY','PERFORMED_FROM_DTM')   
meds = as.data.frame(meds)   
meds = meds[,keep_vars]   
head(meds)   
meds$date  = sapply(strsplit(meds$PERFORMED_FROM_DTM, ' '),'[', 1)   
meds$PERFORMED_FROM_DTM<-NULL   
meds$date = as.Date(meds$date)   
meds =  merge(new_study_days, meds, by=c('ENCNTR_ID', 'date'), all.x
=T)   
meds = as.data.table(meds)   
meds$n = 1   
meds = meds[meds$DRUG_KEY!='NULL',]   
   
meds$var = paste(meds$DRUG_KEY,'_D',meds$day, sep='')   
meds.cast = dcast(meds, ENCNTR_ID ~ var, value.var = 'n' )   
   
demo = merge(demo, meds.cast, by='ENCNTR_ID', all=T)   
rm(meds, meds.cast)   
names(demo)[47000:47100]   
###########################   
vit = fread('//file2/crutter/dissertation/vitals 2118.csv', colClass
es='character')   
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head(vit)   
vit = vit[vit$ENCNTR_ID %in% demo$ENCNTR_ID,]   
vit = as.data.frame(vit)   
vit$ADMIT_DTM = NULL   
vit$date = sapply(strsplit(vit$RECRD_DT_TM,' '),'[',1)   
vit$RECRD_DT_TM=NULL   
head(vit)   
keep_vars = c('ENCNTR_ID','date','FIO2','RESP_RT','SPO2','DIR_SYSTOL
IC','DIR_DIASTOLIC','BLOODGLUC','HEART_RT',   
              'TEMP')   
vit = vit[,keep_vars]   
vit = as.data.table(vit)   
vit = melt(vit, id.vars = c('ENCNTR_ID','date'))   
vit = vit[!is.na(vit$value),]   
   
vit$date=as.Date(vit$date)   
   
vit = merge(vit, new_study_days, by=c('ENCNTR_ID','date'), all.y=T) 
  
vit=vit[!is.na(vit$day),]   
vit$value = as.numeric(vit$value)   
by(vit$value, vit$variable, summary) ### NEED TO GET RID OF STUPID O
UTLIERS   
# next steps - get rid out outliers   
vits_cuts = fread('C:/users/crutter/desktop/vital_ranges_table.csv',
 stringsAsFactors = F)   
vits_cuts$LC = NA   
vits_cuts$UC = NA   
for(i in vits_cuts$Vital){   
  #print(summary(vit.cast$value[vit.cast$variable==i]))   
  vits_cuts$LC[vits_cuts$Vital ==i] = (mean(vit$value[vit$variable==
i], na.rm=T) -    
                                         4*sd(vit$value[vit$variable
==i], na.rm=T))   
  vits_cuts$UC[vits_cuts$Vital ==i] = (mean(vit$value[vit$variable==
i], na.rm=T) +    
                                         4*sd(vit$value[vit$variable
==i], na.rm=T))   
}   
vits_cuts$LC[vits_cuts$LC<0]=0   
fio2 = vit[vit$variable== 'FIO2',]   
vit = vit[vit$variable != 'FIO2',]   
vit = merge(vit, vits_cuts, by.x = 'variable',by.y='Vital', all=T)   
vit = vit[vit$value <= vit$UC & vit$value >=vit$LC,]   
   
vit.cast = dcast(vit, ENCNTR_ID+day~variable, value.var = 'value', f
un.aggregate = median)   
vit.cast = melt(vit.cast, id.vars = c('ENCNTR_ID','day'))   
vit.cast = vit.cast[!is.na(vit.cast$value),]   
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by(vit.cast$value, vit.cast$variable, summary)   
# Then - set up upper and lower limits   
vit.cast = merge(vit.cast, vits_cuts, by.x = 'variable',by.y='Vital'
, all=T)   
vit.cast$LC = NULL   
vit.cast$UC = NULL   
vit.cast$val_cat[vit.cast$value < vit.cast$LL]=1   
vit.cast$val_cat[vit.cast$value >= vit.cast$LL & vit.cast$value <=vi
t.cast$UL]=2   
vit.cast$val_cat[vit.cast$value > vit.cast$UL]=3   
table(vit.cast$val_cat) # verify that all values have been evaluated
   
vit.cast$val = paste(vit.cast$variable,'_D_', vit.cast$day, sep='') 
  
# then cast   
vit.cast = dcast(vit.cast, ENCNTR_ID ~ val, value.var='val_cat')   
for( i in 1:ncol(vit.cast)) set(vit.cast, which(is.na(vit.cast[[i]])
), i , 0)   
   
demo = merge(demo, vit.cast, by='ENCNTR_ID')   
rm(vit, vit.cast, vits_cuts, keep_vars, i, fio2)   
##### save cause vitals take too long   
save.image("C:/Users/crutter/Desktop/merge lab codes3618.RData")   
#####   
icu = fread('c:/users/crutter/desktop/RUTTER_846_ICU_R_AND_B.csv', c
olClasses='character')   
head(icu)   
   
icu = icu[icu$ENCNTR_ID %in% demo$ENCNTR_ID,]   
icu$date = as.Date(icu$SERVC_DT)   
icu$SERVC_DT = NULL   
icu = merge(new_study_days, icu, by=c('ENCNTR_ID','date'))   
icu$var = paste('ICU_D_',icu$day, sep='')   
table(icu$var)   
eids = data.frame(ENCNTR_ID = demo$ENCNTR_ID)   
icu = dcast(icu, ENCNTR_ID~var, value.var='QTY')   
icu = merge(eids, icu, by='ENCNTR_ID', all=T)   
icu[is.na(icu)]<-0   
   
#demo_b = demo   
#demo =demo_b   
demo = merge(demo, icu , by='ENCNTR_ID')   
rm(icu, eids, demo_b)   
####   
dx = fread('c:/users/crutter/desktop/RUTTER_846_DIAGNOSIS2.txt', col
Classes='character')   
dx = dx[dx$ENCNTR_ID %in% demo$ENCNTR_ID,]   
head(dx)   
dx = dx[dx$DIAGNOSIS !='584.9',]   
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dx$code = paste('ICD9_',dx$DIAGNOSIS, sep='')   
head(dx)   
dx$n=1   
dx = dcast(dx, ENCNTR_ID~code, value.var = 'n')   
   
#demo_b = demo   
#demo =demo_b   
   
demo = merge(demo, dx, by='ENCNTR_ID')   
demo_b = demo   
demo$ad_date =NULL   
demo$dc_date = NULL   
demo$los = NULL   
demo$aki_date = NULL   
demo$RETIRED_FLG = NULL   
demo$MRN = NULL   
demo$ADMT_DT = NULL   
demo$DISCHRG_DT=NULL   
demo$DISCHRG_DISP_CD_DES=NULL   
demo$BIRTH_DT=NULL   
demo$combo_tx_date=NULL   
demo$index_date=NULL   
demo$ETHNCTY_CD_DES[demo$ETHNCTY_CD_DES=='NULL']='UNKNOWN'   
demo$RACE_CD_DES[demo$RACE_CD_DES=='NULL']='UNKNOWN'   
save.image("C:/Users/crutter/Desktop/merge lab codes3618.RData")   
write.csv(demo, 'c:/users/crutter/desktop/final_dis_data.csv', row.n
ames=F)   
   
#### subset for 7 day look back   
names(demo)[1:10]   
keep_names = names(demo)[1:7]   
d7_names = names(demo)[grepl('D0$', names(demo))|   
                         grepl('D1$', names(demo))|   
                         grepl('D2$', names(demo))|   
                         grepl('D3$', names(demo))|   
                         grepl('D4$', names(demo))|   
                         grepl('D5$', names(demo))|   
                         grepl('D6$', names(demo))|   
                         grepl('D7$', names(demo))|   
                         grepl('D_0$', names(demo))|   
                         grepl('D_1$', names(demo))|   
                         grepl('D_2$', names(demo))|   
                         grepl('D_3$', names(demo))|   
                         grepl('D_4$', names(demo))|   
                         grepl('D_5$', names(demo))|   
                         grepl('D_6$', names(demo))|   
                         grepl('D_7$', names(demo))|   
                         grepl('^ICD', names(demo))]   
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demo_sub = demo[,c(keep_names, d7_names)]   
write.csv(demo_sub, 'C:/users/crutter/desktop/final subset_data.csv'
, row.names=F)   
 
Python code for machine learning model development 
#Begin imports   
import sklearn.naive_bayes as sknb   
import pandas as pd   
import numpy as np   
import sklearn.metrics as met   
from sklearn.utils import shuffle   
from sklearn.metrics import confusion_matrix   
from sklearn import preprocessing as pe   
from sklearn.svm import SVC    
from sklearn.externals import joblib   
from sklearn.ensemble import RandomForestClassifier   
from sklearn import linear_model   
import keras   
from keras import backend as K   
from sklearn.model_selection import train_test_split   
from sklearn.utils import shuffle   
from keras.utils.np_utils import to_categorical   
from keras.callbacks import EarlyStopping   
from keras.models import load_model   
#End Imports   
   
def fbeta(tp, tn, fp, fn, beta =1):   
    b=beta**2   
    f = ((1+b)*tp)/((1+b)*tp + b*fn + fp)   
   
model_metrics = []   
   
dat = pd.read_csv('c:/users/wru224/desktop/test_sub_dat.csv')   
dat.drop('ENCNTR_ID', axis=1, inplace=True)   
dat.info()   
dat = shuffle(dat, random_state=123)   
dat = pd.get_dummies(dat, drop_first=True )   
dat.dropna(inplace=True)   
dat.info()   
y=dat['AKI'].values   
dat.drop('AKI', axis=1, inplace=True)   
var_names=dat.columns   
   
dat = dat.values   
X_train, X_test, y_train, y_test = train_test_split(dat, y, test_siz
e = 0.05 )   
early_stop_monitor = EarlyStopping(patience=2)   
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############################   
# March 6, 2018 - first model   
# Two 100 node Relu layers with a 2 node softmax layer   
############################   
model = keras.models.Sequential()   
model.add(keras.layers.Dense(100, activation='relu', input_shape=(da
t.shape[1],)))   
model.add(keras.layers.Dense(100, activation='relu'))   
model.add(keras.layers.Dense(2, activation='softmax'))   
model.summary()   
model.compile(optimizer='adam', loss='sparse_categorical_crossentrop
y', metrics=['accuracy'] )   
   
model.fit(X_train, y_train, validation_split=0.1, callbacks=[early_s
top_monitor], verbose=False)   
#model = load_model('c:/users/wru224/desktop/dissertation/models/NN_
model_1_3618.h5')   
y_pred = model.predict(X_test)   
y_pred_pos = y_pred[:,1]   
y_pred_pos = np.round(y_pred_pos)   
tn, fp, fn, tp = confusion_matrix(y_test, y_pred_pos).ravel()   
acc=(tp+tn)/(tp+tn+fp+fn)   
prec= tp/(tp+fp)   
recall = tp/(tp+fn)   
f1= met.f1_score(y_pred=y_pred_pos, y_true=y_test)   
MCC = met.matthews_corrcoef(y_test, y_pred_pos)   
metrics = ["NN_Model_1_3618", tp, tn, fp, fn, acc, prec, recall, f1,
 MCC]   
model_metrics.append(metrics)   
print('============NN_Model_1_3618 Neural Network=============\n',   
      'tp=', tp,'\n',    
    'tn=', tn, '\n',   
    'fp=', fp,'\n',   
    'fn=', fn, '\n',   
    'acc=',acc,'\n',   
    'prec=', prec,'\n',   
    'recall=',recall,'\n',   
    'f1=', f1, '\n',   
    'MCC=', MCC,'\n')   
model.save('c:/users/wru224/desktop/dissertation/models/NN_model_1_3
618.h5')   
####################################################################
############   
model = keras.models.Sequential()   
model.add(keras.layers.Dense(100, activation='relu', input_shape=(da
t.shape[1],)))   
model.add(keras.layers.Dense(100, activation='relu'))   
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model.add(keras.layers.Dense(100, activation='relu'))   
model.add(keras.layers.Dense(2, activation='softmax'))   
model.summary()   
model.compile(optimizer='adam', loss='sparse_categorical_crossentrop
y', metrics=['accuracy'] )   
   
model.fit(X_train, y_train, validation_split=0.1, callbacks=[early_s
top_monitor])   
#model = load_model('c:/users/wru224/desktop/dissertation/models/NN_
model_2_3618.h5')   
y_pred = model.predict(X_test)   
y_pred_pos = y_pred[:,1]   
y_pred_pos = np.round(y_pred_pos)   
tn, fp, fn, tp = confusion_matrix(y_test, y_pred_pos).ravel()   
acc=(tp+tn)/(tp+tn+fp+fn)   
prec= tp/(tp+fp)   
recall = tp/(tp+fn)   
f1 =met.f1_score(y_pred=y_pred_pos, y_true=y_test)   
MCC = met.matthews_corrcoef(y_test, y_pred_pos)   
metrics = ["NN_Model_2_3618", tp, tn, fp, fn, acc, prec, recall, f1,
  MCC]   
model_metrics.append(metrics)   
print('============NN_Model_2_3618 Neural Network=============\n',   
      'tp=', tp,'\n',    
    'tn=', tn, '\n',   
    'fp=', fp,'\n',   
    'fn=', fn, '\n',   
    'acc=',acc,'\n',   
    'prec=', prec,'\n',   
    'recall=',recall,'\n',   
    'f1=', f1, '\n',   
    'MCC=', MCC,'\n')   
model.save('c:/users/wru224/desktop/dissertation/models/NN_model_2_3
618.h5')   
####################################################################
############   
model = keras.models.Sequential()   
model.add(keras.layers.Dense(500, activation='relu', input_shape=(da
t.shape[1],)))   
model.add(keras.layers.Dense(100, activation='relu'))   
model.add(keras.layers.Dense(2, activation='softmax'))   
model.summary()   
model.compile(optimizer='adam', loss='sparse_categorical_crossentrop
y', metrics=['accuracy'] )   
model.fit(X_train, y_train,validation_split=0.1, callbacks=[early_st
op_monitor], verbose=False)   
y_pred = model.predict(X_test)   
y_pred_pos = y_pred[:,1]   
y_pred_pos = np.round(y_pred_pos)   
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tn, fp, fn, tp = confusion_matrix(y_test, y_pred_pos).ravel()   
acc=(tp+tn)/(tp+tn+fp+fn)   
prec= tp/(tp+fp)   
recall = tp/(tp+fn)   
f1 =met.f1_score(y_pred=y_pred_pos, y_true=y_test)   
MCC = met.matthews_corrcoef(y_test, y_pred_pos)   
metrics = ["NN_Model_3_3618", tp, tn, fp, fn, acc, prec, recall, f1,
  MCC]   
model_metrics.append(metrics)   
print('============NN_Model_3_3618 Neural Network=============\n',   
      'tp=', tp,'\n',    
    'tn=', tn, '\n',   
    'fp=', fp,'\n',   
    'fn=', fn, '\n',   
    'acc=',acc,'\n',   
    'prec=', prec,'\n',   
    'recall=',recall,'\n',   
    'f1=', f1, '\n',   
    'MCC=', MCC,'\n')   
model.save('c:/users/wru224/desktop/dissertation/models/NN_model_3_3
618.h5')   
   
############################   
model = keras.models.Sequential()   
model.add(keras.layers.Dense(100, activation='relu', input_shape=(da
t.shape[1],)))   
model.add(keras.layers.Dropout(0.2))   
model.add(keras.layers.Dense(100, activation='relu'))   
model.add(keras.layers.Dropout(0.2))   
model.add(keras.layers.Dense(2, activation='softmax'))   
model.summary()   
model.compile(optimizer='adam', loss='sparse_categorical_crossentrop
y', metrics=['accuracy'] )   
   
model.fit(X_train, y_train, validation_split=0.1, callbacks=[early_s
top_monitor], verbose=False)   
y_pred = model.predict(X_test)   
y_pred_pos = y_pred[:,1]   
y_pred_pos = np.round(y_pred_pos)   
tn, fp, fn, tp = confusion_matrix(y_test, y_pred_pos).ravel()   
acc=(tp+tn)/(tp+tn+fp+fn)   
prec= tp/(tp+fp)   
recall = tp/(tp+fn)   
f1= met.f1_score(y_pred=y_pred_pos, y_true=y_test)   
MCC = met.matthews_corrcoef(y_test, y_pred_pos)   
metrics = ["NN_Model_4_3618", tp, tn, fp, fn, acc, prec, recall, f1,
 MCC]   
model_metrics.append(metrics)   
print('============NN_Model_4_3618 Neural Network=============\n',   
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      'tp=', tp,'\n',    
    'tn=', tn, '\n',   
    'fp=', fp,'\n',   
    'fn=', fn, '\n',   
    'acc=',acc,'\n',   
    'prec=', prec,'\n',   
    'recall=',recall,'\n',   
    'f1=', f1, '\n',   
    'MCC=', MCC,'\n')   
model.save('c:/users/wru224/desktop/dissertation/models/NN_model_4_3
618.h5')   
   
   
####################################################################
##   
clf = sknb.BernoulliNB()   
clf.fit(X_train, y_train)   
y_pred = clf.predict(X_test)   
tn, fp, fn, tp = confusion_matrix(y_test, y_pred).ravel()   
acc=(tp+tn)/(tp+tn+fp+fn)   
prec= tp/(tp+fp)   
recall = tp/(tp+fn)   
f1= met.f1_score(y_test, y_pred)   
MCC = met.matthews_corrcoef(y_test, y_pred)   
metrics = ["NB", tp, tn, fp, fn, acc, prec, recall, f1, MCC]   
model_metrics.append(metrics)   
print('============Naive Bayes=============\n',   
      'tp=', tp,'\n',    
    'tn=', tn, '\n',   
    'fp=', fp,'\n',   
    'fn=', fn, '\n',   
    'acc=',acc,'\n',   
    'prec=', prec,'\n',   
    'recall=',recall,'\n',   
    'f1=', f1, '\n',   
    'MCC=', MCC,'\n')   
####################################################################
############   
rfclf = RandomForestClassifier()   
rfclf.fit(X_train, y_train)   
rf_pred = rfclf.predict(X_test)   
tn, fp, fn, tp = confusion_matrix(y_test, rf_pred).ravel()   
acc=(tp+tn)/(tp+tn+fp+fn)   
prec= tp/(tp+fp)   
recall = tp/(tp+fn)   
f1=  met.f1_score(y_pred= rf_pred, y_true= y_test)   
MCC = met.matthews_corrcoef(y_test, rf_pred)   
metrics = ["RF", tp, tn, fp, fn, acc, prec, recall, f1, MCC]   
print('============Random Forest=============\n',   
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      'tp=', tp,'\n',    
    'tn=', tn, '\n',   
    'fp=', fp,'\n',   
    'fn=', fn, '\n',   
    'acc=',acc,'\n',   
    'prec=', prec,'\n',   
    'recall=',recall,'\n',   
    'f1=', f1, '\n',   
    'MCC=', MCC,'\n')   
   
####################################################################
############   
fit= linear_model.LogisticRegression(C=1.0, penalty='l2',tol=1e-6)   
fit.fit(X=X_train, y=y_train )   
test_pred = fit.predict(X_test)   
tn, fp, fn, tp = confusion_matrix(y_test, test_pred).ravel()   
acc=(tp+tn)/(tp+tn+fp+fn)   
prec= tp/(tp+fp)   
recall = tp/(tp+fn)   
f1= met.f1_score(test_pred, y_test)   
MCC = met.matthews_corrcoef(y_test, test_pred)   
metrics = ["L2", tp, tn, fp, fn, acc, prec, recall, f1, MCC]   
print('============L2 regression=============\n',   
      'tp=', tp,'\n',    
    'tn=', tn, '\n',   
    'fp=', fp,'\n',   
    'fn=', fn, '\n',   
    'acc=',acc,'\n',   
    'prec=', prec,'\n',   
    'recall=',recall,'\n',   
    'f1=', f1, '\n',   
    'MCC=', MCC,'\n')   
model_metrics.append(metrics)   
   
model_metrics_df = pd.DataFrame(model_metrics)   
model_metrics_df.columns = ['model','TP','TN','FP','FN','ACC','PREC'
,'RECALL','F1_score','MCC']   




Appendix E: Summary of machine learning methods 
Rationale 
Attempting to predict the occurrence of an acute kidney injury in patients receiving 
broad-spectrum antimicrobials is a question of classification. We treat the AKI and non-AKI 
patients as distinct binary classes. Several methods exist to predict a class based on known 
information. Due to the nature of this problem, supervised learning can be utilized. Supervised 
learning relies on the presence of known outcomes and predictors. In the case of predicting AKI, 
patient-specific laboratory data can be leveraged to identify AKI using published AKI criteria. In 
our case we used the RIFLE criteria(19) to identify significant changes in creatinine clearance. 
The risk, injury, and failure categories present and evaluated in RIFLE were collapsed into a 
binary indicator variable for AKI vs. no AKI. 
Prior to completing the machine-learning tasks, the clinical data must be preprocessed to 
streamline computation. In the case of categorical variables with multiple categories (ie. Non-
binary variables), variables were converted using one-hot encoding (Figure E.1). Briefly, the 
presence of a feature is encoded as a 1 while the absence is encoded 0. For the laboratory data 
example, a patient might have multiple labs obtained on the same day. If the results were 
discordant, for example, one draw was high and the other normal, both the high and normal flag 
for that lab on that day would be 1 while the low flag would be 0. While this strategy limits 
inference into the sequence of events, it allows us to capture multiple data points for specific 
features that might otherwise be missed.  
Naïve Bayes classifier 
 The Naïve Bayes classifier (NB) is a probabilistic classifier based on Bayes theorem in 
which the condition probability of an event (A) given that a second event (B) has occurred is 
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 In the presented research, the conditional probability of AKI occurring is dependent on 
the interactions between the conditional probability of each feature in the dataset occurring if an 
AKI occurred and the individual probabilities of the feature values occurring. The NB classifier is 
“naïve” due to the strong assumption of independent probabilities.  
Regularized logistic regression 
 In this study, L2 regularized logistic regression (L2) was utilized to predict AKI 
occurrence. This was primarily done to minimize overfitting that may occur with traditional 
logistic regression (LR) methods. The primary difference between L2 and traditional LR is the 
addition of a weight penalty to minimize the potential for learning large parameter estimates that 
may occur with significant overfitting. While this method decreases test-train accuracy, it 
generally improves generalizability to the validation set. The equation for this penalty is shown 
below with (w) representing the parameter weights and λ represents the hyperparameter to control 
regularization strength. 







Random Forest Classifier 
 The random forest classifier (RF) is an ensemble method that acts as an extension of the 
decision tree classifier. Decision trees tend to overfit data when tree depth is too great, resulting 
in learning noise present in data. RF classifiers overcome this limitation by fitting many smaller 
211 
 
trees to the data and selecting a subspace of available features and observations. The final step in 
the process is averaging the resultant model results.  
Neural Network models 
 The fundamental unit of a neural network (NN) is the neuron, or node, which takes a 
numerical input vector and computes a linear combination followed by a nonlinear activation 
function. There are three basic layer types in a NN. First is the input layer, which is the data being 
provided to the model. Second, hidden layers perform the computation previously described and 
pass data further down the network stream. Finally, the output layer computes a specific 
activation function to provide the appropriate output for the model. For example, in a 
classification task such as the projects described, the softmax activation function can be used to 
determine the most likely class. The softmax function can return the probability for a class, which 
is important for use a clinical decision support tool. For hidden layers, one of the most commonly 
used activation function is the rectified linear unit, or ReLU. This function returns the maximum 
of zero or the linear combination passed to the node. This assists in model development by 
avoiding vanishing or exploding gradients. 
Evaluating models 
Formulae for model metrics utilized are shown below.  
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 =
𝑇𝑇𝑃𝑃 +  𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇𝑇𝑇𝐴𝐴𝑇𝑇 𝑝𝑝𝑇𝑇𝑝𝑝𝐴𝐴𝑇𝑇𝐴𝐴𝑇𝑇𝑝𝑝𝑇𝑇𝑝𝑝
 


















Tables and Figures 
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